<!DOCTYPE html><html lang="en" class="bg-surface-base antialiased"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width, initial-scale=1, interactive-widget=resizes-content"/><link rel="stylesheet" href="/_next/static/css/62c4caba71dfda84.css" nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/eb3d87f98fe1565f.css" nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/1b5e561215938d4d.css" nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/0227d069a630d414.css" nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/f87fff2ab93d05a7.css" nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli" data-precedence="next"/><link rel="preload" as="script" fetchPriority="low" nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli" href="/_next/static/chunks/webpack-e121ed42680f327e.js"/><script src="/_next/static/chunks/78a669d9-e7993486b22c4915.js" async="" nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli"></script><script src="/_next/static/chunks/40c4a5a7-abdabb07419d1cfc.js" async="" nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli"></script><script src="/_next/static/chunks/2230-f7c87dc9fa57c408.js" async="" nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli"></script><script src="/_next/static/chunks/main-app-536d4b8fca62396a.js" async="" nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli"></script><script src="/_next/static/chunks/63f0ec43-8ee6a76d70472249.js" async="" nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli"></script><script src="/_next/static/chunks/7670-7326298c9856172b.js" async="" nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli"></script><script src="/_next/static/chunks/282-691fffb366e24ca5.js" async="" nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli"></script><script src="/_next/static/chunks/7515-336759ef5dad2b52.js" async="" nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli"></script><script src="/_next/static/chunks/927-34e2a6da3e15e26b.js" async="" nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli"></script><script src="/_next/static/chunks/5855-243eeca8f0e4cabd.js" async="" nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli"></script><script src="/_next/static/chunks/4393-1c8dff25ec904469.js" async="" nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli"></script><script src="/_next/static/chunks/2225-454cf9f44775e7ce.js" async="" nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli"></script><script src="/_next/static/chunks/7618-43536a8fb0dd3bfe.js" async="" nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js" async="" nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli"></script><script src="/_next/static/chunks/7720-3a1e7e411adba2d3.js" async="" nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli"></script><script src="/_next/static/chunks/7086-1f1c4891d766e04f.js" async="" nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js" async="" nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli"></script><script src="/_next/static/chunks/app/global-error-4d07d20223cd4b4c.js" async="" nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli"></script><script src="/_next/static/chunks/8208b75a-a48e5a4507a0de91.js" async="" nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli"></script><script src="/_next/static/chunks/5497-ab85ef3ea59dd353.js" async="" nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli"></script><script src="/_next/static/chunks/6281-c6e84786dade3614.js" async="" nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli"></script><script src="/_next/static/chunks/2660-d983a7f287e89f18.js" async="" nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli"></script><script src="/_next/static/chunks/5002-9735c25beda556ba.js" async="" nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli"></script><script src="/_next/static/chunks/3655-6717081f7512305a.js" async="" nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli"></script><script src="/_next/static/chunks/8945-e4e3cf487f5e27c7.js" async="" nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli"></script><script src="/_next/static/chunks/9214-a10614844a67ba31.js" async="" nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli"></script><script src="/_next/static/chunks/4789-2080f6497f78b5b6.js" async="" nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli"></script><script src="/_next/static/chunks/app/layout-226f2bd71acf9f9e.js" async="" nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli"></script><script src="/_next/static/chunks/24cf1b50-159cca90b09285e0.js" async="" nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli"></script><script src="/_next/static/chunks/9ffa21ba-c069766d809bd4c7.js" async="" nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli"></script><script src="/_next/static/chunks/600-9a9fcafaaa6c1c4c.js" async="" nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli"></script><script src="/_next/static/chunks/5448-2a3cfd853d899c9a.js" async="" nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli"></script><script src="/_next/static/chunks/8-8ca70ca619d8e099.js" async="" nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js" async="" nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli"></script><script src="/_next/static/chunks/app/error-4a29e9399afba038.js" async="" nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli"></script><script src="/_next/static/chunks/app/not-found-dd95690acf732f18.js" async="" nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli"></script><meta name="next-size-adjust" content=""/><title>Grokipedia</title><meta name="description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><link rel="icon" type="image/x-icon" href="/favicon.ico" sizes="48x48"/><link rel="icon" href="/images/icon-dark.png" media="(prefers-color-scheme: light)" type="image/png"/><link rel="icon" href="/images/icon-light.png" media="(prefers-color-scheme: dark)" type="image/png"/><link rel="apple-touch-icon" href="/icon-192x192.png"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><meta property="og:title" content="Grokipedia"/><meta property="og:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta property="og:url" content="https://grokipedia.com"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en_US"/><meta property="og:type" content="website"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Grokipedia"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Grokipedia"/><meta name="twitter:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><title>Carbapenem-resistant Enterobacterales</title><meta name="description" content="Carbapenem-resistant Enterobacterales (CRE) are gram-negative bacteria in the order Enterobacterales that are resistant to the carbapenem class of antibiotics, considered drugs of last resort for such infections. CRE include carbapenemase-producing Enterobacterales (CPE), which resist via production of an enzyme called a carbapenemase that disables the drug molecule, as well as non-CPE strains resistant through other mechanisms such as reduced outer membrane permeability and efflux pumps...."/><meta name="author" content="system"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="keywords" content="CRE"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><link rel="canonical" href="https://grokipedia.com/page/Carbapenem-resistant_enterobacteriaceae"/><meta property="og:title" content="Carbapenem-resistant Enterobacterales"/><meta property="og:description" content="Carbapenem-resistant Enterobacterales (CRE) are gram-negative bacteria in the order Enterobacterales that are resistant to the carbapenem class of antibiotics, considered drugs of last resort for such infections. CRE include carbapenemase-producing Enterobacterales (CPE), which resist via production of an enzyme called a carbapenemase that disables the drug molecule, as well as non-CPE strains resistant through other mechanisms such as reduced outer membrane permeability and efflux pumps...."/><meta property="og:url" content="https://grokipedia.com/page/Carbapenem-resistant_enterobacteriaceae"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Carbapenem-resistant Enterobacterales"/><meta property="og:type" content="article"/><meta property="article:modified_time" content="1970-01-21T09:19:13.317Z"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Carbapenem-resistant Enterobacterales"/><meta name="twitter:description" content="Carbapenem-resistant Enterobacterales (CRE) are gram-negative bacteria in the order Enterobacterales that are resistant to the carbapenem class of antibiotics, considered drugs of last resort for such infections. CRE include carbapenemase-producing Enterobacterales (CPE), which resist via production of an enzyme called a carbapenemase that disables the drug molecule, as well as non-CPE strains resistant through other mechanisms such as reduced outer membrane permeability and efflux pumps...."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><link rel="icon" href="/favicon.ico" type="image/x-icon" sizes="16x16"/><meta name="sentry-trace" content="6b265e52321fcc27a9f8c3e13d4adf4d-00cfbdfc0b1868b8-1"/><meta name="baggage" content="sentry-environment=production,sentry-public_key=5f2258f71198ee26a355127af230c3a6,sentry-trace_id=6b265e52321fcc27a9f8c3e13d4adf4d,sentry-org_id=4508179396558848,sentry-transaction=GET%20%2Fpage%2F%5Bslug%5D,sentry-sampled=true,sentry-sample_rand=0.38379406507377967,sentry-sample_rate=1"/><script src="/_next/static/chunks/polyfills-42372ed130431b0a.js" noModule="" nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli"></script></head><body class="flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b"><div hidden=""><!--$--><!--/$--></div><script nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli">((a,b,c,d,e,f,g,h)=>{let i=document.documentElement,j=["light","dark"];function k(b){var c;(Array.isArray(a)?a:[a]).forEach(a=>{let c="class"===a,d=c&&f?e.map(a=>f[a]||a):e;c?(i.classList.remove(...d),i.classList.add(f&&f[b]?f[b]:b)):i.setAttribute(a,b)}),c=b,h&&j.includes(c)&&(i.style.colorScheme=c)}if(d)k(d);else try{let a=localStorage.getItem(b)||c,d=g&&"system"===a?window.matchMedia("(prefers-color-scheme: dark)").matches?"dark":"light":a;k(d)}catch(a){}})("class","theme","dark",null,["light","dark"],null,true,true)</script><header class="h-16 bg-surface-base fixed top-0 z-50 w-full"><div class="hidden h-full grid-cols-[1fr_3fr_1fr] items-center gap-4 !py-0 md:grid max-w-full py-6 px-4 w-full mx-auto"><div class="-ml-2 justify-self-start"><a class="cursor-pointer" href="/"><svg width="200" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="mx-auto flex w-full"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full px-3 shadow-none sm:w-80 focus-visible:z-1 mx-auto h-full w-full rounded-full bg-surface-l1" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>âŒ˜</span><span class="text-xs">K</span></div></span></div></button></div><div class="flex items-center gap-2 justify-self-end"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0" type="button" id="radix-_R_7apfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button></div></div><div class="flex h-full items-center md:hidden justify-between max-w-full py-6 px-4 w-full mx-auto pt-8"><div class="flex items-center"><div class="-ml-2"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button" aria-label="Toggle table of contents"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-list h-6 w-6"><path d="M3 12h.01"></path><path d="M3 18h.01"></path><path d="M3 6h.01"></path><path d="M8 12h13"></path><path d="M8 18h13"></path><path d="M8 6h13"></path></svg></button></div><a class="cursor-pointer" href="/"><svg width="160" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="flex items-center gap-1"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0 [&amp;_svg]:!w-5" type="button" id="radix-_R_aipfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-search h-5 w-5"><circle cx="11" cy="11" r="8"></circle><path d="m21 21-4.3-4.3"></path></svg></button></div></div></header><div class="bg-surface-base fixed right-0 top-16 z-50 h-[calc(100vh-4rem)] w-full transform border-l transition-transform duration-300 ease-in-out sm:w-1/2 md:hidden translate-x-full"><div class="flex flex-col gap-4 p-4"><div class="flex flex-row gap-2"><button class="focus-visible:ring-ring inline-flex items-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full shadow-none sm:w-80 h-10 w-full justify-start rounded-full bg-surface-l1 px-4" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>âŒ˜</span><span class="text-xs">K</span></div></span></div></button></div></div></div><div><div class="min-[1350px]:grid min-[1350px]:grid-cols-[1fr_3fr_1fr]"><nav class="bg-surface-base hidden h-[calc(100vh-4rem)] overflow-y-auto px-6 pb-32 min-[1350px]:sticky min-[1350px]:top-16 min-[1350px]:block scrollbar-none [-ms-overflow-style:none] [scrollbar-width:none] [&amp;::-webkit-scrollbar]:hidden [overscroll-behavior:contain] pt-8"><ul class="space-y-2 text-sm"><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#carbapenem-resistant-enterobacterales" class="transition-opacity hover:opacity-100 opacity-50">Carbapenem-resistant Enterobacterales</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#definition" class="transition-opacity hover:opacity-100 opacity-50">Definition</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#risk-factors" class="transition-opacity hover:opacity-100 opacity-50">Risk factors</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#transmission-by-animals" class="transition-opacity hover:opacity-100 opacity-50">Transmission by animals</a></li><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#carbapenem-mechanism" class="transition-opacity hover:opacity-100 opacity-50">Carbapenem Mechanism</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#mechanism" class="transition-opacity hover:opacity-100 opacity-50">Mechanism</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#antibiotic-function" class="transition-opacity hover:opacity-100 opacity-50">Antibiotic function</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#carbapenem-resistance" class="transition-opacity hover:opacity-100 opacity-50">Carbapenem resistance</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#transfer-between-bacteria" class="transition-opacity hover:opacity-100 opacity-50">Transfer between bacteria</a></li><li style="padding-left:2.25rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#gram-negative-bacteria" class="transition-opacity hover:opacity-100 opacity-50">Gram-negative bacteria</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#laboratory-analysis" class="transition-opacity hover:opacity-100 opacity-50">Laboratory analysis</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#agar-plate-method" class="transition-opacity hover:opacity-100 opacity-50">Agar plate method</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#disc-diffusion-method" class="transition-opacity hover:opacity-100 opacity-50">Disc diffusion method</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#confirmatory-tests-for-carbapenemase-production" class="transition-opacity hover:opacity-100 opacity-50">Confirmatory tests for carbapenemase production</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#pcr-method" class="transition-opacity hover:opacity-100 opacity-50">PCR method</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#maldi-tof-ms" class="transition-opacity hover:opacity-100 opacity-50">MALDI-TOF MS</a></li><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#prevention" class="transition-opacity hover:opacity-100 opacity-50">Prevention</a></li><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#treatments" class="transition-opacity hover:opacity-100 opacity-50">Treatments</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#fosfomycin" class="transition-opacity hover:opacity-100 opacity-50">Fosfomycin</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#tigecycline" class="transition-opacity hover:opacity-100 opacity-50">Tigecycline</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#other-antibiotics" class="transition-opacity hover:opacity-100 opacity-50">Other antibiotics</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#epidemiology" class="transition-opacity hover:opacity-100 opacity-50">Epidemiology</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#mortality" class="transition-opacity hover:opacity-100 opacity-50">Mortality</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#public-health-implications" class="transition-opacity hover:opacity-100 opacity-50">Public health implications</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#bacterial-survival-on-surfaces" class="transition-opacity hover:opacity-100 opacity-50">Bacterial survival on surfaces</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#references" class="transition-opacity hover:opacity-100 opacity-50">References</a></li></ul></nav><div class="relative top-16 pb-32 pt-8 px-4 md:px-8"><div class="mx-auto max-w-[850px]"><button data-state="closed" type="button" class="flex items-center"><div class="text-fg-tertiary mb-2 flex cursor-help items-center gap-2 text-sm"><span class="inline-flex items-center justify-center p-0 m-0" data-namespace="@xai/icons" data-slot="icon" style="height:16px;width:16px"><svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 33 33" aria-hidden="true" class="" focusable="false" style="fill:currentColor;height:16px;width:16px"><path fill="currentColor" d="m13.237 21.04 11.082-8.19c.543-.4 1.32-.244 1.578.38 1.363 3.288.754 7.241-1.957 9.955-2.71 2.714-6.482 3.31-9.93 1.954l-3.765 1.745c5.401 3.697 11.96 2.782 16.059-1.324 3.251-3.255 4.258-7.692 3.317-11.693l.008.009c-1.365-5.878.336-8.227 3.82-13.031q.123-.17.247-.345l-4.585 4.59v-.014L13.234 21.044M10.95 23.031c-3.877-3.707-3.208-9.446.1-12.755 2.446-2.449 6.454-3.448 9.952-1.979L24.76 6.56c-.677-.49-1.545-1.017-2.54-1.387A12.465 12.465 0 0 0 8.675 7.901c-3.519 3.523-4.625 8.94-2.725 13.561 1.42 3.454-.907 5.898-3.251 8.364-.83.874-1.664 1.749-2.335 2.674l10.583-9.466"></path></svg></span><span>Fact-checked by Grok<!-- --> <!-- -->4 days ago</span></div></button><article class="text-[16px]"><h1 id="carbapenem-resistant-enterobacterales" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Carbapenem-resistant Enterobacterales<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<span class="mb-4 block break-words text-[1em] leading-7"><strong>Carbapenem-resistant Enterobacterales</strong> (<strong>CRE</strong>) are gram-negative bacteria in the order Enterobacterales that are resistant to the carbapenem class of antibiotics, considered drugs of last resort for such infections. CRE include <strong>carbapenemase-producing Enterobacterales</strong> (<strong>CPE</strong>), which resist via production of an enzyme called a carbapenemase that disables the drug molecule, as well as non-CPE strains resistant through other mechanisms such as reduced outer membrane permeability and efflux pumps. Resistance levels can vary from moderate to severe. Enterobacterales are common gastrointestinal commensals and opportunistic infectious agents.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> Experts regard CRE as a major &quot;superbug&quot; threat.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_m0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> CRE bloodstream infections are associated with mortality rates up to 50%.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_q0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup> Tom Frieden, former head of the Centers for Disease Control and Prevention, referred to CRE as &quot;nightmare bacteria.&quot;<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_u0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_100qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup> Examples of carbapenemases found in CPE include KPC (Klebsiella pneumoniae carbapenemase) and NDM (New Delhi metallo-beta-lactamase), which hydrolyze carbapenems and render them ineffective. As of 2023, NDM-producing CRE infections in the United States had increased by more than 460% since 2019.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_140qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup></span>
<h2 id="definition" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Definition<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">Carbapenem-resistant Enterobacterales (CRE), previously known as carbapenem-resistant Enterobacteriaceae, are defined by the Centers for Disease Control and Prevention (CDC) as Enterobacterales that are nonsusceptible to one or more carbapenem antibiotics, such as imipenem, meropenem, doripenem, or ertapenem, based on minimum inhibitory concentrations (MICs) of â‰¥4 Î¼g/mL for doripenem, meropenem, or imipenem, or â‰¥2 Î¼g/mL for ertapenem.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_41qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup> Surveillance often focuses on specific species, including <em>Escherichia coli</em>, <em>Klebsiella aerogenes</em> (formerly <em>Enterobacter aerogenes</em>), <em>Enterobacter cloacae</em> complex, <em>Klebsiella pneumoniae</em>, and <em>Klebsiella oxytoca</em>, that are also resistant to extended-spectrum cephalosporins. Some definitions exclude ertapenem resistance to emphasize more severe cases.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_101qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup></span>
<h2 id="risk-factors" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Risk factors<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">Hospitals are primary transmission sites for CRE-based infections. Up to 75% of hospital admissions attributed to CRE were from long-term care facilities or transferred from another hospital.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_42qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> Suboptimal maintenance practices are the largest cause of CRE transmission. This includes the failure to adequately clean and disinfect medication cabinets, other surfaces in patient rooms, and portable medical equipment, such as X-ray and ultrasound machines that are used for both CRE and non-CRE patients.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_82qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup> Thus far, CRE have primarily been <span class="inline text-[1em] leading-7">nosocomial</span> infectious agents. Almost all CRE infections occur in people receiving significant medical care in hospitals, long-term acute care facilities, or nursing homes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g2qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup> Independent risk factors for CRE infection include use of <span class="inline text-[1em] leading-7">beta-lactam antibiotics</span> and the use of <span class="inline text-[1em] leading-7">mechanical ventilation</span>. Patients with <span class="inline text-[1em] leading-7">diabetes</span> have also been shown to be at an elevated risk for acquiring CRE infections.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_102qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup> When compared to other hospitalized patients, those admitted from long-term acute care (LTAC) facilities have significantly higher incidence of colonization and infection rates.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_142qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[10]</sup> Patients with recent exposure to LTAC facilities have high rates of colonization or infection with CRE.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_182qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup> A person susceptible to CRE transmission is more likely to have had a significant number of days breathing through a ventilator.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1c2qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup> Infections with carbapenem-resistant <em>Klebsiella pneumoniae</em> were associated with organ/stem cell transplantation, mechanical ventilation, exposure to antimicrobials, and overall longer length of stay in hospitals.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1k2qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup> People most likely to acquire carbapenem-resistant bacteria are those already receiving medical attention.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1o2qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup> In a study carried out at Sheba medical center, there was a trend toward worse <span class="inline text-[1em] leading-7">Charleson Comorbidity</span> scores in patients who acquired CRKP during ICU stay.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_202qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup> Those at highest risk are patients receiving an organ or stem cell implantation, use of mechanical ventilation, or have to have an extended stay in the hospital along with exposure to antimicrobials. A study performed in Singapore, on the acquisition of ertapenem-resistant Enterobacteriaceae to the acquisition of CRE.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_242qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup> revealed that exposure to antibiotics, especially fluoroquinolones and previous hospitalization dramatically increased the risk of acquisition carbapenem-resistant bacteria. This study found that carbapenem-resistant acquisition has a significantly higher mortality rate and poorer clinical response compared to that of the ertapenem-resistance acquisition.</span>
<span class="mb-4 block break-words text-[1em] leading-7">Bacteruria (also known as <span class="inline text-[1em] leading-7">urinary tract infection</span>) caused by CRKp and CSKp have similar risk factors. These include prior antibiotic use, admittance to an ICU, use of a permanent urinary catheter, and previous invasive procedures or operations. A retrospective study of patients with CRKp and CSKp infection asserted that the use of <span class="inline text-[1em] leading-7">cephalosporins</span> (a class of Î²-lactam antibiotics) used before invasive procedures was higher in patients with CRKp infection, suggesting that it is a risk factor.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c3abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In a three-year study, the prevalence of CRE was shown to be proportional to the lengths of stays of the patients in those hospitals. Policies regarding contact precaution for patients infected or colonized by gram-negative pathogens were also observed in hospitals reporting decreases in CRE prevalence.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_43qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[15]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">One case study showed that patients with a compromised immune response are especially susceptible to both CRE exposure and infection. In one study, an elderly patient with <span class="inline text-[1em] leading-7">acute lymphoblastic leukemia</span> being treated in a long-term care facility contracted a CRE infection.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_84abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup> Her age and condition, combined with her environment and regulation by a catheter and mechanical ventilation, all contributed to a higher susceptibility.</span>
<span class="mb-4 block break-words text-[1em] leading-7">Another major risk factor is being in a country with unregulated antibiotic distribution. In countries where antibiotics are over-the-counter and obtainable without a prescription, the incidence and prevalence of antimicrobial resistance, including CRE, are higher. For example, studies on related resistances like ESBL show higher colonization rates in such settings: 6.4% in Japan compared to 58.4% in Thailand and 63.3% in Egypt.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_44qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[17]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In February 2015, the <span class="inline text-[1em] leading-7">FDA</span> reported about a transmission risk when people undergo a gastroenterology procedure called <span class="inline text-[1em] leading-7">endoscopic retrograde cholangiopancreatography</span>, where an <span class="inline text-[1em] leading-7">endoscope</span> enters the mouth, passes the stomach, and ends in the <span class="inline text-[1em] leading-7">duodenum</span>; if incompletely disinfected, the device can transmit CRE from one patient to another.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_k5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[18]</sup> The FDA&#x27;s safety communication came a day after the <span class="inline text-[1em] leading-7">UCLA Health System</span>, Los Angeles, notified more than 100 patients that they may have been infected with CRE during endoscopies between October 2014 and January 2015.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_s5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[19]</sup> The FDA had issued its first notice about the devices in 2009.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_105abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[20]</sup></span>
<h3 id="transmission-by-animals" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Transmission by animals<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Because the spread of CRE bacteria from animals to humans may become a problem in the future, it is advised to monitor CRE in livestock, as well as humans. As of 2024, limited reports describe transmission between animals and humans or animal-to-animal spread, but detection in livestock and wildlife underscores the need for ongoing surveillance.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_46abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup></span>
<h1 id="carbapenem-mechanism" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Carbapenem Mechanism<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<h2 id="mechanism" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Mechanism<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="antibiotic-function" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Antibiotic function<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">The <span class="inline text-[1em] leading-7">Î²-lactam</span> family of antibiotic molecules consists of four groups: penicillins, cephalosporins, carbapenems (such as imipenem, ertapenem, <span class="inline text-[1em] leading-7">meropenem</span> and doripenem) and monobactams.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c8abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[21]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">These antibiotics share common structure and mechanism of action. They enter the <span class="inline text-[1em] leading-7">periplasmic space</span> through <span class="inline text-[1em] leading-7">porins</span>, where they then inhibit <span class="inline text-[1em] leading-7">transpeptidases</span> (which are also known as <span class="inline text-[1em] leading-7">penicillin-binding proteins</span> (PBPs)), enzymes that facilitate peptide cross-links during cell wall synthesis. Their binding to the PBP active site is facilitated in part by their common structure, which is similar to that of D-alanyl-D-alanine. D-Alanyl-D-alanine is a residue on the NAM peptide subunit involved in building <span class="inline text-[1em] leading-7">peptidoglycan</span>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_o8qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[21]</sup> Carbapenem covalently binds to PBPs, which causes transpeptidases to irreversibly lose their catalytic activity.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_s8qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[21]</sup> Inhibition of transpeptidases prevents the formation of cross-links between peptidoglycan polymers and causes a build-up of peptidoglycan precursors. Newly formed peptidoglycan is weakened from the absence of cross-linkages. The continued activity of <span class="inline text-[1em] leading-7">autolysins</span>, that function like lysozymes and cleave glycosidic and peptide bonds of peptidoglycan in periplasm, weakens the cell wall and leads to osmotic bursting of the bacterial cell.</span>
<span class="mb-4 block break-words text-[1em] leading-7">A unique quality of carbapenems is their resistance to hydrolysis by bacterial <span class="inline text-[1em] leading-7">plasmid</span> and chromosomally mediated extended-spectrum Î²-lactamases (ESBL).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_89abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup></span>
<h3 id="carbapenem-resistance" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Carbapenem resistance<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">In general, carbapenem, a <span class="inline text-[1em] leading-7">Î²-lactam antibiotic</span>, targets cells by inhibiting <span class="inline text-[1em] leading-7">transpeptidases</span> (penicillin-binding proteins). This prevents synthesis of <span class="inline text-[1em] leading-7">peptidoglycan</span>, a necessary structural component, leading to cell lysis. Resistance to carbapenem among Enterobacteriaceae and other <span class="inline text-[1em] leading-7">gram-negative bacteria</span> can be acquired through several mechanisms.</span>
<ol class="marker:text-primary my-4 ml-6 list-decimal space-y-2 text-[1em]">
<li class="text-[1em]">Active transport of carbapenem drugs out of the cell, augmented drug <span class="inline text-[1em] leading-7">efflux</span>, has been observed in some resistant species.</li>
<li class="text-[1em]">One mechanism of resistance is mutation in or loss of <span class="inline text-[1em] leading-7">outer membrane</span> <span class="inline text-[1em] leading-7">porins</span>, preventing antibiotics from entering the cells.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_68aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[23]</sup> Changes within the porin protein gene cause a <span class="inline text-[1em] leading-7">frameshift</span>, altering the porin structure and function.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a8aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[23]</sup> Changes in the porin protein hinder the diffusion of carbapenem and other antibiotics into the periplasm.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c8aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[24]</sup> Bacteria that express plasmid-borne <span class="inline text-[1em] leading-7">extended-spectrum Î²-lactamases (ESBL)</span> can become carbapenem-resistant if an <span class="inline text-[1em] leading-7">insertion sequence</span> or four-nucleotide duplication is present within chromosomal genes for outer membrane porin proteins.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i8aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[23]</sup> <em>Klebsiella pneumoniae</em> has been associated with the lack of outer membrane porin proteins, OmpK35 and OmpK36. The loss of OmpK36 porins can be attributed to point mutations that result in premature termination of translation, resulting in a truncated and consequently nonfunctional protein.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_m8aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup> These outer membrane proteins are involved in the transfer of the antimicrobial genetic material in the cell. Loss of either OmpK35 and OmpK36 or only OmpK36<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_o8aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup> leads to carbapenem resistance. In <em>Klebsiella pneumoniae</em> , the lack of either OmpK35 or OmpK36 leads to carbapenem resistance, but with the lack of both proteins, a high level of resistance is present.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_s8aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup> An observed 32- to 64-fold increase in <span class="inline text-[1em] leading-7">minimum inhibitory concentrations</span> occurs for the carbapenems when both proteins are not expressed.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_108aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup></li>
<li class="text-[1em]">CRE produce carbapenemases, a form of Î²-lactamase.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2caqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup> These enzymes cleave the <span class="inline text-[1em] leading-7">Î²-lactam</span> ring, an essential component of Î²-lactam antibiotics that are recognized by and bound to PBPs. Carbapenemases are divided into different classes, depending on the structure of the enzyme and the mechanism by which they hydrolyze the Î²-lactam ring. The two broad categories of carbapenemases are serine-carbapenemases, which contain serine at the active site, and metallocarbapenemases, which contain zinc at the active site. Class A carbapenemases are serine carbapenemases and are encoded on either the chromosome of the bacteria or a plasmid. A serine at position 70 at the active site of this class of enzymes is required for hydrolysis of Î²-lactams to occur. Class D carbapenemases, also referred to as the OXA Î²-lactamases, are serine Î²-lactamases. They are encoded on plasmids and contain a large variability in amino acid sequence. The resistance mechanism for class D carbapenemases is caused by the formation of an acyl intermediate when breaking the Î²-lactam ring. Class B carbapenemases are metallolactamases and require a zinc at the active site for hydrolysis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6caqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[27]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_7caqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[28]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8caqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[29]</sup> Recent studies (as of 2023) highlight emerging co-production of multiple carbapenemases, such as KPC and NDM, and novel variants like KPC-31 resistant to ceftazidime-avibactam, contributing to multidrug resistance.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_acaqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[30]</sup></li>
<li class="text-[1em]">A clinical <span class="inline text-[1em] leading-7">isolate</span> of <em>E. coli</em> from the sputum sample of a patient admitted to a <span class="inline text-[1em] leading-7">Beijing</span> hospital was found to acquire resistance to carbapenem through mutations not previously observed. It involved a mutation of a <span class="inline text-[1em] leading-7">regulator gene</span> <em>marR</em> and the <span class="inline text-[1em] leading-7">expression</span> of a normally non<span class="inline text-[1em] leading-7">translated</span> membrane porin yedS; both mutations were demonstrated to have effects on the ability of this strain of <em>E.coli</em> to resist carbapenems. The strain lacked the <span class="inline text-[1em] leading-7">outer membrane proteins</span> OmpF and OmpC, and showed increased expression of a multidrug <span class="inline text-[1em] leading-7">efflux pump</span>, but did not produce carbapenemase.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_mgaqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[31]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ngaqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[32]</sup></li>
</ol>
<h3 id="transfer-between-bacteria" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Transfer between bacteria<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Gram-negative bacteria can develop and transfer Î²-lactam resistance (including carbapenem resistance) in many ways. They can generate new extended-spectrum Î²-lactamases (ESBL) from the existing spectrum of plasmid-mediated Î²-lactamases through amino acid substitution. They can acquire genes encoding ESBL from environmental bacteria. They can increase the expression of chromosome-encoded Î²-lactamase genes (<em>bla</em> genes) due to regulatory gene and promoter sequence modifications. They can mobilize <em>bla</em> genes through <span class="inline text-[1em] leading-7">integrons</span> or horizontal transfer of genomic islands into other gram-negative species and strains.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gbqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[33]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ibqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[34]</sup> They can disseminate plasmid-mediated carbapenemases. Finally, they can lower or even inhibit the expression of porin genes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_mbqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[35]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Three major classes of enzymes are involved in carbapenem resistance: class A carbapenemases, class B metallo-Î²-lactamases (MBL), and class D Î²-lactamases (OXA). The four known groups of class A carbapenemases are: SME (three types associated with <em>S. marcescens</em>), IMI (present in <em>E. cloacae</em>), GES (16 variants thus far found in <em>P. aeruginosa</em> predominantly but also found in <em>K. pneumoniae</em> and <em>E. coli</em>), and KPC (10 types of <em>K. pneumoniae</em> carbapenemase).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_scabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[35]</sup> At the UVA Medical Center, a transfer mechanism of KPC-dependent carbapenem resistance was discovered in the transmission of a plasmid carrying the transposon (Tn4401), which contains the KPC gene (<em>bla</em> KPC), to several bacteria including <em>Enterobacter cloacae</em> , <em>Klebsiella oxytoca</em> , <em>E. coli</em> , and <em>Citrobacter freundii</em>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1kcabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[36]</sup> The class B metallo-Î²-lactamases (MBLs) are found largely in gram-negative bacteria and environmental bacteria. The subclasses of MBL enzymes are B1, B2, and B3. MBLs have diverse enzymatic functions and have the ability to hydrolyze Î²-lactam antibiotics. The class D Î²-lactamases (OXA), which hydrolyze oxacillin, provide a good example of the variety of mechanisms that can be used to transfer resistance. The <em>bla</em> OXA genes which encode OXA Î²-lactamases are found on both chromosomes and plasmids, and they have their natural reservoir in environmental bacteria and deep-sea microflora. Insertions in the vicinity of these genes have been shown to increase the strength of their promoters and increase resistance. Because of these characteristics, a wide geographic dissemination of OXA carbapenemase resistance in particular has occurred.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1scabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[35]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The facilitated spread of carbapenem resistance appears to have multiple origins and repeated introduction into the UK of bacteria with the <em>bla</em> OXA-48 gene via horizontal transfer of similar plasmids to pOXA-48a. A recent study in the UK examined 26 isolates of Enterobacteriaceae consisting of a diverse set of sequence types (ST) of <em>K. pneumoniae</em> , <em>E. coli</em> , and <em>Enterobacter cloacae</em> producing OXA-48-like carbapenemases. Their findings included:</span>
<ul class="marker:text-primary my-4 ml-6 list-disc space-y-2 text-[1em]">
<li class="text-[1em]">25 of the 26 strains had the <em>bla</em> OXA-48 gene.
<ul class="marker:text-primary my-4 ml-6 list-disc space-y-2 text-[1em]">
<li class="text-[1em]">21 of these isolates had resistance plasmids that could be transferred by conjugation; 20 of these transformants had the three functional genes, <em>repA</em> , <em>traU</em> , and <em>parA</em> found in pOXA-48a.</li>
<li class="text-[1em]">In ST38 <em>E. coli</em> , no OXA-48 transconjugants were found and it only had the <em>parA</em> gene.</li>
</ul>
</li>
<li class="text-[1em]">The Indian strain of <em>K. pneumoniae</em> had an OXA-181-encoding plasmid (which had higher resistance to carbapenem) and also could not be transferred by conjugation and had none of the three functional genes found in pOXA-48a.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_28dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[37]</sup></li>
</ul>
<h4 id="gram-negative-bacteria" class="group relative mb-1.5 mt-7 scroll-mt-24 font-serif text-[1.142857em] font-semibold" node="[object Object]">Gram-negative bacteria<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h4>
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Outer membrane vesicles</span> (OMVs), that can transfer DNA between bacterial cells, are produced by metabolically active bacterial cells, and the OMVs are not the result of <span class="inline text-[1em] leading-7">cell lysis</span> or cell death. Pathogenic strains can produce about 10-25 times more vesicles than a nonpathogenic strain making this highly relevant to carbapenem resistance transfer.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_aeabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[38]</sup> OMVs protect plasmids from being digested extracellularly by <span class="inline text-[1em] leading-7">nucleases</span> that may be found in the environment, thus favoring <span class="inline text-[1em] leading-7">horizontal gene transfer</span>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_meabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[38]</sup></span>
<h2 id="laboratory-analysis" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Laboratory analysis<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="agar-plate-method" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Agar plate method<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Variations are seen in the media used for inoculation. Many studies use media with 1 to 2 mg/L of imipenem. However, bacteria that produce OXA-48 or OXA-181 result in low-level resistance, which cannot be detected efficiently due to the high concentration.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4fqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[39]</sup> Therefore, more recent screening media use broth containing 0.5â€“1 mg/L <span class="inline text-[1em] leading-7">imipenem</span> or 0.5 mg/L <span class="inline text-[1em] leading-7">ertapenem</span>. The downsides to this approach include the delay of results from the inoculation and the inability to identify the type of carbapenemase.</span>
<h3 id="disc-diffusion-method" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Disc diffusion method<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">The disc diffusion method can be used by hospital laboratories to screen for CRE. In this technique, antibiotic discs are placed onto plates of Mueller Hinton agar that have already been inoculated with the sample strain. The plates are then incubated overnight at 37 Â°C. Following incubation, the zones of inhibition surrounding the various antibiotic discs are measured and compared with Clinical and Laboratory Standard Institute guidelines. Identification of KPCs, MBLs and OXAs can be achieved by demonstrating synergistic inhibition with <span class="inline text-[1em] leading-7">phenyl boronic acid</span>, <span class="inline text-[1em] leading-7">EDTA</span> or neither, respectively.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cgqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[40]</sup></span>
<h3 id="confirmatory-tests-for-carbapenemase-production" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Confirmatory tests for carbapenemase production<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Once CRE is suspected based on screening, confirmatory testing for carbapenemase production is recommended. The modified carbapenem inactivation method (mCIM), endorsed by the Clinical and Laboratory Standards Institute (CLSI) since 2015, is a phenotypic test that detects carbapenemase activity by assessing the inactivation of a carbapenem disk by the bacterial isolate, followed by evaluation of residual activity on an indicator organism. It has high sensitivity (&gt;99%) and specificity (&gt;99%) for most carbapenemases in Enterobacteriaceae and can be performed in standard labs with results in 18-24 hours.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4hqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[41]</sup> For metallo-beta-lactamases, an enhanced version (eCIM) using EDTA is used. Genotypic methods, such as PCR, complement these for specific enzyme identification.</span>
<h3 id="pcr-method" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">PCR method<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">PCR-based screening methodologies are in the process of development for a number of genes responsible for resistance. They speed up detection and can readily differentiate between carbapenamase genes-sometimes in a multiplex format. Costs of PCR testing are decreasing and reliability of molecular based tests relates more to gene presence and gene expression for production of the relevant carbapenamase. Nested arbitrary PCR (ARB-PCR) was used during a 2007 CRE outbreak at the University of Virginia Medical Center to identify the specific <em>bla</em> KPC plasmid involved in the transmission of the infection, and researchers suggest that ARB-PCR may also be used to identify other methods of CRE spread.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8iqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[36]</sup></span>
<h3 id="maldi-tof-ms" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">MALDI-TOF MS<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Another study used <span class="inline text-[1em] leading-7">matrix-assisted laser desorption ionization</span>-<span class="inline text-[1em] leading-7">time of flight mass spectrometry</span> (MALDI-TOF MS) to determine resistance patterns in bacteria from freshly positive blood cultures. MALDI-TOF MS can detect changes in mass to charge ratios. Cabapenem-resistant bacteria often employ Î²-lactamases, which physically disrupt the structure of Î²-lactam antibiotics. Since this causes a change in the mass of the antibiotic, resistant bacteria are detectable by MALDI-TOF MS. Accepted clinical tests often require an overnight incubation before reading the result, but MALDI-TOF MS can return results in just 4â€“5 hours.</span>
<span class="mb-4 block break-words text-[1em] leading-7">MALDI-TOF cannot detect resistant bacteria, which do not physically disrupt the Î²-lactam antibiotic, i.e. where no mass change occurs. Therefore, the method serves best as a first screen for patients admitted to the hospital, but should be followed with secondary testing.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4kabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[42]</sup></span>
<h1 id="prevention" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Prevention<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<span class="mb-4 block break-words text-[1em] leading-7">Researchers found environmental reservoirs of CRE bacteria in ICU sinks and drains. Despite multiple attempts to sterilize these sinks and drains, using detergents and steam, the hospital staff was unsuccessful in getting rid of the CRE. Due to the bacterial resistance to cleaning measures, staff should take extreme precaution in maintaining sterile environments in hospitals not yet infected with the CRE-resistant bacteria.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4labav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[43]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">A major means of transmission is through sinks, so staff should take extra precaution in maintaining sterile conditions. Hospitals could reduce transmission by creating sinks with designs that could reduce backsplash. Another method to reduce transmission from sink to sink is to have sink brushes in each room that would be for cleaning that individual sink alone. Hospital staff should be trained to never dispose of clinical waste down the sinks in patient rooms. A hospital in Melbourne, Australia, implemented similar strategies as these to reduce transmission and prevent further infection of more ICU patients. Armed with the knowledge of their status as CRE transmission sites, hospitals must take special care to monitor CRE outbreaks within their wards. Efficient and accurate detection of CRE is the first step. Enterobacteriaceae are most commonly found in the intestinal flora. Using stool and rectal swabs are, thus, the most reliable methods for testing resistance.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4lqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[43]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">A specific ICD-10-CM billing code (Z22.350) for carriers of carbapenem-resistant Enterobacterales was introduced effective October 1, 2023, aiding national tracking of CRE in the U.S. Another challenge facing efforts to control transmission is the fact that although long-term care facilities have been heavily indicated as the primary centers for incidence, amplification, and spread of CRE, studies that have controlled for this transmission have still found CRE spreading in other affiliated hospitals, indicating that long-term acute-care facilities are likely not the sole culprit in the spread of CRE and other multidrug-resistant organisms.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4mabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">One method found effective is to screen and isolate incoming patients from other facilities, and renew focus on hand washing. While challenges persist in antibiotic development due to resistance evolution, several new agents active against CRE, such as cefiderocol (approved 2019) and eravacycline (approved 2018), have been developed and authorized.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4mqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[44]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6mqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[45]</sup> Studies have found that CRE incidence and prevalence can be reduced by applying targeted interventions including increased hygiene measures and equipment sterilization, even in populations where the prevalence of infection exceeds 50% of patients.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_amqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup> However, additional environmental cleaning to control transmission has not been verified by controlled trials.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_emqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[46]</sup> The involvement of local and national public health authorities will likely be critical to ensure broader and more sustainable implementation of these measures.</span>
<span class="mb-4 block break-words text-[1em] leading-7">Prevention is a top priority for reducing person-to-person transmission of CRE. This is especially true because limited treatment options are available to use after carbapenem resistance develops. Most current research calls for a coordinated, multifaceted approach to infection prevention and containment, and the Centers for Disease Control and Prevention have issued guidelines for the control of CRE transmission.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4nabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[47]</sup> In September 2025, the CDC reported a five-fold rise in New Delhi metallo-Î²-lactamase (NDM)-producing CRE infections from 2019 to 2023, highlighting the ongoing need for robust surveillance and prevention efforts.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8nabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> Experts advocate for a proactive approach, based on the belief that it will be most cost-effective to combat the problem before it is established. However, when immediate financial and personnel resources are limited, healthcare administrators may be forced to respond reactively, aiming to reduce any further transmission.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cnabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[48]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Although a consensus exists for the need of prevention protocols, infection control practices often vary among hospitals, even within close geographic area. In a survey of 15 hospitals within the Toronto area, many hospitals employed varying combinations of basic infection control practices. Eight different practices were observed among the 15 hospitals, some of which included in the most recent publication of guidelines from the Public Health Agency of Canada.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4nqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[49]</sup> Some of these recommendations include laboratory testing, active surveillance, screening (rectal swab, urine culture), hand hygiene, personal protective equipment, environmental cleaning, laundry waste management, and isolation with dedicated equipment and nursing staff. However, only five hospitals had written policies describing how to respond to an outbreak.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8nqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[50]</sup> Many public health initiatives are moving towards a more standardized approach at multiple levels: among local facilities (especially long-term and acute care), regional hospitals, national institutions, and global practices. A standardized approach of prevention may help to more effectively reduce the emergence of CRE.</span>
<span class="mb-4 block break-words text-[1em] leading-7">An infection control plan was implemented at the Kaplan Medical Center in Israel to control a hospital outbreak of carbapenem-resistant K. pneumoniae. The comprehensive plan included guidelines for cohorting patients in separate locations, cleaning with 1,000 ppm hypochlorite, screening for isolates from rectal swabs, and distribution of educational instruction sheets, lectures for all medical staff, and training. The hospital also implemented an automated computer system that updated patient charts when new cases were reported, if patients were carriers, and what precautions to take when dealing with such patients. This plan was evaluated in a quasiexperimental study through the incidence of clinical cases, the rate of cross-infection, and the rate of screening for carriage in admitted patients with increased risk of carriage. The study had a 16-fold decrease in the incidence of resistant K. pneumoniae, which was sustained for 30 months. The plan can provide a model for other hospitals to contain outbreaks of carbapenem-resistant bacteria.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4oabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[51]</sup> A reduction in the use of unnecessary invasive devices, including urinary catheters, could help reduce CRE transmission.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8oabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Several methods have been tested for their effectiveness at improving thorough intensive-care unit environmental hygiene. A study conducted in 2010 across 3532 high risk environmental surfaces in 260 intensive care unit rooms in 27 acute-care hospitals (ICUs) assessed the consistency at which these surfaces met base line cleaning standards. Only 49.5% of the high-risk object surfaces were found to meet this baseline criterion. The least-cleaned objects were bathroom light switches, room door knobs, and bed pan cleaners. Significant improvements in ICU room cleaning was achieved through a structured approach that incorporated a simple, highly objective surface targeting method and repeated performance feedback to environmental surface personnel. Specific methods included implementing an objective evaluation process, environmental surfaces staff education, programmatic feedback, and continuous training to minimize the spread of hospital-associated infections. The authors noted an improvement in the thoroughness of cleaning at 71% from baseline for the entire group of hospitals involved.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4oqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[52]</sup></span>
<h1 id="treatments" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Treatments<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<h2 id="fosfomycin" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Fosfomycin<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">Fosfomycin is an antimicrobial agent that inhibits UDP-N-acetylglucosamine enolpyruvyl transferase (MurA), an enzyme catalyzing an early step in bacterial cell wall synthesis. It has activity against some gram-negative and gram-positive aerobic bacteria, including certain multidrug-resistant Enterobacteriaceae. A systematic review of 17 antimicrobial susceptibility studies on fosfomycin against ESBL-producing Enterobacteriaceae found that 11 reported over 90% of isolates susceptible.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4qabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[53]</sup> For CRE specifically, fosfomycin is recommended by IDSA guidelines (as of 2024) for uncomplicated cystitis if susceptible, particularly for <em>E. coli</em>, but not for complicated infections or non-urinary sites due to limited evidence.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cqabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[53]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_eqabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[45]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Resistance to fosfomycin in Enterobacteriaceae is typically chromosomally encoded rather than plasmid-mediated, which may limit its spread but does not eliminate it in CRE contexts.</span>
<h2 id="tigecycline" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Tigecycline<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">Tigecycline, a glycylcycline antibiotic, exhibits activity against Enterobacteriaceae that display tetracycline resistance due to its higher affinity for ribosomal binding sites compared to tetracycline. A 2008 systematic review of 26 microbiological and 10 clinical studies found high in vitro susceptibility (&gt;90% by FDA criteria) for MDR <em>E. coli</em> and <em>K. pneumoniae</em>, including some carbapenem-resistant isolates.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_crqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[54]</sup> However, susceptibility varies by breakpoints (lower by EUCAST), and clinical use is limited.</span>
<span class="mb-4 block break-words text-[1em] leading-7">Per IDSA 2024 guidance, tigecycline is an alternative for CRE intra-abdominal or peritoneal infections but should be avoided for bloodstream infections, pneumonia, or urinary tract infections due to suboptimal pharmacokinetics, including low serum concentrations and rapid tissue distribution.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4sabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[55]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6sabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[54]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8sabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[45]</sup> It is not considered a first-line agent for carbapenemase-producing CRE.</span>
<h2 id="other-antibiotics" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Other antibiotics<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">For urinary tract infections associated with ESBL-producing Enterobacteriaceae, oral alternatives to fosfomycin include nitrofurantoin, pivmecillinam, and co-amoxiclav.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4tabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[53]</sup> For CRE uncomplicated cystitis, IDSA recommends nitrofurantoin, trimethoprim-sulfamethoxazole, or fluoroquinolones if susceptible; for pyelonephritis or complicated UTI, ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol are preferred if applicable to the carbapenemase type.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8tabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[53]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_atabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[45]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">A case report described treatment of persistent CRE bacteremia in a patient with acute lymphoblastic leukemia using colistin, amikacin, tigecycline, and gentamicin during chemotherapy.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4tqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup> Colistin (a polymyxin) shows activity against some carbapenemase-producing CRE but resistance is emerging, and it is reserved for alternatives due to nephrotoxicity; IDSA suggests it in combination for severe infections like pneumonia or bloodstream infections when preferred agents are unavailable.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8tqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[56]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_atqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[45]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Current IDSA 2024 guidance prefers monotherapy with active agents over combinations to prevent resistance. For KPC-producing CRE (most common in the US), preferred treatments outside the urinary tract include ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-cilastatin-relebactam; cefiderocol is an alternative. For metallo-beta-lactamase producers (e.g., NDM), ceftazidime-avibactam plus aztreonam or cefiderocol are preferred. For OXA-48-like, ceftazidime-avibactam is preferred.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4uabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[56]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6uabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[57]</sup> These agents were developed from earlier investigational Î²-lactamase inhibitors like avibactam (NXL104, approved 2015 in ceftazidime-avibactam) and relebactam (MK-7655, approved 2020 in imipenem-cilastatin-relebactam). Eravacycline, approved in 2018, is an alternative similar to tigecycline for certain sites but avoided for BSI and pneumonia.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_auabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[56]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cuabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[45]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In vitro studies suggest rifampin has synergistic activity with other agents against CRE, but clinical data are limited.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4uqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[56]</sup></span>
<h2 id="epidemiology" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Epidemiology<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">Prior to 1992, CRE were relatively uncommon in the U.S. According to data from the National Nosocomial Infection Service, between 1986 and 1990, only 2.3% of 1825 Enterobacteriaceae isolates sampled were found to be resistant.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4vqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">According to the U.S. Centers for Disease Control, CRE producing what was the most common type of carbapenem-destroying enzyme in 2001 were first detected in a North Carolina hospital in 1996.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_50abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[58]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_70abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[59]</sup> Since then, they have been identified in health care facilities in 41 other states. In 2012, 3% of patients in Chicago-area ICUs carried CRE.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_b0abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> The same data indicated a 30% colonization rate in long-term care facilities (e.g. nursing homes), where patients are not symptomatic. During just the first half of 2012, almost 200 hospitals and long-term acute care facilities treated at least one patient infected with these bacteria.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_f0abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">CRE have become increasingly common in the US. As of 2025, the Centers for Disease Control and Prevention (CDC) reported a sharp rise in carbapenemase-producing CRE, particularly those producing New Delhi metallo-Î²-lactamase (NDM-CRE), with infections surging more than 460% between 2019 and 2023. Early 2024 data indicate levels remained at or above 2023 figures, with annual NDM-positive CRE cases in New York City increasing from 58 in 2019 to 388 in 2024. The Meropenem Yearly Susceptibility Test Information Collection Program noted that resistance within <em>K. pneumoniae</em> alone increased from 0.6% in 2004 to 5.6% in 2008.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_90qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup> The first outbreak involving colistin-resistant, carbapenem-resistant <em>K. pneumoniae</em> (CRKP) in the U.S. was discovered in Detroit, Michigan in 2009, involving three different healthcare institutions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[60]</sup> In an active surveillance study in seven U.S. states over two years, the crude overall incidence of CRE was 2.93 per 100,000 population. Georgia and Maryland had a significantly higher than predicted incidence adjusted for age and race.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_l0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Increases in CRE have not been limited to the US. By 2011, CRE was reported in at least 22 countries.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_51abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup> The European Centre for Disease Prevention and Control (ECDC) assessed CRE as a significant ongoing threat in Europe as of February 2025, with high mortality risks associated with infections like those caused by <em>K. pneumoniae</em> and <em>E. coli</em>. Global systematic reviews from 2024 indicate rising prevalence, particularly of NDM-producing strains in Asia, and overall increasing trends in carbapenem-resistant Enterobacteriaceae across regions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup> Between 2009 and 2012, 10 cases of CRE infections were documented in ICU patients in a Melbourne, Australia, hospital.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_l1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[43]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Some cases of CRE are associated with receipt of medical care in the US. Strains found in Israel had genetic similarity to strains from the US.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_51qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[43]</sup> Hospital handwashing stations were found to be environmental reservoirs for CRE after screening all wet-area locations, including sinks, water fountains, and ice machines. The main reservoirs for CRE were the ICU sinks, and inappropriate cleaning methods accounted for transmission from sink to sink. The CRE strains in the sinks and the strains infecting the ICU patients were identical per genetic analysis. At-risk patients were being infected in the hospital setting.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_91qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[43]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">A study, conducted in 2016â€“2017 at a pediatric hospital in Kathmandu, Nepal, detected the presence of the blaNDM-1 gene among carbapenem-resistant Escherichia coli and Klebsiella pneumoniae isolates confirmed by the Modified Hodge Test, analyzing 1503 clinical samples collected over six months. Genetic analysis revealed that half of the E. coli and two-thirds of the K. pneumoniae carbapenemase-producing isolates carried the blaNDM-1 gene, highlighting the prevalence of this resistance mechanism in Nepal.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_52abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[61]</sup></span>
<h3 id="mortality" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Mortality<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">CRE resistance depends upon a number of factors such as the health of the patient, whether the patient has recently undergone a transplant, risk of co-infection, and use of multiple antibiotics.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_53abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[62]</sup> Carbapenem minimal inhibitory concentrations (MICs) results may be more predictive of clinical patient outcomes than the current categorical classification of the MICs being listed as susceptible, intermediate, or resistant.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_93abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[63]</sup> The study aimed to define an all-cause hospital mortality breakpoint for carbapenem MICs that were adjusted for risk factors. Another objective was to determine if a similar breakpoint existed for indirect outcomes, such as the time to death and length of stay after infection for survivors. Seventy-one patients were included, of which 52 patients survived and 19 patients died. Classification and regression tree analysis determined a split of organism MIC between 2 and 4 mg/liter and predicted differences in mortality (16.1% for 2 mg/liter versus 76.9% for 4 mg/liter). In logistic regression controlling for confounders, each imipenem MIC doubling dilution doubled the probability of death. This classification scheme correctly predicted 82.6% of cases. Patients were accordingly stratified to MICs of â‰¤2 mg/liter (58 patients) and â‰¥4 mg/liter (13 patients). Patients in the group with a MIC of â‰¥4 mg/liter tended to be more ill. Secondary outcomes were also similar between groups. Patients with organisms that had an MIC of â‰¥4 mg/liter had worse outcomes than those with isolates of an MIC of â‰¤2 mg/liter.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d3abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[63]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">At New York Presbyterian Hospital, part of Columbia University Medical Center in New York, NY, a study was conducted on the significant rise in carbapenem resistance in <em>K. pneumoniae</em> from 1999 to 2007. Following a positive blood culture from a patient, overall mortality was 23% in 7 days, 42% in 30 days, and 60% by the end of hospitalization. The overall in-hospital mortality rate was 48%.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_93qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[64]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">At Soroka Medical Center, an Israeli university teaching hospital, a study was done between October 2005 and October 2008 to determine the direct mortality rate associated with carbapenem-resistant <em>K. pneumoniae</em> bloodstream infections. The crude mortality rate for those with the resistant bacteremia was 71.9%, and the attributable mortality rate was determined to be 50% with a 95% confidence interval. The crude mortality rate for control subjects was 21.9%. As a result of the study, Soroka Medical Center started an intensive program designed to prevent the spread of carbapenem-resistant <em>K. pneumoniae</em>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d4abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[65]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">A 2013 retrospective study at the Shaare Zedek Medical Center of patients with urinary tract infections (bacteriuria) caused by carbapenem-resistant <em>Klebsiella pneumoniae</em> (CRKp) showed no statistically significant difference in mortality rates from patients with bacteriuria caused by carbapenem-susceptible <em>K. pneumoniae</em> (CSKp). A 29% mortality rate was seen in patients with CRKp infection compared to a 25% mortality rate in patients with CSKp infections that produced extended-spectrum beta-lactamase (ESBL). Both mortality rates were considerably higher than that of patients with drug-susceptible urosepsis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d4qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup> Most patients in the study had other illnesses, including dementia, immune compromise, kidney failure, or diabetes mellitus. The main risk factor for death found by the study was being bedridden, which significantly increased the chance of death. This suggests that the deaths were due to reasons other than bacteriuria. Total length of hospitalization was somewhat longer in patients with CRKp infections (28 Â± 33 days compared to 22 Â± 28 days for patients with CSKp infection).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h4qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In a case-control study of 99 patients compared with 99 controls at Mount Sinai Hospital (Manhattan), a 1,171 bed tertiary care teaching hospital, 38% of patients in long-term care that were affected by CRE died from <em>K. pneumoniae</em> infection. Patients had risk factors including diabetes, HIV infection, heart disease, liver disease, chronic kidney disease, one was a transplant recipient. 72% of patients who were released from the hospital with CRE were readmitted within 90 days.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_95abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[66]</sup> A 2008 study at Mount Sinai identified outcomes associated with Carbapenem-resistant <em>K. pneumoniae</em> infections, in which patients in need of organ or stem cell transplants, mechanical ventilation, prolonged hospitalization, or prior treatment with carbapenems, had an increased probability of infection with Carbapenem-resistant <em>K. pneumoniae</em>. A combination of antibiotics worked to treat infection and survival rates of infected patients increased when the focus of infection was removed.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_l5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[67]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">CRE infections can set in about 12 days after liver transplantation, and 18% of those patients died a year after transplantation in a 2012 study.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_55qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[68]</sup> Recent studies indicate high mortality persists; for example, a 2025 analysis of enterobacterial bloodstream infections reported an overall lethality rate of 37.7% among CRE cases, with rates up to 80% for severe bloodstream infections.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_95qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_b5qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[27]</sup></span>
<h2 id="public-health-implications" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Public health implications<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="bacterial-survival-on-surfaces" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Bacterial survival on surfaces<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Studies have found prolonged viability of bacteria on stainless-steel surfaces at room temperature. In a specific study, <span class="inline text-[1em] leading-7">stainless steel</span> was inoculated with 107 CFU/cm2 <em>E. coli</em> and <em>K. pneumoniae</em> , containing blaCTX-M-15 and blaNDM-1 (antibiotic-resistant genes) respectively. Thirty days later (at room temperature, 22Ëš C), 104 viable cells remained; and, after 100 days, 100 CFU/cm2 of <em>E. coli</em> remained.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_l7abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[69]</sup> Subsequent studies, including a 2024 review, have confirmed copper&#x27;s antimicrobial activity against CRE and other multidrug-resistant bacteria on hospital surfaces, with reductions in microbial load of up to 83% in clinical trials.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_p7abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[70]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In contrast, on <span class="inline text-[1em] leading-7">copper</span> and copper alloy surfaces, rapid death of antibiotic-resistant bacterial strains, as well as destruction of plasmid and genomic DNA, can be observed. Studies suggest that exposure to dry copper surfaces inhibits the respiration and growth of producers by releasing copper ions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_97qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[69]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Increased horizontal gene transfer (HGT) is observed simultaneously with cell viability on stainless steel surfaces. HGT is one of the major factors responsible for creating antibiotic resistance in bacteria. This suggests that immediate decontamination of surfaces is important in preventing the spread of antibiotic resistance genes. It has also been shown that horizontal transfer of antibiotic-resistant Î²-lactamase genes does not occur on antimicrobial copper surfaces. As copper surfaces degrade naked DNA (and plasmid DNA in antibiotic-resistant <em>E. coli</em> and <em>K. pneumoniae</em>), copper surfaces would halt HGT.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d8abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[69]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Horizontal gene transfer has been demonstrated to occur readily on dry surfaces such as stainless steel, but not on copper and copper alloy surfaces. The rate of bacterial death increased proportionally with the percentage of copper in the copper alloy surface. This can be very important in future clinical and community settings, as an increase in copper utilization in hospital room equipment could help to greatly reduce the spread of antibiotic-resistant infection and the horizontal gene transfer of this antibiotic resistance.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_58qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[69]</sup> However, recent research has shown that exposure to copper surfaces may promote the evolution of copper resistance in Enterobacteriaceae, potentially leading to co-selection of antibiotic resistance traits, which warrants further investigation for sustained use in healthcare environments.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_98qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[71]</sup></span></article><div id="references" class="min-w-0 scroll-mt-8 overflow-hidden"><div class="text-[16px]"><h2 id="references" node="[object Object]" class="mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden">References</h2></div><ol class="columns-1 gap-x-12 [counter-reset:item] md:columns-2"><li id="1" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.health.nsw.gov.au/Infectious/diseases/Pages/cpe.aspx" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Carbapenemase-producing Enterobacterales&quot;</a>. <em><a href="http://www.health.nsw.gov.au" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">www.health.nsw.gov.au</a></em>. Retrieved 2025-07-27.</span></div></li><li id="2" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Peter Eisler (November 29, 2012). <a href="https://www.usatoday.com/story/news/nation/2012/11/29/bacteria-deadly-hospital-infection/1727667/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Deadly superbugs invade U.S. health care facilities&quot;</a>. USA Today. Retrieved December 1, 2012.</span></div></li><li id="3" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.cdc.gov/media/releases/2013/p0305_deadly_bacteria.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;CDC: Action needed now to halt spread of deadly bacteria: Data show more inpatients suffering infections from bacteria resistant to all or nearly all antibiotics&quot;</a> (Press release). The Centers for Disease Control. March 5, 2013. Retrieved March 5, 2013. &quot;During just the first half of 2012, almost 200 hospitals and long-term acute-care facilities treated at least one patient infected with these bacteria.&quot;</span></div></li><li id="4" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Breslow, Jason (8 Jan 2014). <a href="https://www.pbs.org/wgbh/frontline/article/illinois-nightmare-bacteria-outbreak-raises-alarms/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Illinois &quot;Nightmare Bacteria&quot; Outbreak Raises Alarms&quot;</a>. <em>PBS.org</em>. Retrieved 24 Apr 2014.</span></div></li><li id="https://www.cdc.gov/media/releases/2025/2025-cdc-report-finds-sharp-rise-in-dangerous-drug-resistant-bacteria.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.cdc.gov/media/releases/2025/2025-cdc-report-finds-sharp-rise-in-dangerous-drug-resistant-bacteria.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.cdc.gov/media/releases/2025/2025-cdc-report-finds-sharp-rise-in-dangerous-drug-resistant-bacteria.html</a></span></div></li><li id="https://www.cdc.gov/cre/about/index.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.cdc.gov/cre/about/index.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.cdc.gov/cre/about/index.html</a></span></div></li><li id="6" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Guh Alice Y.; Bulens Sandra N.; Mu Yi; Jacob Jesse T.; Reno Jessica; et al. (2015). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6492240" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Epidemiology of Carbapenem-Resistant Enterobacteriaceae in 7 US Communities, 2012-2013&quot;</a>. <em>JAMA</em>. <strong>314</strong> (14): 1479â€“87. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1001%2Fjama.2015.12480" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1001/jama.2015.12480</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6492240" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">6492240</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/26436831" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">26436831</a>.</span></div></li><li id="7" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Perez, F; Van Duin, D (2013). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3960994" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Carbapenem-resistant Enterobacteriaceae: A menace to our most vulnerable patients&quot;</a>. <em>Cleveland Clinic Journal of Medicine</em>. <strong>80</strong> (4): 225â€“33. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.3949%2Fccjm.80a.12182" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.3949/ccjm.80a.12182</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3960994" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">3960994</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/23547093" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">23547093</a>.</span></div></li><li id="8" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Chitnis, AS; Caruthers, PS; Rao, AK; Lamb, J; Lurvey, R; Beau De Rochars, V; Kitchel, B; Cancio, M; et al. (2012). <a href="https://zenodo.org/record/1235704" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Outbreak of carbapenem-resistant enterobacteriaceae at a long-term acute care hospital: Sustained reductions in transmission through active surveillance and targeted interventions&quot;</a>. <em>Infection Control and Hospital Epidemiology</em>. <strong>33</strong> (10): 984â€“92. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1086%2F667738" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1086/667738</a>. <span class="inline text-[1em] leading-7">JSTOR</span> <a href="https://www.jstor.org/stable/667738" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">667738</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/22961017" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">22961017</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:27480055" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">27480055</a>.</span></div></li><li id="9" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Choi, JP; Cho, EH; Lee, SJ; Lee, ST; Koo, MS; Song, YG (2012). &quot;Influx of multidrug resistant, Gram-negative bacteria (MDRGNB) in a public hospital among elderly patients from long-term care facilities: a single-center pilot study&quot;. <em>Archives of Gerontology and Geriatrics</em>. <strong>54</strong> (Marchâ€“April): 19â€“22. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2Fj.archger.2011.05.026" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/j.archger.2011.05.026</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/21764147" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">21764147</a>.</span></div></li><li id="11" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Gupta, N.; Limbago, B. M.; Patel, J. B.; Kallen, A. J. (2011). &quot;Carbapenem-Resistant Enterobacteriaceae: Epidemiology and Prevention&quot;. <em>Clinical Infectious Diseases</em>. <strong>53</strong> (1): 60â€“7. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1093%2Fcid%2Fcir202" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1093/cid/cir202</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/21653305" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">21653305</a>.</span></div></li><li id="12" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Debby, B.D.; Ganor, O.; Yasmin, M.; David, L.; Nathan, K.; Ilana, T.; Dalit, S.; Smollan, G.; Galia, R. (August 2012). <a href="https://doi.org/10.1007%2Fs10096-011-1506-5" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Epidemiology of carbapenem resistant Klebsiella pneumoniae colonization in an intensive care unit&quot;</a>. <em>European Journal of Clinical Microbiology &amp; Infectious Diseases</em>. <strong>31</strong> (8): 1811â€“7. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1007%2Fs10096-011-1506-5" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1007/s10096-011-1506-5</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/22246509" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">22246509</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:18052294" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">18052294</a>.</span></div></li><li id="13" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Teo, J; Cai, Y; Tang, S; Lee, W; Tan, TY; Tan, TT; Kwa, AL (2012). Spellberg, Brad (ed.). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3312905" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Risk Factors, Molecular Epidemiology and Outcomes of Ertapenem-Resistant, Carbapenem-Susceptible Enterobacteriaceae: A Case-Case-Control Study&quot;</a>. <em>PLOS ONE</em>. <strong>7</strong> (3): e34254. <span class="inline text-[1em] leading-7">Bibcode</span>:<a href="https://ui.adsabs.harvard.edu/abs/2012PLoSO...734254T" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">2012PLoSO...734254T</a>. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1371%2Fjournal.pone.0034254" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1371/journal.pone.0034254</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3312905" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">3312905</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/22461908" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">22461908</a>.</span></div></li><li id="14" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Shilo, S; Assous, MV; Lachish, T; Kopuit, P; Bdolah-Abram, T; Yinnon, AM; Wiener-Well, Y (2013). &quot;Risk factors for bacteriuria with carbapenem-resistant Klebsiella pneumoniae and its impact on mortality: A case-control study&quot;. <em>Infection</em>. <strong>41</strong> (2): 503â€“9. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1007%2Fs15010-012-0380-0" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1007/s15010-012-0380-0</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/23271210" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">23271210</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:10515716" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10515716</a>.</span></div></li><li id="15" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Landman, David; Elizabeth Babu; Neha Shah; Paul Kelly; Olafisoye Olawole; Martin Backer; Simona Bratu; John Quale (6 February 2012). <a href="https://doi.org/10.1093%2Fjac%2Fdks063" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Transmission of carbapenem-resistant pathogens in New York City hospitals: progress and frustration&quot;</a>. <em>Journal of Antimicrobial Chemotherapy</em>. <strong>67</strong> (6): 1427â€“1431. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1093%2Fjac%2Fdks063" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1093/jac/dks063</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/22378678" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">22378678</a>.</span></div></li><li id="16" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Muchtar, E; Paul, M; Horowitz, A; Shpilberg, O; Raanani, P (March 2012). &quot;Persistent carbapenem-resistant Klebsiella pneumoniae bacteremia in a patient with acute lymphoblastic leukemia&quot;. <em>The Israel Medical Association Journal</em>. <strong>14</strong> (3): 195â€“7. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/22675865" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">22675865</a>.</span></div></li><li id="10" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Savard, P; Perl, TM (2012). &quot;A call for action: managing the emergence of multidrug-resistant Enterobacteriaceae in the acute care settings&quot;. <em>Current Opinion in Infectious Diseases</em>. <strong>25</strong> (4): 371â€“7. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1097%2FQCO.0b013e3283558c17" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1097/QCO.0b013e3283558c17</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/22766646" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">22766646</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:23670404" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">23670404</a>.</span></div></li><li id="17" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://web.archive.org/web/20150220024405/http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm434871.htm" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Design of Endoscopic Retrograde Cholangiopancreatography (ERCP) Duodenoscopes May Impede Effective Cleaning: FDA Safety Communication&quot;</a>. <em>fda.gov</em>. 20 February 2015. Archived from <a href="http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm434871.htm" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">the original</a> on 20 February 2015. Retrieved 13 April 2022.</span></div></li><li id="18" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Steve Gorman (20 February 2015). <a href="https://www.reuters.com/article/us-usa-ucla-bacteria-idUSKBN0LN0ZS20150219" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;L.A. hospital warns 179 patients possibly exposed to &#x27;superbug&#x27;&quot;</a>. <em>Reuters</em>. <a href="https://web.archive.org/web/20150220011923/http://www.reuters.com/article/2015/02/19/us-usa-ucla-bacteria-idUSKBN0LN0ZS20150219" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Archived</a> from the original on 20 February 2015. Retrieved 20 February 2015.</span></div></li><li id="19" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Sharon Begley, Toni Clarke (20 February 2015). <a href="https://www.reuters.com/article/us-usa-ucla-devices-idUSKBN0LO02Q20150220" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;FDA knew devices spread fatal &#x27;superbug&#x27; but does not order fix&quot;</a>. <em>Reuters</em>. <a href="https://web.archive.org/web/20150220020020/http://www.reuters.com/article/2015/02/20/us-usa-ucla-devices-idUSKBN0LO02Q20150220" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Archived</a> from the original on 20 February 2015. Retrieved 20 February 2015.</span></div></li><li id="20" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Nordman, P; Dortet L; Poirel L (May 2012). &quot;Carbapenem resistance in Enterobacteriaceae: here is the storm!&quot;. <em>Trends in Molecular Medicine</em>. <strong>18</strong> (5doi=10.1016/j.molmed.2012.03.003): 263â€“72. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2Fj.molmed.2012.03.003" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/j.molmed.2012.03.003</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/22480775" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">22480775</a>.</span></div></li><li id="21" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Martin, SI; Kaye, KM (2004). &quot;Beta-lactam antibiotics: newer formulations and newer agents&quot;. <em>Infectious Disease Clinics of North America</em>. <strong>18</strong> (3): 603â€“619. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2Fj.idc.2004.04.006" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/j.idc.2004.04.006</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/15308278" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">15308278</a>.</span></div></li><li id="22" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Little, ML; Qin, X; Zerr, DM; Weissman, SJ (2012). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3237943" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Molecular diversity in mechanisms of carbapenem resistance in paediatric Enterobacteriaceae&quot;</a>. <em>International Journal of Antimicrobial Agents</em>. <strong>39</strong> (1): 52â€“57. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2Fj.ijantimicag.2011.09.014" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/j.ijantimicag.2011.09.014</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3237943" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">3237943</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/22055532" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">22055532</a>.</span></div></li><li id="23" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Logan, LK (2012). <a href="https://doi.org/10.1093%2Fcid%2Fcis543" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Carbapenem-resistant enterobacteriaceae: an emerging problem in children&quot;</a>. <em>Clinical Infectious Diseases</em>. <strong>55</strong> (6): 852â€“859. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1093%2Fcid%2Fcis543" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1093/cid/cis543</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/22700827" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">22700827</a>.</span></div></li><li id="24" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Shin, So Youn; Bae, IK; Kim, J; Jeong, SH; Yong, D; Kim, JM; Lee, K (2012). &quot;Resistance to carbapenems in sequence type 11 <em>Klebsiella pneumoniae</em> is related to DHA-1 and loss of OmpK35 and/or OmpK36&quot;. <em>Journal of Medical Microbiology</em>. <strong>61</strong> (Pt 2): 239â€“245. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1099%2Fjmm.0.037036-0" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1099/jmm.0.037036-0</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/21940650" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">21940650</a>.</span></div></li><li id="25" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Sho, Takehiko; Tetsuro Muratani; Ryoichi Hamasuna; Hiroko Yakushiji; Naohiro Fujimoto; Tetsuro Matsumoto (2013). &quot;The Mechanism of High-Level Carbapenem Resistance in <em>Klebsiella pneumoniae</em> : Underlying Ompk36-Deficient Strains Represent a Threat of Emerging High-Level Carbapenem-Resistant K. pneumoniae with IMP-1 Î²-Lactamase Production in Japan&quot;. <em>Microbial Drug Resistance</em>. <strong>19</strong> (4): 274â€“81. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1089%2Fmdr.2012.0248" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1089/mdr.2012.0248</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/23514607" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">23514607</a>.</span></div></li><li id="26" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Nordmann, Patrice; et al. (May 2012). &quot;Carbapenem resistance in Enterobacteriaceae: here is the storm!&quot;. <em>Trends in Molecular Medicine</em>. <strong>18</strong> (5): 263â€“272. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2Fj.molmed.2012.03.003" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/j.molmed.2012.03.003</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/22480775" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">22480775</a>.</span></div></li><li id="27" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Queenan, Anne Marie; Karen Bush (July 2007). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1932750" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Carbapenemases: the Versatile Î²-Lactamases&quot;</a>. <em>Clinical Microbiology Reviews</em>. <strong>20</strong> (3): 440â€“458. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1128%2FCMR.00001-07" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1128/CMR.00001-07</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1932750" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1932750</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/17630334" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">17630334</a>.</span></div></li><li id="28" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Patel, Gopi; Bonomo (March 2013). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3596785" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;&quot;Stormy waters ahead&quot;: global emergence of carbapenemases&quot;</a>. <em>Frontiers in Microbiology</em>. <strong>4</strong> : 48. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.3389%2Ffmicb.2013.00048" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.3389/fmicb.2013.00048</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3596785" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">3596785</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/23504089" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">23504089</a>.</span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC10305383/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10305383/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC10305383/</a></span></div></li><li id="29" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Press Release (26 March 2013). <a href="http://now.tufts.edu/news-releases/new-study-identifies-unique-mechanisms-antibi" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;New Study Identifies Unique Mechanisms of Antibiotic Resistance&quot;</a>. <span class="inline text-[1em] leading-7">Tufts University</span>. Retrieved 25 April 2013.</span></div></li><li id="30" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Levy, Stuart; Warner, Douglas; Yang, Qiwen; Duval, Valerie; Chen, Minjun; Xu, Yingchun (2013). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3623324" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Involvement of MarR and YedS in Carbapenem Resistance in a Clinical Isolate of Escherichia coli from China&quot;</a>. <em><span class="inline text-[1em] leading-7">Antimicrobial Agents and Chemotherapy</span></em>. <strong>57</strong> (4): 1935â€“1937. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1128%2FAAC.02445-12" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1128/AAC.02445-12</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3623324" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">3623324</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/23318808" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">23318808</a>.</span></div></li><li id="32" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Hudson, Corey; Bent, Zachary; Meagher, Robert; Williams, Kelly (June 6, 2014). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4048246" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Resistance Determinants and Mobile Genetic Elements of an NDM-1-Encoding <em>Klebsiella pneumoniae</em> Strain&quot;</a>. <em>PLOS ONE</em>. <strong>9</strong> (6): e99209. <span class="inline text-[1em] leading-7">Bibcode</span>:<a href="https://ui.adsabs.harvard.edu/abs/2014PLoSO...999209H" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">2014PLoSO...999209H</a>. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1371%2Fjournal.pone.0099209" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1371/journal.pone.0099209</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4048246" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">4048246</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/24905728" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">24905728</a>.</span></div></li><li id="33" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Pulcrano, G; Pignanelli, S; Vollaro, A; Esposito, M; Iula, VD; Roscetto, E; Soriano, AA; Catania, MR (Jun 2016). &quot;Isolation of Enterobacter aerogenes carrying blaTEM-1 and blaKPC-3 genes recovered from a hospital Intensive Care Unit&quot;. <em>APMIS</em>. <strong>124</strong> (6): 516â€“21. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1111%2Fapm.12528" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1111/apm.12528</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/27004836" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">27004836</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:33234690" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">33234690</a>.</span></div></li><li id="34" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Pfeifer, Yvonne; Cullik, Angela; Witte, Wolfgang (Aug 2010). &quot;Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens&quot;. <em>Int J Med Microbiol</em>. <strong>300</strong> (6): 371â€“9. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2Fj.ijmm.2010.04.005" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/j.ijmm.2010.04.005</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/20537585" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">20537585</a>.</span></div></li><li id="35" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Mathers, AJ; Cox, HL; Kitchel, B; Bonatti, H; Brassinga, AK; Carroll, J; Scheld, WM; Hazen, KC; Sifri, CD (2011). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202755" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Molecular Dissection of an Outbreak of Carbapenem-Resistant Enterobacteriaceae Reveals Intergenus KPC Carbapenemase Transmission through a Promiscuous Plasmid&quot;</a>. <em>mBio</em>. <strong>2</strong> (6): e00204â€“11. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1128%2FmBio.00204-11" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1128/mBio.00204-11</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202755" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">3202755</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/22045989" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">22045989</a>.</span></div></li><li id="36" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Dimou, V; Dhanji, H; Pike, R; Livermore, DM; Woodford, N (2012). <a href="https://doi.org/10.1093%2Fjac%2Fdks124" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Characterization of Enterobacteriaceae producing OXA-48-like carbapenemases in the UK&quot;</a>. <em>The Journal of Antimicrobial Chemotherapy</em>. <strong>67</strong> (7): 1660â€“5. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1093%2Fjac%2Fdks124" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1093/jac/dks124</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/22532467" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">22532467</a>.,</span></div></li><li id="37" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Rumbo, Carlos; FernÃ¡ndez-Moreira, E; Merino, M; Poza, M; Mendez, JA; Soares, NC; Mosquera, A; Chaves, F; Bou, G (July 2011). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3122458" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Horizontal transfer of the OXA-24 carbapenemase gene via outer membrane vesicles: a new mechanism of dissemination of carbapenem resistance genes in Acinetobacter baumanni&quot;</a>. <em>Antimicrobial Agents and Chemotherapy</em>. 7. <strong>55</strong> (7): 3084â€“3090. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1128%2FAAC.00929-10" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1128/AAC.00929-10</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3122458" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">3122458</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/21518847" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">21518847</a>.</span></div></li><li id="38" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Landman, D; Salvani, JK; Bratu, S; Quale, J (November 2005). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1287836" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Evaluation of techniques for detection of carbapenem-resistant <em>Klebsiella pneumoniae</em> in stool surveillance cultures&quot;</a>. <em>Journal of Clinical Microbiology</em>. <strong>43</strong> (11): 5639â€“41. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1128%2FJCM.43.11.5639-5641.2005" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1128/JCM.43.11.5639-5641.2005</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1287836" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1287836</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/16272497" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">16272497</a>.</span></div></li><li id="39" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Pournaras S; et al. (2013). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3754636" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;A Combined Disk Test for Direct Differentiation of Carbapenemase-Producing Enterobacteriaceae in Surveillance Rectal Swabs&quot;</a>. <em>J Clin Microbiol</em>. <strong>51</strong> (9): 2986â€“90. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1128%2FJCM.00901-13" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1128/JCM.00901-13</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3754636" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">3754636</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/23843486" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">23843486</a>.</span></div></li><li id="https://journals.asm.org/doi/10.1128/jcm.00193-17" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://journals.asm.org/doi/10.1128/jcm.00193-17" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://journals.asm.org/doi/10.1128/jcm.00193-17</a></span></div></li><li id="40" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Sparbier, Katrin; Schubert, S; Weller, U; Boogen, C; Kostrzewa, M (May 2012). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3295133" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry-Based FUnctional Assay for Rapid Detection of Resistance against B-Lactam Antibiotics&quot;</a>. <em>Journal of Clinical Microbiology</em>. <strong>50</strong> (3): 927â€“937. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1128%2FJCM.05737-11" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1128/JCM.05737-11</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3295133" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">3295133</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/22205812" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">22205812</a>.</span></div></li><li id="41" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Kotsanas, Despina; Wijesooriya, WR; Korman, TM; Gillespie, EE; Wright, L; Snook, K; Williams, N; Bell, JM; et al. (18 March 2013). <a href="https://doi.org/10.5694%2Fmja12.11757" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;&quot;Down the drain&quot;: carbapenem-resistant bacteria in intensive care unit patients and handwashing sinks&quot;</a>. <em>Medical Journal of Australia</em>. <strong>198</strong> (5): 267â€“269. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.5694%2Fmja12.11757" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.5694/mja12.11757</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/23496403" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">23496403</a>.</span></div></li><li id="https://www.fda.gov/news-events/press-announcements/fda-approves-new-antibiotic-treat-complicated-urinary-tract-and-complicated-intra-abdominal-infections" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.fda.gov/news-events/press-announcements/fda-approves-new-antibiotic-treat-complicated-urinary-tract-and-complicated-intra-abdominal-infections" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.fda.gov/news-events/press-announcements/fda-approves-new-antibiotic-treat-complicated-urinary-tract-and-complicated-intra-abdominal-infections</a></span></div></li><li id="https://www.idsociety.org/practice-guideline/amr-guidance/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.idsociety.org/practice-guideline/amr-guidance/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.idsociety.org/practice-guideline/amr-guidance/</a></span></div></li><li id="42" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Kahn, A. S.; Dancer, Humphreys (October 2012). &quot;Priorities in the prevention and control of multidrug-resistant Enterobacteriaceae in hospitals&quot;. <em>Journal of Hospital Infection</em>. <strong>82</strong> (2): 85â€“93. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2Fj.jhin.2012.06.013" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/j.jhin.2012.06.013</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/22863084" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">22863084</a>.</span></div></li><li id="43" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.cdc.gov/hai/organisms/cre/cre-toolkit/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;CDC Infection Control Guidelines&quot;</a>. 2019-11-04.</span></div></li><li id="44" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Bilavsky, E; Schwaber, MJ; Carmeli, Y (2010). &quot;How to stem the tide of carbapenemase-producing enterobacteriaceae?: Proactive versus reactive strategies&quot;. <em>Current Opinion in Infectious Diseases</em>. <strong>23</strong> (4): 327â€“31. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1097%2FQCO.0b013e32833b3571" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1097/QCO.0b013e32833b3571</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/20581673" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">20581673</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:20036704" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">20036704</a>.</span></div></li><li id="45" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="http://www.phac-aspc.gc.ca/nois-sinp/guide/ipcm-mpci/ipcm-mpci-eng.php" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Canadian Public Health Infection Prevention Guidelines&quot;</a>. 2010-11-12.</span></div></li><li id="46" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Lowe, C; Katz, K; McGeer, A; Muller, MP; Toronto Esbl Working, Group (2012). &quot;Disparity in infection control practices for multidrug-resistant Enterobacteriaceae&quot;. <em>American Journal of Infection Control</em>. <strong>40</strong> (9): 836â€“9. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2Fj.ajic.2011.11.008" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/j.ajic.2011.11.008</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/22361360" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">22361360</a>. <code class="text-fg-solar bg-fg-solar-opaque break-all rounded px-2 align-middle font-mono text-sm" node="[object Object]">{{cite journal}}</code>: <code class="text-fg-solar bg-fg-solar-opaque break-all rounded px-2 align-middle font-mono text-sm" node="[object Object]">|first5=</code> has generic name (help)</span></div></li><li id="47" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Ciobotaro, P; Oved, M; Nadir, E; Bardenstein, R; Zimhony, O (October 2011). &quot;An effective intervention to limit the spread of an epidemic carbapenem-resistant <em>Klebsiella pneumoniae</em> strain in an acute care setting: from theory to practice&quot;. <em>American Journal of Infection Control</em>. <strong>39</strong> (8): 671â€“7. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2Fj.ajic.2011.05.004" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/j.ajic.2011.05.004</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/21864942" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">21864942</a>.</span></div></li><li id="48" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Carling, Philip C.; Michael F. Parry; Lou Ann Bruno-Murtha; Brian Dick (2010). &quot;Improving environmental hygiene in 27 intensive care units to decrease multidrug-resistant bacterial transmission&quot;. <em>Critical Care Medicine</em>. <strong>38</strong> (4): 1054â€“1059. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1097%2FCCM.0b013e3181cdf705" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1097/CCM.0b013e3181cdf705</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/20081531" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">20081531</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:16166524" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">16166524</a>.</span></div></li><li id="49" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Falagas, ME; Kastoris, AC; Kapaskelis, AM; Karageorgopoulos, DE (2010). &quot;Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: A systematic review&quot;. <em>The Lancet Infectious Diseases</em>. <strong>10</strong> (1): 43â€“50. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2FS1473-3099%2809%2970325-1" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/S1473-3099(09)70325-1</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/20129148" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">20129148</a>.</span></div></li><li id="51" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Kelesidis T, Karageorgopoulos DE, Kelesidis I, Falagas ME (1 August 2008). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8445635" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies&quot;</a>. <em>Journal of Antimicrobial Chemotherapy</em>. <strong>62</strong> (5): 895â€“904. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1093%2Fjac%2Fdkn311" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1093/jac/dkn311</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8445635" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">8445635</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/18676620" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">18676620</a>.</span></div></li><li id="50" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.merckmanuals.com/professional/infectious-diseases/bacteria-and-antibacterial-drugs/tigecycline" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Tigecycline - Infectious Diseases&quot;</a>. <em>Merck Manuals Professional Edition</em>. Retrieved 2019-09-26.</span></div></li><li id="52" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Kanj, Souha; Zeina A. Kanafani (March 2011). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3046948" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Current Concepts in Antimicrobial Therapy Against Resistant Gram-Negative Organisms: Extended-Spectrum Î²-lactamase-Producing Enterobacteriaceae, Carbapenem-Resistant Enterobacteriaceae, and Multidrug-Resistant Pseudomonas aeruginosa&quot;</a>. <em>Mayo Clinic Proceedings</em>. <strong>86</strong> (3): 250â€“259. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.4065%2Fmcp.2010.0674" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.4065/mcp.2010.0674</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3046948" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">3046948</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/21364117" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">21364117</a>.</span></div></li><li id="https://www.idsociety.org/practice-guidance/amr-guidance/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.idsociety.org/practice-guidance/amr-guidance/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.idsociety.org/practice-guidance/amr-guidance/</a></span></div></li><li id="54" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Yigit, H; Queenan, AM; Anderson, GJ; Domenech-Sanchez, A; Biddle, JW; Steward, CD; Alberti, S; Bush, K; Tenover, FC (April 2001). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC90438" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of <em>Klebsiella pneumoniae</em> &quot;</a>. <em>Antimicrobial Agents and Chemotherapy</em>. <strong>45</strong> (4): 1151â€“1161. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1128%2FAAC.45.4.1151-1161.2001" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1128/AAC.45.4.1151-1161.2001</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC90438" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">90438</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/11257029" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">11257029</a>.</span></div></li><li id="55" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Temkin E, Adler A, Lerner A, Carmeli Y (2014). <a href="https://web.archive.org/web/20200530092436/https://www.openaccessrepository.it/record/21450" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Carbapenem-resistant Enterobacteriaceae: biology, epidemiology, and management&quot;</a>. <em>Annals of the New York Academy of Sciences</em>. <strong>1323</strong> (1): 22â€“42. <span class="inline text-[1em] leading-7">Bibcode</span>:<a href="https://ui.adsabs.harvard.edu/abs/2014NYASA1323...22T" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">2014NYASA1323...22T</a>. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1111%2Fnyas.12537" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1111/nyas.12537</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/25195939" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">25195939</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:28242426" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">28242426</a>. Archived from <a href="https://www.openaccessrepository.it/record/21450" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">the original</a> on May 30, 2020.</span></div></li><li id="56" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Marchaim, D; Chopra, T; Pogue, JM; Perez, F; Hujer, AM; Rudin, S; Endimiani, A; Navon-Venezia, S; et al. (2011). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3028794" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Outbreak of colistin-resistant, carbapenem-resistant <em>Klebsiella pneumoniae</em> in metropolitan Detroit, Michigan&quot;</a>. <em>Antimicrobial Agents and Chemotherapy</em>. <strong>55</strong> (2): 593â€“9. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1128%2FAAC.01020-10" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1128/AAC.01020-10</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3028794" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">3028794</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/21115786" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">21115786</a>.</span></div></li><li id="57" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Binod, G.C.; Sapkota, R.; Rayamajhee, B.; Poudel, P.; Thapa, S.; Lekhak, S.; Khanal, S. (2018). <a href="https://www.sciencedirect.com/science/article/pii/S187167841831358X" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Detection of blaNDM-1 gene among the carbapenem resistant Escherichia coli and Klebsiella pneumoniae isolates&quot;</a>. <em>New Biotechnology</em>. <strong>44</strong> (Supplement): S119. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2Fj.nbt.2018.05.1038" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/j.nbt.2018.05.1038</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/1871-6784" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1871-6784</a>.</span></div></li><li id="58" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Bonomo, RA; van Duin, D; Kaye, KS; Neuner, EA (2013). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3947910" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes&quot;</a>. <em>Diagnostic Microbiology and Infectious Disease</em>. <strong>75</strong> (2): 115â€“120. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2Fj.diagmicrobio.2012.11.009" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/j.diagmicrobio.2012.11.009</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3947910" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">3947910</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/23290507" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">23290507</a>.</span></div></li><li id="59" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Esterly, JS; Wagner, J; McLaughlin, MM; Postelnick, MJ; Qi, C; Scheetz, MH (2012). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3421845" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Evaluation of Clinical Outcomes in Patients with Bloodstream Infections Due to Gram-Negative Bacteria According to Carbapenem MIC Stratification&quot;</a>. <em>Antimicrobial Agents and Chemotherapy</em>. <strong>56</strong> (9): 4885â€“4890. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1128%2FAAC.06365-11" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1128/AAC.06365-11</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3421845" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">3421845</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/22777044" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">22777044</a>.</span></div></li><li id="60" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Nguyen, M; Eschenauer, GA; Bryan, M; O&#x27;Neil, K; Furuya, EY; Della-Latta, P; Kubin, CJ (June 2010). &quot;Carbapenem-resistant <em>Klebsiella pneumoniae</em> bacteremia: factors correlated with clinical and microbiologic outcomes&quot;. <em>Diagnostic Microbiology and Infectious Disease</em>. <strong>67</strong> (2): 180â€“4. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2Fj.diagmicrobio.2010.02.001" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/j.diagmicrobio.2010.02.001</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/20356699" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">20356699</a>.</span></div></li><li id="61" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Borer, A; Saidel-Odes, L; Riesenberg, K; Eskira, S; Peled, N; Nativ, R; Schlaeffer, F; Sherf, M (October 2009). &quot;Attributable mortality rate for carbapenem-resistant <em>Klebsiella pneumoniae</em> bacteremia&quot;. <em>Infection Control and Hospital Epidemiology</em>. <strong>30</strong> (10): 972â€“6. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1086%2F605922" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1086/605922</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/19712030" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">19712030</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:33001455" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">33001455</a>.</span></div></li><li id="62" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Calfee, DP; Patel, G; Huprikar, S; Factor, SH; Jenkins, SG (2008). &quot;Outcomes of carbapenem-resistant <em>Klebsiella pneumoniae</em> infection and the impact of antimicrobial and adjunctive therapies&quot;. <em>Infection Control and Hospital Epidemiology</em>. <strong>29</strong> (12): 1099â€“1106. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1086%2F592412" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1086/592412</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/18973455" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">18973455</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:23992125" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">23992125</a>.</span></div></li><li id="63" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Patel, Gopi; Huprikar, S; Factor, SH; Jenkins, SG; Calfee, DP (December 2008). &quot;Outcomes of Carbapenem-Resistant <em>Klebsiella pneumoniae</em> Infection and the Impact of Antimicrobial and Adjunctive Therapies&quot;. <em>Infection Control &amp; Hospital Epidemiology</em>. <strong>29</strong> (12): 1099â€“1106. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1086%2F592412" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1086/592412</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/18973455" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">18973455</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:23992125" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">23992125</a>.</span></div></li><li id="64" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Kalpoe, JS; Sonnenberg, E; Factor, SH; del Rio Martin, J; Schiano, T; Patel, G; Huprikar, S (2012). <a href="https://doi.org/10.1002%2Flt.23374" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Mortality associated with carbapenem-resistant <em>Klebsiella pneumoniae</em> infections in liver transplant recipient&quot;</a>. <em>Liver Transplantation</em>. <strong>18</strong> (4): 468â€“474. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1002%2Flt.23374" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1002/lt.23374</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/22467548" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">22467548</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:46280258" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">46280258</a>.</span></div></li><li id="65" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Warnes, Sarah L.; Highmore, C. J.; Keevil, C. W. (November 27, 2012). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3509412" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Horizontal Transfer of Antibiotic Resistance Genes on Abiotic Touch Surfaces: Implications for Public Health&quot;</a>. <em>mBio</em>. <strong>3</strong> (6): e00489â€“12. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1128%2FmBio.00489-12" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1128/mBio.00489-12</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3509412" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">3509412</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/23188508" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">23188508</a>.</span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC11920907/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11920907/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC11920907/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC11190421/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11190421/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC11190421/</a></span></div></li></ol></div><div class="text-fg-secondary text-xs [&amp;_*]:mb-2"><hr class="border-border-l1 my-8 rounded-sm border-t"/>
<span class="mb-4 block break-words text-[1em] leading-7">The content is adapted from <a href="https://en.wikipedia.org/wiki/Carbapenem-resistant_enterobacteriaceae" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Wikipedia</a>, licensed under Creative Commons Attribution-ShareAlike 4.0 License.</span></div></div></div><div class="hidden min-[1400px]:block"></div></div></div><!--$--><!--/$--><div role="region" aria-label="Notifications (F8)" tabindex="-1" style="pointer-events:none"><ol tabindex="-1" class="pointer-events-none fixed top-0 z-[100] flex max-h-screen w-full flex-col-reverse p-4 max-sm:left-0 sm:bottom-0 sm:right-0 sm:top-auto sm:max-w-[420px] sm:flex-col pl-16 pr-2 pt-16 sm:px-4"></ol></div><script type="application/json" id="server-client-data-experimentation">{"status":"uninitialized"}</script><script src="/_next/static/chunks/webpack-e121ed42680f327e.js" nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli" id="_R_" async=""></script><script nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli">(self.__next_f=self.__next_f||[]).push([0])</script><script nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli">self.__next_f.push([1,"1:\"$Sreact.fragment\"\n3:I[91363,[],\"\"]\n4:I[23775,[],\"\"]\n5:I[57654,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"PageHeaderProvider\"]\n6:I[17618,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"HeaderContent\"]\n7:I[25529,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"6751\",\"static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js\"],\"default\"]\n9:I[6666,[],\"OutletBoundary\"]\nb:I[80415,[],\"AsyncMetadataOutlet\"]\nd:I[6666,[],\"ViewportBoundary\"]\nf:I[6666,[],\"MetadataBoundary\"]\n10:\"$Sreact.suspense\"\n12:I[95909,[\"4219\",\"static/chunks/app/global-error-4d07d20223cd4b4c.js\"],\"default\"]\n"])</script><script nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli">self.__next_f.push([1,"13:I[51498,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"ConstantsProvider\"]\n"])</script><script nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli">self.__next_f.push([1,"14:I[91073,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli">self.__next_f.push([1,"15:I[38642,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli">self.__next_f.push([1,"16:I[99648,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli">self.__next_f.push([1,"17:I[78825,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli">self.__next_f.push([1,"18:I[8550,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MixpanelProvider\"]\n"])</script><script nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli">self.__next_f.push([1,"19:I[12290,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MobileTocProvider\"]\n"])</script><script nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli">self.__next_f.push([1,"1a:I[53947,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"NuqsAdapter\"]\n"])</script><script nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli">self.__next_f.push([1,"1b:I[91873,[\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8039\",\"static/chunks/app/error-4a29e9399afba038.js\"],\"default\"]\n1c:I[5091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"4345\",\"static/chunks/app/not-found-dd95690acf732f18.js\"],\"default\"]\n"])</script><script nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli">self.__next_f.push([1,"1d:I[16091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli">self.__next_f.push([1,":HL[\"/_next/static/media/1f2316909698f815.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/3d4419af2cf8609b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/4dec29efcaeb336c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/74452ea3ef0f9101.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/904ef0a86fe32a00.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/d886a03bcda7ad8f.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/e1447589d6f59c4b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/f5a90156f8995c8c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/css/62c4caba71dfda84.css\",\"style\",{\"nonce\":\"YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli\"}]\n:HL[\"/_next/static/css/eb3d87f98fe1565f.css\",\"style\",{\"nonce\":\"YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli\"}]\n:HL[\"/_next/static/css/1b5e561215938d4d.css\",\"style\",{\"nonce\":\"YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli\"}]\n:HL[\"/_next/static/css/0227d069a630d414.css\",\"style\",{\"nonce\":\"YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli\"}]\n:HL[\"/_next/static/css/f87fff2ab93d05a7.css\",\"style\",{\"nonce\":\"YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli\"}]\n"])</script><script nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli">self.__next_f.push([1,"0:{\"P\":null,\"b\":\"BpM29AX4fmgcUxZ_6t0le\",\"p\":\"\",\"c\":[\"\",\"page\",\"Carbapenem-resistant_enterobacteriaceae\"],\"i\":false,\"f\":[[[\"\",{\"children\":[\"page\",{\"children\":[[\"slug\",\"Carbapenem-resistant_enterobacteriaceae\",\"d\"],{\"children\":[\"__PAGE__\",{}]}]}]},\"$undefined\",\"$undefined\",true],[\"\",[\"$\",\"$1\",\"c\",{\"children\":[[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/62c4caba71dfda84.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli\"}],[\"$\",\"link\",\"1\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/eb3d87f98fe1565f.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli\"}],[\"$\",\"link\",\"2\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/1b5e561215938d4d.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli\"}],[\"$\",\"link\",\"3\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/0227d069a630d414.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli\"}]],\"$L2\"]}],{\"children\":[\"page\",[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}],{\"children\":[[\"slug\",\"Carbapenem-resistant_enterobacteriaceae\",\"d\"],[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L5\",null,{\"children\":[[\"$\",\"$L6\",null,{\"maxWidth\":\"full\",\"mobileOptions\":{\"right\":{\"showFixedIssues\":true,\"showThemeSwitcher\":true,\"showSearch\":true,\"showTableOfContents\":true}}}],[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L7\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}]]}],{\"children\":[\"__PAGE__\",[\"$\",\"$1\",\"c\",{\"children\":[\"$L8\",[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/f87fff2ab93d05a7.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli\"}]],[\"$\",\"$L9\",null,{\"children\":[\"$La\",[\"$\",\"$Lb\",null,{\"promise\":\"$@c\"}]]}]]}],{},null,false]},null,false]},null,false]},null,false],[\"$\",\"$1\",\"h\",{\"children\":[null,[[\"$\",\"$Ld\",null,{\"children\":\"$Le\"}],[\"$\",\"meta\",null,{\"name\":\"next-size-adjust\",\"content\":\"\"}]],[\"$\",\"$Lf\",null,{\"children\":[\"$\",\"div\",null,{\"hidden\":true,\"children\":[\"$\",\"$10\",null,{\"fallback\":null,\"children\":\"$L11\"}]}]}]]}],false]],\"m\":\"$undefined\",\"G\":[\"$12\",[]],\"s\":false,\"S\":false}\n"])</script><script nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli">self.__next_f.push([1,"2:[\"$\",\"html\",null,{\"lang\":\"en\",\"className\":\"bg-surface-base antialiased\",\"suppressHydrationWarning\":true,\"children\":[[\"$\",\"head\",null,{\"children\":[[\"$\",\"title\",null,{\"children\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"type\":\"image/x-icon\",\"href\":\"/favicon.ico\",\"sizes\":\"48x48\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-dark.png\",\"media\":\"(prefers-color-scheme: light)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-light.png\",\"media\":\"(prefers-color-scheme: dark)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"apple-touch-icon\",\"href\":\"/icon-192x192.png\"}],[\"$\",\"link\",null,{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\"}],[\"$\",\"meta\",null,{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",null,{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"meta\",null,{\"property\":\"og:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"property\":\"og:url\",\"content\":\"https://grokipedia.com\"}],[\"$\",\"meta\",null,{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:locale\",\"content\":\"en_US\"}],[\"$\",\"meta\",null,{\"property\":\"og:type\",\"content\":\"website\"}],[\"$\",\"meta\",null,{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:alt\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}]]}],[\"$\",\"body\",null,{\"className\":\"flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b\",\"children\":[[\"$\",\"$L13\",null,{\"children\":[\"$\",\"$L14\",null,{\"children\":[\"$\",\"$L15\",null,{\"defaultTheme\":\"dark\",\"nonce\":\"YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli\",\"children\":[\"$\",\"$L16\",null,{\"children\":[\"$\",\"$L17\",null,{\"children\":[\"$\",\"$L18\",null,{\"children\":[\"$\",\"$L19\",null,{\"children\":[\"$\",\"$L1a\",null,{\"children\":[[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$1b\",\"errorStyles\":[],\"errorScripts\":[],\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L1c\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}],[\"$\",\"$L1d\",null,{}]]}]}]}]}]}]}]}]}],[\"$\",\"script\",null,{\"type\":\"application/json\",\"id\":\"server-client-data-experimentation\",\"children\":\"{\\\"status\\\":\\\"uninitialized\\\"}\"}]]}]]}]\n"])</script><script nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli">self.__next_f.push([1,"e:[[\"$\",\"meta\",\"0\",{\"charSet\":\"utf-8\"}],[\"$\",\"meta\",\"1\",{\"name\":\"viewport\",\"content\":\"width=device-width, initial-scale=1, interactive-widget=resizes-content\"}]]\na:null\n"])</script><script nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli">self.__next_f.push([1,"1e:I[42712,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"HydrationBoundary\"]\n"])</script><script nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli">self.__next_f.push([1,"21:I[6367,[],\"IconMark\"]\n1f:Tb2a7,"])</script><script nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli">self.__next_f.push([1,"# Carbapenem-resistant Enterobacterales\n\n**Carbapenem-resistant Enterobacterales** (**CRE**) are gram-negative bacteria in the order Enterobacterales that are resistant to the carbapenem class of antibiotics, considered drugs of last resort for such infections. CRE include **carbapenemase-producing Enterobacterales** (**CPE**), which resist via production of an enzyme called a carbapenemase that disables the drug molecule, as well as non-CPE strains resistant through other mechanisms such as reduced outer membrane permeability and efflux pumps. Resistance levels can vary from moderate to severe. Enterobacterales are common gastrointestinal commensals and opportunistic infectious agents.[1] Experts regard CRE as a major \"superbug\" threat.[2] CRE bloodstream infections are associated with mortality rates up to 50%.[3] Tom Frieden, former head of the Centers for Disease Control and Prevention, referred to CRE as \"nightmare bacteria.\"[3][4] Examples of carbapenemases found in CPE include KPC (Klebsiella pneumoniae carbapenemase) and NDM (New Delhi metallo-beta-lactamase), which hydrolyze carbapenems and render them ineffective. As of 2023, NDM-producing CRE infections in the United States had increased by more than 460% since 2019.[](https://www.cdc.gov/media/releases/2025/2025-cdc-report-finds-sharp-rise-in-dangerous-drug-resistant-bacteria.html)\n# Carbapenem-resistant Enterobacterales\n\n## Definition\n\nCarbapenem-resistant Enterobacterales (CRE), previously known as carbapenem-resistant Enterobacteriaceae, are defined by the Centers for Disease Control and Prevention (CDC) as Enterobacterales that are nonsusceptible to one or more carbapenem antibiotics, such as imipenem, meropenem, doripenem, or ertapenem, based on minimum inhibitory concentrations (MICs) of â‰¥4 Î¼g/mL for doripenem, meropenem, or imipenem, or â‰¥2 Î¼g/mL for ertapenem.[](https://www.cdc.gov/cre/about/index.html) Surveillance often focuses on specific species, including _Escherichia coli_, _Klebsiella aerogenes_ (formerly _Enterobacter aerogenes_), _Enterobacter cloacae_ complex, _Klebsiella pneumoniae_, and _Klebsiella oxytoca_, that are also resistant to extended-spectrum cephalosporins. Some definitions exclude ertapenem resistance to emphasize more severe cases.[6]\n## Risk factors\n\nHospitals are primary transmission sites for CRE-based infections. Up to 75% of hospital admissions attributed to CRE were from long-term care facilities or transferred from another hospital.[7] Suboptimal maintenance practices are the largest cause of CRE transmission. This includes the failure to adequately clean and disinfect medication cabinets, other surfaces in patient rooms, and portable medical equipment, such as X-ray and ultrasound machines that are used for both CRE and non-CRE patients.[8] Thus far, CRE have primarily been [nosocomial](Hospital-acquired_infection \"Hospital-acquired infection\") infectious agents. Almost all CRE infections occur in people receiving significant medical care in hospitals, long-term acute care facilities, or nursing homes.[3] Independent risk factors for CRE infection include use of [beta-lactam antibiotics](Beta-lactam_antibiotics \"Beta-lactam antibiotics\") and the use of [mechanical ventilation](Mechanical_ventilation \"Mechanical ventilation\"). Patients with [diabetes](Diabetes \"Diabetes\") have also been shown to be at an elevated risk for acquiring CRE infections.[8] When compared to other hospitalized patients, those admitted from long-term acute care (LTAC) facilities have significantly higher incidence of colonization and infection rates.[9] Patients with recent exposure to LTAC facilities have high rates of colonization or infection with CRE.[6] A person susceptible to CRE transmission is more likely to have had a significant number of days breathing through a ventilator.[8] Infections with carbapenem-resistant _Klebsiella pneumoniae_ were associated with organ/stem cell transplantation, mechanical ventilation, exposure to antimicrobials, and overall longer length of stay in hospitals.[11] People most likely to acquire carbapenem-resistant bacteria are those already receiving medical attention.[11] In a study carried out at Sheba medical center, there was a trend toward worse [Charleson Comorbidity](Comorbidity#Charlson_Comorbidity_Index_\\(CCI\\) \"Comorbidity\") scores in patients who acquired CRKP during ICU stay.[12] Those at highest risk are patients receiving an organ or stem cell implantation, use of mechanical ventilation, or have to have an extended stay in the hospital along with exposure to antimicrobials. A study performed in Singapore, on the acquisition of ertapenem-resistant Enterobacteriaceae to the acquisition of CRE.[13] revealed that exposure to antibiotics, especially fluoroquinolones and previous hospitalization dramatically increased the risk of acquisition carbapenem-resistant bacteria. This study found that carbapenem-resistant acquisition has a significantly higher mortality rate and poorer clinical response compared to that of the ertapenem-resistance acquisition. \n\nBacteruria (also known as [urinary tract infection](Urinary_tract_infection \"Urinary tract infection\")) caused by CRKp and CSKp have similar risk factors. These include prior antibiotic use, admittance to an ICU, use of a permanent urinary catheter, and previous invasive procedures or operations. A retrospective study of patients with CRKp and CSKp infection asserted that the use of [cephalosporins](Cephalosporin \"Cephalosporin\") (a class of Î²-lactam antibiotics) used before invasive procedures was higher in patients with CRKp infection, suggesting that it is a risk factor.[14]\n\nIn a three-year study, the prevalence of CRE was shown to be proportional to the lengths of stays of the patients in those hospitals. Policies regarding contact precaution for patients infected or colonized by gram-negative pathogens were also observed in hospitals reporting decreases in CRE prevalence.[15]\n\nOne case study showed that patients with a compromised immune response are especially susceptible to both CRE exposure and infection. In one study, an elderly patient with [acute lymphoblastic leukemia](Acute_lymphoblastic_leukemia \"Acute lymphoblastic leukemia\") being treated in a long-term care facility contracted a CRE infection.[16] Her age and condition, combined with her environment and regulation by a catheter and mechanical ventilation, all contributed to a higher susceptibility. \n\nAnother major risk factor is being in a country with unregulated antibiotic distribution. In countries where antibiotics are over-the-counter and obtainable without a prescription, the incidence and prevalence of antimicrobial resistance, including CRE, are higher. For example, studies on related resistances like ESBL show higher colonization rates in such settings: 6.4% in Japan compared to 58.4% in Thailand and 63.3% in Egypt.[10]\n\nIn February 2015, the [FDA](FDA \"FDA\") reported about a transmission risk when people undergo a gastroenterology procedure called [endoscopic retrograde cholangiopancreatography](Endoscopic_retrograde_cholangiopancreatography \"Endoscopic retrograde cholangiopancreatography\"), where an [endoscope](Upper_endoscopy \"Upper endoscopy\") enters the mouth, passes the stomach, and ends in the [duodenum](Duodenum \"Duodenum\"); if incompletely disinfected, the device can transmit CRE from one patient to another.[17] The FDA's safety communication came a day after the [UCLA Health System](UCLA_Health_System \"UCLA Health System\"), Los Angeles, notified more than 100 patients that they may have been infected with CRE during endoscopies between October 2014 and January 2015.[18] The FDA had issued its first notice about the devices in 2009.[19]\n\n### Transmission by animals\n\nBecause the spread of CRE bacteria from animals to humans may become a problem in the future, it is advised to monitor CRE in livestock, as well as humans. As of 2024, limited reports describe transmission between animals and humans or animal-to-animal spread, but detection in livestock and wildlife underscores the need for ongoing surveillance.[](https://www.cdc.gov/cre/about/index.html)\n# Carbapenem Mechanism\n\n## Mechanism\n\n### Antibiotic function\n\nThe [Î²-lactam](Î²-lactam) family of antibiotic molecules consists of four groups: penicillins, cephalosporins, carbapenems (such as imipenem, ertapenem, [meropenem](Meropenem) and doripenem) and monobactams.[20]\n\nThese antibiotics share common structure and mechanism of action. They enter the [periplasmic space](Periplasmic_space) through [porins](Porins), where they then inhibit [transpeptidases](DD-Transpeptidase) (which are also known as [penicillin-binding proteins](Penicillin-binding_proteins) (PBPs)), enzymes that facilitate peptide cross-links during cell wall synthesis. Their binding to the PBP active site is facilitated in part by their common structure, which is similar to that of D-alanyl-D-alanine. D-Alanyl-D-alanine is a residue on the NAM peptide subunit involved in building [peptidoglycan](Peptidoglycan).[20] Carbapenem covalently binds to PBPs, which causes transpeptidases to irreversibly lose their catalytic activity.[20] Inhibition of transpeptidases prevents the formation of cross-links between peptidoglycan polymers and causes a build-up of peptidoglycan precursors. Newly formed peptidoglycan is weakened from the absence of cross-linkages. The continued activity of [autolysins](Autolysins), that function like lysozymes and cleave glycosidic and peptide bonds of peptidoglycan in periplasm, weakens the cell wall and leads to osmotic bursting of the bacterial cell. \n\nA unique quality of carbapenems is their resistance to hydrolysis by bacterial [plasmid](Plasmid) and chromosomally mediated extended-spectrum Î²-lactamases (ESBL).[21]\n\n### Carbapenem resistance\n\nIn general, carbapenem, a [Î²-lactam antibiotic](Î²-lactam_antibiotic), targets cells by inhibiting [transpeptidases](DD-Transpeptidase) (penicillin-binding proteins). This prevents synthesis of [peptidoglycan](Peptidoglycan), a necessary structural component, leading to cell lysis. Resistance to carbapenem among Enterobacteriaceae and other [gram-negative bacteria](Gram-negative_bacteria) can be acquired through several mechanisms. \n\n1. Active transport of carbapenem drugs out of the cell, augmented drug [efflux](Efflux_(microbiology)), has been observed in some resistant species.\n2. One mechanism of resistance is mutation in or loss of [outer membrane](Bacterial_outer_membrane) [porins](Porin_(protein)), preventing antibiotics from entering the cells.[22] Changes within the porin protein gene cause a [frameshift](Frameshift_mutation), altering the porin structure and function.[22] Changes in the porin protein hinder the diffusion of carbapenem and other antibiotics into the periplasm.[23] Bacteria that express plasmid-borne [extended-spectrum Î²-lactamases (ESBL)](Î²-lactamase) can become carbapenem-resistant if an [insertion sequence](Insertion_sequence) or four-nucleotide duplication is present within chromosomal genes for outer membrane porin proteins.[22] _Klebsiella pneumoniae_ has been associated with the lack of outer membrane porin proteins, OmpK35 and OmpK36. The loss of OmpK36 porins can be attributed to point mutations that result in premature termination of translation, resulting in a truncated and consequently nonfunctional protein.[24] These outer membrane proteins are involved in the transfer of the antimicrobial genetic material in the cell. Loss of either OmpK35 and OmpK36 or only OmpK36[24] leads to carbapenem resistance. In _Klebsiella pneumoniae_ , the lack of either OmpK35 or OmpK36 leads to carbapenem resistance, but with the lack of both proteins, a high level of resistance is present.[25] An observed 32- to 64-fold increase in [minimum inhibitory concentrations](Minimum_inhibitory_concentration) occurs for the carbapenems when both proteins are not expressed.[25]\n3. CRE produce carbapenemases, a form of Î²-lactamase.[24] These enzymes cleave the [Î²-lactam](Î²-lactam) ring, an essential component of Î²-lactam antibiotics that are recognized by and bound to PBPs. Carbapenemases are divided into different classes, depending on the structure of the enzyme and the mechanism by which they hydrolyze the Î²-lactam ring. The two broad categories of carbapenemases are serine-carbapenemases, which contain serine at the active site, and metallocarbapenemases, which contain zinc at the active site. Class A carbapenemases are serine carbapenemases and are encoded on either the chromosome of the bacteria or a plasmid. A serine at position 70 at the active site of this class of enzymes is required for hydrolysis of Î²-lactams to occur. Class D carbapenemases, also referred to as the OXA Î²-lactamases, are serine Î²-lactamases. They are encoded on plasmids and contain a large variability in amino acid sequence. The resistance mechanism for class D carbapenemases is caused by the formation of an acyl intermediate when breaking the Î²-lactam ring. Class B carbapenemases are metallolactamases and require a zinc at the active site for hydrolysis.[26][27][28] Recent studies (as of 2023) highlight emerging co-production of multiple carbapenemases, such as KPC and NDM, and novel variants like KPC-31 resistant to ceftazidime-avibactam, contributing to multidrug resistance.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10305383/)\n4. A clinical [isolate](Isolation_(microbiology)) of _E. coli_ from the sputum sample of a patient admitted to a [Beijing](Beijing) hospital was found to acquire resistance to carbapenem through mutations not previously observed. It involved a mutation of a [regulator gene](Regulator_gene) _marR_ and the [expression](Gene_expression) of a normally non[translated](Translation_(biology)) membrane porin yedS; both mutations were demonstrated to have effects on the ability of this strain of _E.coli_ to resist carbapenems. The strain lacked the [outer membrane proteins](Virulence-related_outer_membrane_protein_family) OmpF and OmpC, and showed increased expression of a multidrug [efflux pump](Efflux_(microbiology)), but did not produce carbapenemase.[29][30]\n\n### Transfer between bacteria\n\nGram-negative bacteria can develop and transfer Î²-lactam resistance (including carbapenem resistance) in many ways. They can generate new extended-spectrum Î²-lactamases (ESBL) from the existing spectrum of plasmid-mediated Î²-lactamases through amino acid substitution. They can acquire genes encoding ESBL from environmental bacteria. They can increase the expression of chromosome-encoded Î²-lactamase genes (_bla_ genes) due to regulatory gene and promoter sequence modifications. They can mobilize _bla_ genes through [integrons](Integron) or horizontal transfer of genomic islands into other gram-negative species and strains.[32][33] They can disseminate plasmid-mediated carbapenemases. Finally, they can lower or even inhibit the expression of porin genes.[34]\n\nThree major classes of enzymes are involved in carbapenem resistance: class A carbapenemases, class B metallo-Î²-lactamases (MBL), and class D Î²-lactamases (OXA). The four known groups of class A carbapenemases are: SME (three types associated with _S. marcescens_), IMI (present in _E. cloacae_), GES (16 variants thus far found in _P. aeruginosa_ predominantly but also found in _K. pneumoniae_ and _E. coli_), and KPC (10 types of _K. pneumoniae_ carbapenemase).[34] At the UVA Medical Center, a transfer mechanism of KPC-dependent carbapenem resistance was discovered in the transmission of a plasmid carrying the transposon (Tn4401), which contains the KPC gene (_bla_ KPC), to several bacteria including _Enterobacter cloacae_ , _Klebsiella oxytoca_ , _E. coli_ , and _Citrobacter freundii_.[35] The class B metallo-Î²-lactamases (MBLs) are found largely in gram-negative bacteria and environmental bacteria. The subclasses of MBL enzymes are B1, B2, and B3. MBLs have diverse enzymatic functions and have the ability to hydrolyze Î²-lactam antibiotics. The class D Î²-lactamases (OXA), which hydrolyze oxacillin, provide a good example of the variety of mechanisms that can be used to transfer resistance. The _bla_ OXA genes which encode OXA Î²-lactamases are found on both chromosomes and plasmids, and they have their natural reservoir in environmental bacteria and deep-sea microflora. Insertions in the vicinity of these genes have been shown to increase the strength of their promoters and increase resistance. Because of these characteristics, a wide geographic dissemination of OXA carbapenemase resistance in particular has occurred.[34]\n\nThe facilitated spread of carbapenem resistance appears to have multiple origins and repeated introduction into the UK of bacteria with the _bla_ OXA-48 gene via horizontal transfer of similar plasmids to pOXA-48a. A recent study in the UK examined 26 isolates of Enterobacteriaceae consisting of a diverse set of sequence types (ST) of _K. pneumoniae_ , _E. coli_ , and _Enterobacter cloacae_ producing OXA-48-like carbapenemases. Their findings included: \n\n* 25 of the 26 strains had the _bla_ OXA-48 gene. \n  * 21 of these isolates had resistance plasmids that could be transferred by conjugation; 20 of these transformants had the three functional genes, _repA_ , _traU_ , and _parA_ found in pOXA-48a.\n  * In ST38 _E. coli_ , no OXA-48 transconjugants were found and it only had the _parA_ gene.\n* The Indian strain of _K. pneumoniae_ had an OXA-181-encoding plasmid (which had higher resistance to carbapenem) and also could not be transferred by conjugation and had none of the three functional genes found in pOXA-48a.[36]\n\n#### Gram-negative bacteria\n\n[Outer membrane vesicles](Outer_membrane_vesicle) (OMVs), that can transfer DNA between bacterial cells, are produced by metabolically active bacterial cells, and the OMVs are not the result of [cell lysis](Cell_lysis) or cell death. Pathogenic strains can produce about 10-25 times more vesicles than a nonpathogenic strain making this highly relevant to carbapenem resistance transfer.[37] OMVs protect plasmids from being digested extracellularly by [nucleases](Nuclease) that may be found in the environment, thus favoring [horizontal gene transfer](Horizontal_gene_transfer).[37]\n## Laboratory analysis\n\n### Agar plate method\n\nVariations are seen in the media used for inoculation. Many studies use media with 1 to 2 mg/L of imipenem. However, bacteria that produce OXA-48 or OXA-181 result in low-level resistance, which cannot be detected efficiently due to the high concentration.[38] Therefore, more recent screening media use broth containing 0.5â€“1 mg/L [imipenem](Imipenem \"Imipenem\") or 0.5 mg/L [ertapenem](Ertapenem \"Ertapenem\"). The downsides to this approach include the delay of results from the inoculation and the inability to identify the type of carbapenemase. \n\n### Disc diffusion method\n\nThe disc diffusion method can be used by hospital laboratories to screen for CRE. In this technique, antibiotic discs are placed onto plates of Mueller Hinton agar that have already been inoculated with the sample strain. The plates are then incubated overnight at 37 Â°C. Following incubation, the zones of inhibition surrounding the various antibiotic discs are measured and compared with Clinical and Laboratory Standard Institute guidelines. Identification of KPCs, MBLs and OXAs can be achieved by demonstrating synergistic inhibition with [phenyl boronic acid](Phenyl_boronic_acid \"Phenyl boronic acid\"), [EDTA](Ethylenediaminetetraacetic_acid \"Ethylenediaminetetraacetic acid\") or neither, respectively.[39]\n\n### Confirmatory tests for carbapenemase production\n\nOnce CRE is suspected based on screening, confirmatory testing for carbapenemase production is recommended. The modified carbapenem inactivation method (mCIM), endorsed by the Clinical and Laboratory Standards Institute (CLSI) since 2015, is a phenotypic test that detects carbapenemase activity by assessing the inactivation of a carbapenem disk by the bacterial isolate, followed by evaluation of residual activity on an indicator organism. It has high sensitivity (\u003e99%) and specificity (\u003e99%) for most carbapenemases in Enterobacteriaceae and can be performed in standard labs with results in 18-24 hours.[](https://journals.asm.org/doi/10.1128/jcm.00193-17) For metallo-beta-lactamases, an enhanced version (eCIM) using EDTA is used. Genotypic methods, such as PCR, complement these for specific enzyme identification.\n\n### PCR method\n\nPCR-based screening methodologies are in the process of development for a number of genes responsible for resistance. They speed up detection and can readily differentiate between carbapenamase genes-sometimes in a multiplex format. Costs of PCR testing are decreasing and reliability of molecular based tests relates more to gene presence and gene expression for production of the relevant carbapenamase. Nested arbitrary PCR (ARB-PCR) was used during a 2007 CRE outbreak at the University of Virginia Medical Center to identify the specific _bla_ KPC plasmid involved in the transmission of the infection, and researchers suggest that ARB-PCR may also be used to identify other methods of CRE spread.[35]\n\n### MALDI-TOF MS\n\nAnother study used [matrix-assisted laser desorption ionization](Matrix-assisted_laser_desorption/ionization \"Matrix-assisted laser desorption/ionization\")-[time of flight mass spectrometry](Time_of_flight_mass_spectrometry \"Time of flight mass spectrometry\") (MALDI-TOF MS) to determine resistance patterns in bacteria from freshly positive blood cultures. MALDI-TOF MS can detect changes in mass to charge ratios. Cabapenem-resistant bacteria often employ Î²-lactamases, which physically disrupt the structure of Î²-lactam antibiotics. Since this causes a change in the mass of the antibiotic, resistant bacteria are detectable by MALDI-TOF MS. Accepted clinical tests often require an overnight incubation before reading the result, but MALDI-TOF MS can return results in just 4â€“5 hours. \n\nMALDI-TOF cannot detect resistant bacteria, which do not physically disrupt the Î²-lactam antibiotic, i.e. where no mass change occurs. Therefore, the method serves best as a first screen for patients admitted to the hospital, but should be followed with secondary testing.[40]\n# Prevention\n\nResearchers found environmental reservoirs of CRE bacteria in ICU sinks and drains. Despite multiple attempts to sterilize these sinks and drains, using detergents and steam, the hospital staff was unsuccessful in getting rid of the CRE. Due to the bacterial resistance to cleaning measures, staff should take extreme precaution in maintaining sterile environments in hospitals not yet infected with the CRE-resistant bacteria.[41]\n\nA major means of transmission is through sinks, so staff should take extra precaution in maintaining sterile conditions. Hospitals could reduce transmission by creating sinks with designs that could reduce backsplash. Another method to reduce transmission from sink to sink is to have sink brushes in each room that would be for cleaning that individual sink alone. Hospital staff should be trained to never dispose of clinical waste down the sinks in patient rooms. A hospital in Melbourne, Australia, implemented similar strategies as these to reduce transmission and prevent further infection of more ICU patients. Armed with the knowledge of their status as CRE transmission sites, hospitals must take special care to monitor CRE outbreaks within their wards. Efficient and accurate detection of CRE is the first step. Enterobacteriaceae are most commonly found in the intestinal flora. Using stool and rectal swabs are, thus, the most reliable methods for testing resistance.[41]\n\nA specific ICD-10-CM billing code (Z22.350) for carriers of carbapenem-resistant Enterobacterales was introduced effective October 1, 2023, aiding national tracking of CRE in the U.S. Another challenge facing efforts to control transmission is the fact that although long-term care facilities have been heavily indicated as the primary centers for incidence, amplification, and spread of CRE, studies that have controlled for this transmission have still found CRE spreading in other affiliated hospitals, indicating that long-term acute-care facilities are likely not the sole culprit in the spread of CRE and other multidrug-resistant organisms.[8]\n\nOne method found effective is to screen and isolate incoming patients from other facilities, and renew focus on hand washing. While challenges persist in antibiotic development due to resistance evolution, several new agents active against CRE, such as cefiderocol (approved 2019) and eravacycline (approved 2018), have been developed and authorized.[](https://www.fda.gov/news-events/press-announcements/fda-approves-new-antibiotic-treat-complicated-urinary-tract-and-complicated-intra-abdominal-infections)[](https://www.idsociety.org/practice-guideline/amr-guidance/) Studies have found that CRE incidence and prevalence can be reduced by applying targeted interventions including increased hygiene measures and equipment sterilization, even in populations where the prevalence of infection exceeds 50% of patients.[8] However, additional environmental cleaning to control transmission has not been verified by controlled trials.[42] The involvement of local and national public health authorities will likely be critical to ensure broader and more sustainable implementation of these measures. \n\nPrevention is a top priority for reducing person-to-person transmission of CRE. This is especially true because limited treatment options are available to use after carbapenem resistance develops. Most current research calls for a coordinated, multifaceted approach to infection prevention and containment, and the Centers for Disease Control and Prevention have issued guidelines for the control of CRE transmission.[43] In September 2025, the CDC reported a five-fold rise in New Delhi metallo-Î²-lactamase (NDM)-producing CRE infections from 2019 to 2023, highlighting the ongoing need for robust surveillance and prevention efforts.[](https://www.cdc.gov/media/releases/2025/2025-cdc-report-finds-sharp-rise-in-dangerous-drug-resistant-bacteria.html) Experts advocate for a proactive approach, based on the belief that it will be most cost-effective to combat the problem before it is established. However, when immediate financial and personnel resources are limited, healthcare administrators may be forced to respond reactively, aiming to reduce any further transmission.[44]\n\nAlthough a consensus exists for the need of prevention protocols, infection control practices often vary among hospitals, even within close geographic area. In a survey of 15 hospitals within the Toronto area, many hospitals employed varying combinations of basic infection control practices. Eight different practices were observed among the 15 hospitals, some of which included in the most recent publication of guidelines from the Public Health Agency of Canada.[45] Some of these recommendations include laboratory testing, active surveillance, screening (rectal swab, urine culture), hand hygiene, personal protective equipment, environmental cleaning, laundry waste management, and isolation with dedicated equipment and nursing staff. However, only five hospitals had written policies describing how to respond to an outbreak.[46] Many public health initiatives are moving towards a more standardized approach at multiple levels: among local facilities (especially long-term and acute care), regional hospitals, national institutions, and global practices. A standardized approach of prevention may help to more effectively reduce the emergence of CRE. \n\nAn infection control plan was implemented at the Kaplan Medical Center in Israel to control a hospital outbreak of carbapenem-resistant K. pneumoniae. The comprehensive plan included guidelines for cohorting patients in separate locations, cleaning with 1,000 ppm hypochlorite, screening for isolates from rectal swabs, and distribution of educational instruction sheets, lectures for all medical staff, and training. The hospital also implemented an automated computer system that updated patient charts when new cases were reported, if patients were carriers, and what precautions to take when dealing with such patients. This plan was evaluated in a quasiexperimental study through the incidence of clinical cases, the rate of cross-infection, and the rate of screening for carriage in admitted patients with increased risk of carriage. The study had a 16-fold decrease in the incidence of resistant K. pneumoniae, which was sustained for 30 months. The plan can provide a model for other hospitals to contain outbreaks of carbapenem-resistant bacteria.[47] A reduction in the use of unnecessary invasive devices, including urinary catheters, could help reduce CRE transmission.[8]\n\nSeveral methods have been tested for their effectiveness at improving thorough intensive-care unit environmental hygiene. A study conducted in 2010 across 3532 high risk environmental surfaces in 260 intensive care unit rooms in 27 acute-care hospitals (ICUs) assessed the consistency at which these surfaces met base line cleaning standards. Only 49.5% of the high-risk object surfaces were found to meet this baseline criterion. The least-cleaned objects were bathroom light switches, room door knobs, and bed pan cleaners. Significant improvements in ICU room cleaning was achieved through a structured approach that incorporated a simple, highly objective surface targeting method and repeated performance feedback to environmental surface personnel. Specific methods included implementing an objective evaluation process, environmental surfaces staff education, programmatic feedback, and continuous training to minimize the spread of hospital-associated infections. The authors noted an improvement in the thoroughness of cleaning at 71% from baseline for the entire group of hospitals involved.[48]\n# Treatments\n\n## Fosfomycin\n\nFosfomycin is an antimicrobial agent that inhibits UDP-N-acetylglucosamine enolpyruvyl transferase (MurA), an enzyme catalyzing an early step in bacterial cell wall synthesis. It has activity against some gram-negative and gram-positive aerobic bacteria, including certain multidrug-resistant Enterobacteriaceae. A systematic review of 17 antimicrobial susceptibility studies on fosfomycin against ESBL-producing Enterobacteriaceae found that 11 reported over 90% of isolates susceptible.[49] For CRE specifically, fosfomycin is recommended by IDSA guidelines (as of 2024) for uncomplicated cystitis if susceptible, particularly for _E. coli_, but not for complicated infections or non-urinary sites due to limited evidence.[49][](https://www.idsociety.org/practice-guideline/amr-guidance/)\n\nResistance to fosfomycin in Enterobacteriaceae is typically chromosomally encoded rather than plasmid-mediated, which may limit its spread but does not eliminate it in CRE contexts.\n\n## Tigecycline\n\nTigecycline, a glycylcycline antibiotic, exhibits activity against Enterobacteriaceae that display tetracycline resistance due to its higher affinity for ribosomal binding sites compared to tetracycline. A 2008 systematic review of 26 microbiological and 10 clinical studies found high in vitro susceptibility (\u003e90% by FDA criteria) for MDR _E. coli_ and _K. pneumoniae_, including some carbapenem-resistant isolates.[51] However, susceptibility varies by breakpoints (lower by EUCAST), and clinical use is limited.\n\nPer IDSA 2024 guidance, tigecycline is an alternative for CRE intra-abdominal or peritoneal infections but should be avoided for bloodstream infections, pneumonia, or urinary tract infections due to suboptimal pharmacokinetics, including low serum concentrations and rapid tissue distribution.[50][51][](https://www.idsociety.org/practice-guideline/amr-guidance/) It is not considered a first-line agent for carbapenemase-producing CRE.\n\n## Other antibiotics\n\nFor urinary tract infections associated with ESBL-producing Enterobacteriaceae, oral alternatives to fosfomycin include nitrofurantoin, pivmecillinam, and co-amoxiclav.[49] For CRE uncomplicated cystitis, IDSA recommends nitrofurantoin, trimethoprim-sulfamethoxazole, or fluoroquinolones if susceptible; for pyelonephritis or complicated UTI, ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol are preferred if applicable to the carbapenemase type.[49][](https://www.idsociety.org/practice-guideline/amr-guidance/)\n\nA case report described treatment of persistent CRE bacteremia in a patient with acute lymphoblastic leukemia using colistin, amikacin, tigecycline, and gentamicin during chemotherapy.[16] Colistin (a polymyxin) shows activity against some carbapenemase-producing CRE but resistance is emerging, and it is reserved for alternatives due to nephrotoxicity; IDSA suggests it in combination for severe infections like pneumonia or bloodstream infections when preferred agents are unavailable.[52][](https://www.idsociety.org/practice-guideline/amr-guidance/)\n\nCurrent IDSA 2024 guidance prefers monotherapy with active agents over combinations to prevent resistance. For KPC-producing CRE (most common in the US), preferred treatments outside the urinary tract include ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-cilastatin-relebactam; cefiderocol is an alternative. For metallo-beta-lactamase producers (e.g., NDM), ceftazidime-avibactam plus aztreonam or cefiderocol are preferred. For OXA-48-like, ceftazidime-avibactam is preferred.[52][](https://www.idsociety.org/practice-guidance/amr-guidance/) These agents were developed from earlier investigational Î²-lactamase inhibitors like avibactam (NXL104, approved 2015 in ceftazidime-avibactam) and relebactam (MK-7655, approved 2020 in imipenem-cilastatin-relebactam). Eravacycline, approved in 2018, is an alternative similar to tigecycline for certain sites but avoided for BSI and pneumonia.[52][](https://www.idsociety.org/practice-guideline/amr-guidance/)\n\nIn vitro studies suggest rifampin has synergistic activity with other agents against CRE, but clinical data are limited.[52]\n## Epidemiology\n\nPrior to 1992, CRE were relatively uncommon in the U.S. According to data from the National Nosocomial Infection Service, between 1986 and 1990, only 2.3% of 1825 Enterobacteriaceae isolates sampled were found to be resistant.[11]\n\nAccording to the U.S. Centers for Disease Control, CRE producing what was the most common type of carbapenem-destroying enzyme in 2001 were first detected in a North Carolina hospital in 1996.[54][55] Since then, they have been identified in health care facilities in 41 other states. In 2012, 3% of patients in Chicago-area ICUs carried CRE.[2] The same data indicated a 30% colonization rate in long-term care facilities (e.g. nursing homes), where patients are not symptomatic. During just the first half of 2012, almost 200 hospitals and long-term acute care facilities treated at least one patient infected with these bacteria.[3]\n\nCRE have become increasingly common in the US. As of 2025, the Centers for Disease Control and Prevention (CDC) reported a sharp rise in carbapenemase-producing CRE, particularly those producing New Delhi metallo-Î²-lactamase (NDM-CRE), with infections surging more than 460% between 2019 and 2023. Early 2024 data indicate levels remained at or above 2023 figures, with annual NDM-positive CRE cases in New York City increasing from 58 in 2019 to 388 in 2024. The Meropenem Yearly Susceptibility Test Information Collection Program noted that resistance within _K. pneumoniae_ alone increased from 0.6% in 2004 to 5.6% in 2008.[11] The first outbreak involving colistin-resistant, carbapenem-resistant _K. pneumoniae_ (CRKP) in the U.S. was discovered in Detroit, Michigan in 2009, involving three different healthcare institutions.[56] In an active surveillance study in seven U.S. states over two years, the crude overall incidence of CRE was 2.93 per 100,000 population. Georgia and Maryland had a significantly higher than predicted incidence adjusted for age and race.[6]\n\nIncreases in CRE have not been limited to the US. By 2011, CRE was reported in at least 22 countries.[11] The European Centre for Disease Prevention and Control (ECDC) assessed CRE as a significant ongoing threat in Europe as of February 2025, with high mortality risks associated with infections like those caused by _K. pneumoniae_ and _E. coli_. Global systematic reviews from 2024 indicate rising prevalence, particularly of NDM-producing strains in Asia, and overall increasing trends in carbapenem-resistant Enterobacteriaceae across regions.[11] Between 2009 and 2012, 10 cases of CRE infections were documented in ICU patients in a Melbourne, Australia, hospital.[41]\n\nSome cases of CRE are associated with receipt of medical care in the US. Strains found in Israel had genetic similarity to strains from the US.[41] Hospital handwashing stations were found to be environmental reservoirs for CRE after screening all wet-area locations, including sinks, water fountains, and ice machines. The main reservoirs for CRE were the ICU sinks, and inappropriate cleaning methods accounted for transmission from sink to sink. The CRE strains in the sinks and the strains infecting the ICU patients were identical per genetic analysis. At-risk patients were being infected in the hospital setting.[41]\n\nA study, conducted in 2016â€“2017 at a pediatric hospital in Kathmandu, Nepal, detected the presence of the blaNDM-1 gene among carbapenem-resistant Escherichia coli and Klebsiella pneumoniae isolates confirmed by the Modified Hodge Test, analyzing 1503 clinical samples collected over six months. Genetic analysis revealed that half of the E. coli and two-thirds of the K. pneumoniae carbapenemase-producing isolates carried the blaNDM-1 gene, highlighting the prevalence of this resistance mechanism in Nepal.[57]\n\n### Mortality\n\nCRE resistance depends upon a number of factors such as the health of the patient, whether the patient has recently undergone a transplant, risk of co-infection, and use of multiple antibiotics.[58] Carbapenem minimal inhibitory concentrations (MICs) results may be more predictive of clinical patient outcomes than the current categorical classification of the MICs being listed as susceptible, intermediate, or resistant.[59] The study aimed to define an all-cause hospital mortality breakpoint for carbapenem MICs that were adjusted for risk factors. Another objective was to determine if a similar breakpoint existed for indirect outcomes, such as the time to death and length of stay after infection for survivors. Seventy-one patients were included, of which 52 patients survived and 19 patients died. Classification and regression tree analysis determined a split of organism MIC between 2 and 4 mg/liter and predicted differences in mortality (16.1% for 2 mg/liter versus 76.9% for 4 mg/liter). In logistic regression controlling for confounders, each imipenem MIC doubling dilution doubled the probability of death. This classification scheme correctly predicted 82.6% of cases. Patients were accordingly stratified to MICs of â‰¤2 mg/liter (58 patients) and â‰¥4 mg/liter (13 patients). Patients in the group with a MIC of â‰¥4 mg/liter tended to be more ill. Secondary outcomes were also similar between groups. Patients with organisms that had an MIC of â‰¥4 mg/liter had worse outcomes than those with isolates of an MIC of â‰¤2 mg/liter.[59]\n\nAt New York Presbyterian Hospital, part of Columbia University Medical Center in New York, NY, a study was conducted on the significant rise in carbapenem resistance in _K. pneumoniae_ from 1999 to 2007. Following a positive blood culture from a patient, overall mortality was 23% in 7 days, 42% in 30 days, and 60% by the end of hospitalization. The overall in-hospital mortality rate was 48%.[60]\n\nAt Soroka Medical Center, an Israeli university teaching hospital, a study was done between October 2005 and October 2008 to determine the direct mortality rate associated with carbapenem-resistant _K. pneumoniae_ bloodstream infections. The crude mortality rate for those with the resistant bacteremia was 71.9%, and the attributable mortality rate was determined to be 50% with a 95% confidence interval. The crude mortality rate for control subjects was 21.9%. As a result of the study, Soroka Medical Center started an intensive program designed to prevent the spread of carbapenem-resistant _K. pneumoniae_.[61]\n\nA 2013 retrospective study at the Shaare Zedek Medical Center of patients with urinary tract infections (bacteriuria) caused by carbapenem-resistant _Klebsiella pneumoniae_ (CRKp) showed no statistically significant difference in mortality rates from patients with bacteriuria caused by carbapenem-susceptible _K. pneumoniae_ (CSKp). A 29% mortality rate was seen in patients with CRKp infection compared to a 25% mortality rate in patients with CSKp infections that produced extended-spectrum beta-lactamase (ESBL). Both mortality rates were considerably higher than that of patients with drug-susceptible urosepsis.[14] Most patients in the study had other illnesses, including dementia, immune compromise, kidney failure, or diabetes mellitus. The main risk factor for death found by the study was being bedridden, which significantly increased the chance of death. This suggests that the deaths were due to reasons other than bacteriuria. Total length of hospitalization was somewhat longer in patients with CRKp infections (28 Â± 33 days compared to 22 Â± 28 days for patients with CSKp infection).[14]\n\nIn a case-control study of 99 patients compared with 99 controls at Mount Sinai Hospital (Manhattan), a 1,171 bed tertiary care teaching hospital, 38% of patients in long-term care that were affected by CRE died from _K. pneumoniae_ infection. Patients had risk factors including diabetes, HIV infection, heart disease, liver disease, chronic kidney disease, one was a transplant recipient. 72% of patients who were released from the hospital with CRE were readmitted within 90 days.[62] A 2008 study at Mount Sinai identified outcomes associated with Carbapenem-resistant _K. pneumoniae_ infections, in which patients in need of organ or stem cell transplants, mechanical ventilation, prolonged hospitalization, or prior treatment with carbapenems, had an increased probability of infection with Carbapenem-resistant _K. pneumoniae_. A combination of antibiotics worked to treat infection and survival rates of infected patients increased when the focus of infection was removed.[63]\n\nCRE infections can set in about 12 days after liver transplantation, and 18% of those patients died a year after transplantation in a 2012 study.[64] Recent studies indicate high mortality persists; for example, a 2025 analysis of enterobacterial bloodstream infections reported an overall lethality rate of 37.7% among CRE cases, with rates up to 80% for severe bloodstream infections.[24][26]\n## Public health implications\n\n### Bacterial survival on surfaces\n\nStudies have found prolonged viability of bacteria on stainless-steel surfaces at room temperature. In a specific study, [stainless steel](Stainless_steel \"Stainless steel\") was inoculated with 107 CFU/cm2 _E. coli_ and _K. pneumoniae_ , containing blaCTX-M-15 and blaNDM-1 (antibiotic-resistant genes) respectively. Thirty days later (at room temperature, 22Ëš C), 104 viable cells remained; and, after 100 days, 100 CFU/cm2 of _E. coli_ remained.[65] Subsequent studies, including a 2024 review, have confirmed copper's antimicrobial activity against CRE and other multidrug-resistant bacteria on hospital surfaces, with reductions in microbial load of up to 83% in clinical trials.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11920907/)\n\nIn contrast, on [copper](Copper \"Copper\") and copper alloy surfaces, rapid death of antibiotic-resistant bacterial strains, as well as destruction of plasmid and genomic DNA, can be observed. Studies suggest that exposure to dry copper surfaces inhibits the respiration and growth of producers by releasing copper ions.[65]\n\nIncreased horizontal gene transfer (HGT) is observed simultaneously with cell viability on stainless steel surfaces. HGT is one of the major factors responsible for creating antibiotic resistance in bacteria. This suggests that immediate decontamination of surfaces is important in preventing the spread of antibiotic resistance genes. It has also been shown that horizontal transfer of antibiotic-resistant Î²-lactamase genes does not occur on antimicrobial copper surfaces. As copper surfaces degrade naked DNA (and plasmid DNA in antibiotic-resistant _E. coli_ and _K. pneumoniae_), copper surfaces would halt HGT.[65]\n\nHorizontal gene transfer has been demonstrated to occur readily on dry surfaces such as stainless steel, but not on copper and copper alloy surfaces. The rate of bacterial death increased proportionally with the percentage of copper in the copper alloy surface. This can be very important in future clinical and community settings, as an increase in copper utilization in hospital room equipment could help to greatly reduce the spread of antibiotic-resistant infection and the horizontal gene transfer of this antibiotic resistance.[65] However, recent research has shown that exposure to copper surfaces may promote the evolution of copper resistance in Enterobacteriaceae, potentially leading to co-selection of antibiotic resistance traits, which warrants further investigation for sustained use in healthcare environments.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11190421/)"])</script><script nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli">self.__next_f.push([1,"8:[\"$\",\"$L1e\",null,{\"state\":{\"mutations\":[],\"queries\":[{\"dehydratedAt\":1761886055962,\"state\":{\"data\":{\"page\":{\"citations\":[{\"id\":\"1\",\"title\":\"** [\\\"Carbapenemase-producing Enterobacterales\\\"](https://www.health.nsw.gov.au/Infectious/diseases/Pages/cpe.aspx). _www.health.nsw.gov.au_. Retrieved 2025-07-27.\",\"description\":\"1. **^** [\\\"Carbapenemase-producing Enterobacterales\\\"](https://www.health.nsw.gov.au/Infectious/diseases/Pages/cpe.aspx). _www.health.nsw.gov.au_. Retrieved 2025-07-27.\",\"url\":\"https://www.health.nsw.gov.au/Infectious/diseases/Pages/cpe.aspx\",\"favicon\":\"\"},{\"id\":\"2\",\"title\":\"_**a**_ _**b**_ _**c**_ Peter Eisler (November 29, 2012). [\\\"Deadly superbugs invade U.S. health care facilities\\\"](https://www.usatoday.com/story/news/nation/2012/11/29/bacteria-deadly-hospital-infection/1727667/). USA Today. Retrieved December 1, 2012.\",\"description\":\"2. ^ _**a**_ _**b**_ _**c**_ Peter Eisler (November 29, 2012). [\\\"Deadly superbugs invade U.S. health care facilities\\\"](https://www.usatoday.com/story/news/nation/2012/11/29/bacteria-deadly-hospital-infection/1727667/). USA Today. Retrieved December 1, 2012.\",\"url\":\"https://www.usatoday.com/story/news/nation/2012/11/29/bacteria-deadly-hospital-infection/1727667/\",\"favicon\":\"\"},{\"id\":\"3\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ [\\\"CDC: Action needed now to halt spread of deadly bacteria: Data show more inpatients suffering infections from bacteria resistant to all or nearly all antibiotics\\\"](https://www.cdc.gov/media/releases/2013/p0305_deadly_bacteria.html) (Press release). The Centers for Disease Control. March 5, 2013. Retrieved March 5, 2013. \\\"During just the first half of 2012, almost 200 hospitals and long-term acute-care facilities treated at least one patient infected with these bacteria.\\\"\",\"description\":\"3. ^ _**a**_ _**b**_ _**c**_ _**d**_ [\\\"CDC: Action needed now to halt spread of deadly bacteria: Data show more inpatients suffering infections from bacteria resistant to all or nearly all antibiotics\\\"](https://www.cdc.gov/media/releases/2013/p0305_deadly_bacteria.html) (Press release). The Centers for Disease Control. March 5, 2013. Retrieved March 5, 2013. \\\"During just the first half of 2012, almost 200 hospitals and long-term acute-care facilities treated at least one patient infected with these bacteria.\\\"\",\"url\":\"https://www.cdc.gov/media/releases/2013/p0305_deadly_bacteria.html\",\"favicon\":\"\"},{\"id\":\"4\",\"title\":\"** Breslow, Jason (8 Jan 2014). [\\\"Illinois \\\"Nightmare Bacteria\\\" Outbreak Raises Alarms\\\"](https://www.pbs.org/wgbh/frontline/article/illinois-nightmare-bacteria-outbreak-raises-alarms/). _PBS.org_. Retrieved 24 Apr 2014.\",\"description\":\"4. **^** Breslow, Jason (8 Jan 2014). [\\\"Illinois \\\"Nightmare Bacteria\\\" Outbreak Raises Alarms\\\"](https://www.pbs.org/wgbh/frontline/article/illinois-nightmare-bacteria-outbreak-raises-alarms/). _PBS.org_. Retrieved 24 Apr 2014.\",\"url\":\"https://www.pbs.org/wgbh/frontline/article/illinois-nightmare-bacteria-outbreak-raises-alarms/\",\"favicon\":\"\"},{\"id\":\"5\",\"title\":\"** [\\\"Pseudomonas aeruginosa - HAI\\\"](https://www.cdc.gov/hai/outbreaks/pseudomonas-aeruginosa.html). _CDC_. February 2021. Retrieved 13 April 2022.\",\"description\":\"5. **^** [\\\"Pseudomonas aeruginosa - HAI\\\"](https://www.cdc.gov/hai/outbreaks/pseudomonas-aeruginosa.html). _CDC_. February 2021. Retrieved 13 April 2022.\",\"url\":\"https://www.cdc.gov/hai/outbreaks/pseudomonas-aeruginosa.html\",\"favicon\":\"\"},{\"id\":\"6\",\"title\":\"_**a**_ _**b**_ Guh Alice Y.; Bulens Sandra N.; Mu Yi; Jacob Jesse T.; Reno Jessica; et al. (2015). [\\\"Epidemiology of Carbapenem-Resistant Enterobacteriaceae in 7 US Communities, 2012-2013\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6492240). _JAMA_. **314** (14): 1479â€“87\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1001/jama.2015.12480](https://doi.org/10.1001%2Fjama.2015.12480). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [6492240](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6492240). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [26436831](https://pubmed.ncbi.nlm.nih.gov/26436831).\",\"description\":\"6. ^ _**a**_ _**b**_ Guh Alice Y.; Bulens Sandra N.; Mu Yi; Jacob Jesse T.; Reno Jessica; et al. (2015). [\\\"Epidemiology of Carbapenem-Resistant Enterobacteriaceae in 7 US Communities, 2012-2013\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6492240). _JAMA_. **314** (14): 1479â€“87\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1001/jama.2015.12480](https://doi.org/10.1001%2Fjama.2015.12480). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [6492240](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6492240). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [26436831](https://pubmed.ncbi.nlm.nih.gov/26436831).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6492240\",\"favicon\":\"\"},{\"id\":\"7\",\"title\":\"** Perez, F; Van Duin, D (2013). [\\\"Carbapenem-resistant Enterobacteriaceae: A menace to our most vulnerable patients\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3960994). _Cleveland Clinic Journal of Medicine_. **80** (4): 225â€“33\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.3949/ccjm.80a.12182](https://doi.org/10.3949%2Fccjm.80a.12182). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3960994](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3960994). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [23547093](https://pubmed.ncbi.nlm.nih.gov/23547093).\",\"description\":\"7. **^** Perez, F; Van Duin, D (2013). [\\\"Carbapenem-resistant Enterobacteriaceae: A menace to our most vulnerable patients\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3960994). _Cleveland Clinic Journal of Medicine_. **80** (4): 225â€“33\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.3949/ccjm.80a.12182](https://doi.org/10.3949%2Fccjm.80a.12182). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3960994](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3960994). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [23547093](https://pubmed.ncbi.nlm.nih.gov/23547093).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3960994\",\"favicon\":\"\"},{\"id\":\"8\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ Chitnis, AS; Caruthers, PS; Rao, AK; Lamb, J; Lurvey, R; Beau De Rochars, V; Kitchel, B; Cancio, M; et al. (2012). [\\\"Outbreak of carbapenem-resistant enterobacteriaceae at a long-term acute care hospital: Sustained reductions in transmission through active surveillance and targeted interventions\\\"](https://zenodo.org/record/1235704). _Infection Control and Hospital Epidemiology_. **33** (10): 984â€“92\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1086/667738](https://doi.org/10.1086%2F667738). [JSTOR](JSTOR_\\\\(identifier\\\\) \\\"JSTOR \\\\(identifier\\\\)\\\") [667738](https://www.jstor.org/stable/667738). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22961017](https://pubmed.ncbi.nlm.nih.gov/22961017). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [27480055](https://api.semanticscholar.org/CorpusID:27480055).\",\"description\":\"8. ^ _**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ Chitnis, AS; Caruthers, PS; Rao, AK; Lamb, J; Lurvey, R; Beau De Rochars, V; Kitchel, B; Cancio, M; et al. (2012). [\\\"Outbreak of carbapenem-resistant enterobacteriaceae at a long-term acute care hospital: Sustained reductions in transmission through active surveillance and targeted interventions\\\"](https://zenodo.org/record/1235704). _Infection Control and Hospital Epidemiology_. **33** (10): 984â€“92\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1086/667738](https://doi.org/10.1086%2F667738). [JSTOR](JSTOR_\\\\(identifier\\\\) \\\"JSTOR \\\\(identifier\\\\)\\\") [667738](https://www.jstor.org/stable/667738). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22961017](https://pubmed.ncbi.nlm.nih.gov/22961017). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [27480055](https://api.semanticscholar.org/CorpusID:27480055).\",\"url\":\"https://zenodo.org/record/1235704\",\"favicon\":\"\"},{\"id\":\"9\",\"title\":\"** Choi, JP; Cho, EH; Lee, SJ; Lee, ST; Koo, MS; Song, YG (2012). \\\"Influx of multidrug resistant, Gram-negative bacteria (MDRGNB) in a public hospital among elderly patients from long-term care facilities: a single-center pilot study\\\". _Archives of Gerontology and Geriatrics_. **54** (Marchâ€“April): 19â€“22\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.archger.2011.05.026](https://doi.org/10.1016%2Fj.archger.2011.05.026). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [21764147](https://pubmed.ncbi.nlm.nih.gov/21764147).\",\"description\":\"9. **^** Choi, JP; Cho, EH; Lee, SJ; Lee, ST; Koo, MS; Song, YG (2012). \\\"Influx of multidrug resistant, Gram-negative bacteria (MDRGNB) in a public hospital among elderly patients from long-term care facilities: a single-center pilot study\\\". _Archives of Gerontology and Geriatrics_. **54** (Marchâ€“April): 19â€“22\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.archger.2011.05.026](https://doi.org/10.1016%2Fj.archger.2011.05.026). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [21764147](https://pubmed.ncbi.nlm.nih.gov/21764147).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"10\",\"title\":\"_**a**_ _**b**_ Savard, P; Perl, TM (2012). \\\"A call for action: managing the emergence of multidrug-resistant Enterobacteriaceae in the acute care settings\\\". _Current Opinion in Infectious Diseases_. **25** (4): 371â€“7\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1097/QCO.0b013e3283558c17](https://doi.org/10.1097%2FQCO.0b013e3283558c17). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22766646](https://pubmed.ncbi.nlm.nih.gov/22766646). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [23670404](https://api.semanticscholar.org/CorpusID:23670404).\",\"description\":\"10. ^ _**a**_ _**b**_ Savard, P; Perl, TM (2012). \\\"A call for action: managing the emergence of multidrug-resistant Enterobacteriaceae in the acute care settings\\\". _Current Opinion in Infectious Diseases_. **25** (4): 371â€“7\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1097/QCO.0b013e3283558c17](https://doi.org/10.1097%2FQCO.0b013e3283558c17). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22766646](https://pubmed.ncbi.nlm.nih.gov/22766646). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [23670404](https://api.semanticscholar.org/CorpusID:23670404).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"11\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ _**e**_ Gupta, N.; Limbago, B. M.; Patel, J. B.; Kallen, A. J. (2011). \\\"Carbapenem-Resistant Enterobacteriaceae: Epidemiology and Prevention\\\". _Clinical Infectious Diseases_. **53** (1): 60â€“7\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1093/cid/cir202](https://doi.org/10.1093%2Fcid%2Fcir202). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [21653305](https://pubmed.ncbi.nlm.nih.gov/21653305).\",\"description\":\"11. ^ _**a**_ _**b**_ _**c**_ _**d**_ _**e**_ Gupta, N.; Limbago, B. M.; Patel, J. B.; Kallen, A. J. (2011). \\\"Carbapenem-Resistant Enterobacteriaceae: Epidemiology and Prevention\\\". _Clinical Infectious Diseases_. **53** (1): 60â€“7\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1093/cid/cir202](https://doi.org/10.1093%2Fcid%2Fcir202). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [21653305](https://pubmed.ncbi.nlm.nih.gov/21653305).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"12\",\"title\":\"** Debby, B.D.; Ganor, O.; Yasmin, M.; David, L.; Nathan, K.; Ilana, T.; Dalit, S.; Smollan, G.; Galia, R. (August 2012). [\\\"Epidemiology of carbapenem resistant Klebsiella pneumoniae colonization in an intensive care unit\\\"](https://doi.org/10.1007%2Fs10096-011-1506-5). _European Journal of Clinical Microbiology \u0026 Infectious Diseases_. **31** (8): 1811â€“7\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1007/s10096-011-1506-5](https://doi.org/10.1007%2Fs10096-011-1506-5). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22246509](https://pubmed.ncbi.nlm.nih.gov/22246509). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [18052294](https://api.semanticscholar.org/CorpusID:18052294).\",\"description\":\"12. **^** Debby, B.D.; Ganor, O.; Yasmin, M.; David, L.; Nathan, K.; Ilana, T.; Dalit, S.; Smollan, G.; Galia, R. (August 2012). [\\\"Epidemiology of carbapenem resistant Klebsiella pneumoniae colonization in an intensive care unit\\\"](https://doi.org/10.1007%2Fs10096-011-1506-5). _European Journal of Clinical Microbiology \u0026 Infectious Diseases_. **31** (8): 1811â€“7\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1007/s10096-011-1506-5](https://doi.org/10.1007%2Fs10096-011-1506-5). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22246509](https://pubmed.ncbi.nlm.nih.gov/22246509). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [18052294](https://api.semanticscholar.org/CorpusID:18052294).\",\"url\":\"https://doi.org/10.1007%2Fs10096-011-1506-5\",\"favicon\":\"\"},{\"id\":\"13\",\"title\":\"** Teo, J; Cai, Y; Tang, S; Lee, W; Tan, TY; Tan, TT; Kwa, AL (2012). Spellberg, Brad (ed.). [\\\"Risk Factors, Molecular Epidemiology and Outcomes of Ertapenem-Resistant, Carbapenem-Susceptible Enterobacteriaceae: A Case-Case-Control Study\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3312905). _PLOS ONE_. **7** (3): e34254. [Bibcode](Bibcode_\\\\(identifier\\\\) \\\"Bibcode \\\\(identifier\\\\)\\\"):[2012PLoSO...734254T](https://ui.adsabs.harvard.edu/abs/2012PLoSO...734254T). [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1371/journal.pone.0034254](https://doi.org/10.1371%2Fjournal.pone.0034254). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3312905](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3312905). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22461908](https://pubmed.ncbi.nlm.nih.gov/22461908).\",\"description\":\"13. **^** Teo, J; Cai, Y; Tang, S; Lee, W; Tan, TY; Tan, TT; Kwa, AL (2012). Spellberg, Brad (ed.). [\\\"Risk Factors, Molecular Epidemiology and Outcomes of Ertapenem-Resistant, Carbapenem-Susceptible Enterobacteriaceae: A Case-Case-Control Study\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3312905). _PLOS ONE_. **7** (3): e34254. [Bibcode](Bibcode_\\\\(identifier\\\\) \\\"Bibcode \\\\(identifier\\\\)\\\"):[2012PLoSO...734254T](https://ui.adsabs.harvard.edu/abs/2012PLoSO...734254T). [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1371/journal.pone.0034254](https://doi.org/10.1371%2Fjournal.pone.0034254). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3312905](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3312905). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22461908](https://pubmed.ncbi.nlm.nih.gov/22461908).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3312905\",\"favicon\":\"\"},{\"id\":\"14\",\"title\":\"_**a**_ _**b**_ _**c**_ Shilo, S; Assous, MV; Lachish, T; Kopuit, P; Bdolah-Abram, T; Yinnon, AM; Wiener-Well, Y (2013). \\\"Risk factors for bacteriuria with carbapenem-resistant Klebsiella pneumoniae and its impact on mortality: A case-control study\\\". _Infection_. **41** (2): 503â€“9\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1007/s15010-012-0380-0](https://doi.org/10.1007%2Fs15010-012-0380-0). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [23271210](https://pubmed.ncbi.nlm.nih.gov/23271210). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [10515716](https://api.semanticscholar.org/CorpusID:10515716).\",\"description\":\"14. ^ _**a**_ _**b**_ _**c**_ Shilo, S; Assous, MV; Lachish, T; Kopuit, P; Bdolah-Abram, T; Yinnon, AM; Wiener-Well, Y (2013). \\\"Risk factors for bacteriuria with carbapenem-resistant Klebsiella pneumoniae and its impact on mortality: A case-control study\\\". _Infection_. **41** (2): 503â€“9\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1007/s15010-012-0380-0](https://doi.org/10.1007%2Fs15010-012-0380-0). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [23271210](https://pubmed.ncbi.nlm.nih.gov/23271210). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [10515716](https://api.semanticscholar.org/CorpusID:10515716).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"15\",\"title\":\"** Landman, David; Elizabeth Babu; Neha Shah; Paul Kelly; Olafisoye Olawole; Martin Backer; Simona Bratu; John Quale (6 February 2012). [\\\"Transmission of carbapenem-resistant pathogens in New York City hospitals: progress and frustration\\\"](https://doi.org/10.1093%2Fjac%2Fdks063). _Journal of Antimicrobial Chemotherapy_. **67** (6): 1427â€“1431\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1093/jac/dks063](https://doi.org/10.1093%2Fjac%2Fdks063). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22378678](https://pubmed.ncbi.nlm.nih.gov/22378678).\",\"description\":\"15. **^** Landman, David; Elizabeth Babu; Neha Shah; Paul Kelly; Olafisoye Olawole; Martin Backer; Simona Bratu; John Quale (6 February 2012). [\\\"Transmission of carbapenem-resistant pathogens in New York City hospitals: progress and frustration\\\"](https://doi.org/10.1093%2Fjac%2Fdks063). _Journal of Antimicrobial Chemotherapy_. **67** (6): 1427â€“1431\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1093/jac/dks063](https://doi.org/10.1093%2Fjac%2Fdks063). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22378678](https://pubmed.ncbi.nlm.nih.gov/22378678).\",\"url\":\"https://doi.org/10.1093%2Fjac%2Fdks063\",\"favicon\":\"\"},{\"id\":\"16\",\"title\":\"_**a**_ _**b**_ Muchtar, E; Paul, M; Horowitz, A; Shpilberg, O; Raanani, P (March 2012). \\\"Persistent carbapenem-resistant Klebsiella pneumoniae bacteremia in a patient with acute lymphoblastic leukemia\\\". _The Israel Medical Association Journal_. **14** (3): 195â€“7\\\\. [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22675865](https://pubmed.ncbi.nlm.nih.gov/22675865).\",\"description\":\"16. ^ _**a**_ _**b**_ Muchtar, E; Paul, M; Horowitz, A; Shpilberg, O; Raanani, P (March 2012). \\\"Persistent carbapenem-resistant Klebsiella pneumoniae bacteremia in a patient with acute lymphoblastic leukemia\\\". _The Israel Medical Association Journal_. **14** (3): 195â€“7\\\\. [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22675865](https://pubmed.ncbi.nlm.nih.gov/22675865).\",\"url\":\"PMID_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"17\",\"title\":\"** [\\\"Design of Endoscopic Retrograde Cholangiopancreatography (ERCP) Duodenoscopes May Impede Effective Cleaning: FDA Safety Communication\\\"](https://web.archive.org/web/20150220024405/http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm434871.htm). _fda.gov_. 20 February 2015. Archived from [the original](http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm434871.htm) on 20 February 2015. Retrieved 13 April 2022.\",\"description\":\"17. **^** [\\\"Design of Endoscopic Retrograde Cholangiopancreatography (ERCP) Duodenoscopes May Impede Effective Cleaning: FDA Safety Communication\\\"](https://web.archive.org/web/20150220024405/http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm434871.htm). _fda.gov_. 20 February 2015. Archived from [the original](http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm434871.htm) on 20 February 2015. Retrieved 13 April 2022.\",\"url\":\"https://web.archive.org/web/20150220024405/http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm434871.htm\",\"favicon\":\"\"},{\"id\":\"18\",\"title\":\"** Steve Gorman (20 February 2015). [\\\"L.A. hospital warns 179 patients possibly exposed to 'superbug'\\\"](https://www.reuters.com/article/us-usa-ucla-bacteria-idUSKBN0LN0ZS20150219). _Reuters_. [Archived](https://web.archive.org/web/20150220011923/http://www.reuters.com/article/2015/02/19/us-usa-ucla-bacteria-idUSKBN0LN0ZS20150219) from the original on 20 February 2015. Retrieved 20 February 2015.\",\"description\":\"18. **^** Steve Gorman (20 February 2015). [\\\"L.A. hospital warns 179 patients possibly exposed to 'superbug'\\\"](https://www.reuters.com/article/us-usa-ucla-bacteria-idUSKBN0LN0ZS20150219). _Reuters_. [Archived](https://web.archive.org/web/20150220011923/http://www.reuters.com/article/2015/02/19/us-usa-ucla-bacteria-idUSKBN0LN0ZS20150219) from the original on 20 February 2015. Retrieved 20 February 2015.\",\"url\":\"https://www.reuters.com/article/us-usa-ucla-bacteria-idUSKBN0LN0ZS20150219\",\"favicon\":\"\"},{\"id\":\"19\",\"title\":\"** Sharon Begley, Toni Clarke (20 February 2015). [\\\"FDA knew devices spread fatal 'superbug' but does not order fix\\\"](https://www.reuters.com/article/us-usa-ucla-devices-idUSKBN0LO02Q20150220). _Reuters_. [Archived](https://web.archive.org/web/20150220020020/http://www.reuters.com/article/2015/02/20/us-usa-ucla-devices-idUSKBN0LO02Q20150220) from the original on 20 February 2015. Retrieved 20 February 2015.\",\"description\":\"19. **^** Sharon Begley, Toni Clarke (20 February 2015). [\\\"FDA knew devices spread fatal 'superbug' but does not order fix\\\"](https://www.reuters.com/article/us-usa-ucla-devices-idUSKBN0LO02Q20150220). _Reuters_. [Archived](https://web.archive.org/web/20150220020020/http://www.reuters.com/article/2015/02/20/us-usa-ucla-devices-idUSKBN0LO02Q20150220) from the original on 20 February 2015. Retrieved 20 February 2015.\",\"url\":\"https://www.reuters.com/article/us-usa-ucla-devices-idUSKBN0LO02Q20150220\",\"favicon\":\"\"},{\"id\":\"20\",\"title\":\"_**a**_ _**b**_ _**c**_ Nordman, P; Dortet L; Poirel L (May 2012). \\\"Carbapenem resistance in Enterobacteriaceae: here is the storm!\\\". _Trends in Molecular Medicine_. **18** (5doi=10.1016/j.molmed.2012.03.003): 263â€“72\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.molmed.2012.03.003](https://doi.org/10.1016%2Fj.molmed.2012.03.003). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22480775](https://pubmed.ncbi.nlm.nih.gov/22480775).\",\"description\":\"20. ^ _**a**_ _**b**_ _**c**_ Nordman, P; Dortet L; Poirel L (May 2012). \\\"Carbapenem resistance in Enterobacteriaceae: here is the storm!\\\". _Trends in Molecular Medicine_. **18** (5doi=10.1016/j.molmed.2012.03.003): 263â€“72\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.molmed.2012.03.003](https://doi.org/10.1016%2Fj.molmed.2012.03.003). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22480775](https://pubmed.ncbi.nlm.nih.gov/22480775).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"21\",\"title\":\"** Martin, SI; Kaye, KM (2004). \\\"Beta-lactam antibiotics: newer formulations and newer agents\\\". _Infectious Disease Clinics of North America_. **18** (3): 603â€“619\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.idc.2004.04.006](https://doi.org/10.1016%2Fj.idc.2004.04.006). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [15308278](https://pubmed.ncbi.nlm.nih.gov/15308278).\",\"description\":\"21. **^** Martin, SI; Kaye, KM (2004). \\\"Beta-lactam antibiotics: newer formulations and newer agents\\\". _Infectious Disease Clinics of North America_. **18** (3): 603â€“619\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.idc.2004.04.006](https://doi.org/10.1016%2Fj.idc.2004.04.006). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [15308278](https://pubmed.ncbi.nlm.nih.gov/15308278).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"22\",\"title\":\"_**a**_ _**b**_ _**c**_ Little, ML; Qin, X; Zerr, DM; Weissman, SJ (2012). [\\\"Molecular diversity in mechanisms of carbapenem resistance in paediatric Enterobacteriaceae\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3237943). _International Journal of Antimicrobial Agents_. **39** (1): 52â€“57\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.ijantimicag.2011.09.014](https://doi.org/10.1016%2Fj.ijantimicag.2011.09.014). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3237943](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3237943). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22055532](https://pubmed.ncbi.nlm.nih.gov/22055532).\",\"description\":\"22. ^ _**a**_ _**b**_ _**c**_ Little, ML; Qin, X; Zerr, DM; Weissman, SJ (2012). [\\\"Molecular diversity in mechanisms of carbapenem resistance in paediatric Enterobacteriaceae\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3237943). _International Journal of Antimicrobial Agents_. **39** (1): 52â€“57\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.ijantimicag.2011.09.014](https://doi.org/10.1016%2Fj.ijantimicag.2011.09.014). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3237943](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3237943). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22055532](https://pubmed.ncbi.nlm.nih.gov/22055532).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3237943\",\"favicon\":\"\"},{\"id\":\"23\",\"title\":\"** Logan, LK (2012). [\\\"Carbapenem-resistant enterobacteriaceae: an emerging problem in children\\\"](https://doi.org/10.1093%2Fcid%2Fcis543). _Clinical Infectious Diseases_. **55** (6): 852â€“859\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1093/cid/cis543](https://doi.org/10.1093%2Fcid%2Fcis543). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22700827](https://pubmed.ncbi.nlm.nih.gov/22700827).\",\"description\":\"23. **^** Logan, LK (2012). [\\\"Carbapenem-resistant enterobacteriaceae: an emerging problem in children\\\"](https://doi.org/10.1093%2Fcid%2Fcis543). _Clinical Infectious Diseases_. **55** (6): 852â€“859\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1093/cid/cis543](https://doi.org/10.1093%2Fcid%2Fcis543). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22700827](https://pubmed.ncbi.nlm.nih.gov/22700827).\",\"url\":\"https://doi.org/10.1093%2Fcid%2Fcis543\",\"favicon\":\"\"},{\"id\":\"24\",\"title\":\"_**a**_ _**b**_ _**c**_ Shin, So Youn; Bae, IK; Kim, J; Jeong, SH; Yong, D; Kim, JM; Lee, K (2012). \\\"Resistance to carbapenems in sequence type 11 _Klebsiella pneumoniae_ is related to DHA-1 and loss of OmpK35 and/or OmpK36\\\". _Journal of Medical Microbiology_. **61** (Pt 2): 239â€“245\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1099/jmm.0.037036-0](https://doi.org/10.1099%2Fjmm.0.037036-0). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [21940650](https://pubmed.ncbi.nlm.nih.gov/21940650).\",\"description\":\"24. ^ _**a**_ _**b**_ _**c**_ Shin, So Youn; Bae, IK; Kim, J; Jeong, SH; Yong, D; Kim, JM; Lee, K (2012). \\\"Resistance to carbapenems in sequence type 11 _Klebsiella pneumoniae_ is related to DHA-1 and loss of OmpK35 and/or OmpK36\\\". _Journal of Medical Microbiology_. **61** (Pt 2): 239â€“245\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1099/jmm.0.037036-0](https://doi.org/10.1099%2Fjmm.0.037036-0). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [21940650](https://pubmed.ncbi.nlm.nih.gov/21940650).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"25\",\"title\":\"_**a**_ _**b**_ Sho, Takehiko; Tetsuro Muratani; Ryoichi Hamasuna; Hiroko Yakushiji; Naohiro Fujimoto; Tetsuro Matsumoto (2013). \\\"The Mechanism of High-Level Carbapenem Resistance in _Klebsiella pneumoniae_ : Underlying Ompk36-Deficient Strains Represent a Threat of Emerging High-Level Carbapenem-Resistant K. pneumoniae with IMP-1 Î²-Lactamase Production in Japan\\\". _Microbial Drug Resistance_. **19** (4): 274â€“81\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1089/mdr.2012.0248](https://doi.org/10.1089%2Fmdr.2012.0248). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [23514607](https://pubmed.ncbi.nlm.nih.gov/23514607).\",\"description\":\"25. ^ _**a**_ _**b**_ Sho, Takehiko; Tetsuro Muratani; Ryoichi Hamasuna; Hiroko Yakushiji; Naohiro Fujimoto; Tetsuro Matsumoto (2013). \\\"The Mechanism of High-Level Carbapenem Resistance in _Klebsiella pneumoniae_ : Underlying Ompk36-Deficient Strains Represent a Threat of Emerging High-Level Carbapenem-Resistant K. pneumoniae with IMP-1 Î²-Lactamase Production in Japan\\\". _Microbial Drug Resistance_. **19** (4): 274â€“81\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1089/mdr.2012.0248](https://doi.org/10.1089%2Fmdr.2012.0248). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [23514607](https://pubmed.ncbi.nlm.nih.gov/23514607).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"26\",\"title\":\"** Nordmann, Patrice; et al. (May 2012). \\\"Carbapenem resistance in Enterobacteriaceae: here is the storm!\\\". _Trends in Molecular Medicine_. **18** (5): 263â€“272\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.molmed.2012.03.003](https://doi.org/10.1016%2Fj.molmed.2012.03.003). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22480775](https://pubmed.ncbi.nlm.nih.gov/22480775).\",\"description\":\"26. **^** Nordmann, Patrice; et al. (May 2012). \\\"Carbapenem resistance in Enterobacteriaceae: here is the storm!\\\". _Trends in Molecular Medicine_. **18** (5): 263â€“272\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.molmed.2012.03.003](https://doi.org/10.1016%2Fj.molmed.2012.03.003). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22480775](https://pubmed.ncbi.nlm.nih.gov/22480775).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"27\",\"title\":\"** Queenan, Anne Marie; Karen Bush (July 2007). [\\\"Carbapenemases: the Versatile Î²-Lactamases\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1932750). _Clinical Microbiology Reviews_. **20** (3): 440â€“458\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1128/CMR.00001-07](https://doi.org/10.1128%2FCMR.00001-07). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [1932750](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1932750). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [17630334](https://pubmed.ncbi.nlm.nih.gov/17630334).\",\"description\":\"27. **^** Queenan, Anne Marie; Karen Bush (July 2007). [\\\"Carbapenemases: the Versatile Î²-Lactamases\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1932750). _Clinical Microbiology Reviews_. **20** (3): 440â€“458\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1128/CMR.00001-07](https://doi.org/10.1128%2FCMR.00001-07). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [1932750](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1932750). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [17630334](https://pubmed.ncbi.nlm.nih.gov/17630334).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1932750\",\"favicon\":\"\"},{\"id\":\"28\",\"title\":\"** Patel, Gopi; Bonomo (March 2013). [\\\"\\\"Stormy waters ahead\\\": global emergence of carbapenemases\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3596785). _Frontiers in Microbiology_. **4** : 48. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.3389/fmicb.2013.00048](https://doi.org/10.3389%2Ffmicb.2013.00048). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3596785](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3596785). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [23504089](https://pubmed.ncbi.nlm.nih.gov/23504089).\",\"description\":\"28. **^** Patel, Gopi; Bonomo (March 2013). [\\\"\\\"Stormy waters ahead\\\": global emergence of carbapenemases\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3596785). _Frontiers in Microbiology_. **4** : 48. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.3389/fmicb.2013.00048](https://doi.org/10.3389%2Ffmicb.2013.00048). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3596785](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3596785). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [23504089](https://pubmed.ncbi.nlm.nih.gov/23504089).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3596785\",\"favicon\":\"\"},{\"id\":\"29\",\"title\":\"** Press Release (26 March 2013). [\\\"New Study Identifies Unique Mechanisms of Antibiotic Resistance\\\"](http://now.tufts.edu/news-releases/new-study-identifies-unique-mechanisms-antibi). [Tufts University](Tufts_University \\\"Tufts University\\\"). Retrieved 25 April 2013.\",\"description\":\"29. **^** Press Release (26 March 2013). [\\\"New Study Identifies Unique Mechanisms of Antibiotic Resistance\\\"](http://now.tufts.edu/news-releases/new-study-identifies-unique-mechanisms-antibi). [Tufts University](Tufts_University \\\"Tufts University\\\"). Retrieved 25 April 2013.\",\"url\":\"http://now.tufts.edu/news-releases/new-study-identifies-unique-mechanisms-antibi\",\"favicon\":\"\"},{\"id\":\"30\",\"title\":\"** Levy, Stuart; Warner, Douglas; Yang, Qiwen; Duval, Valerie; Chen, Minjun; Xu, Yingchun (2013). [\\\"Involvement of MarR and YedS in Carbapenem Resistance in a Clinical Isolate of Escherichia coli from China\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3623324). _[Antimicrobial Agents and Chemotherapy](Antimicrobial_Agents_and_Chemotherapy \\\"Antimicrobial Agents and Chemotherapy\\\")_. **57** (4): 1935â€“1937\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1128/AAC.02445-12](https://doi.org/10.1128%2FAAC.02445-12). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3623324](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3623324). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [23318808](https://pubmed.ncbi.nlm.nih.gov/23318808).\",\"description\":\"30. **^** Levy, Stuart; Warner, Douglas; Yang, Qiwen; Duval, Valerie; Chen, Minjun; Xu, Yingchun (2013). [\\\"Involvement of MarR and YedS in Carbapenem Resistance in a Clinical Isolate of Escherichia coli from China\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3623324). _[Antimicrobial Agents and Chemotherapy](Antimicrobial_Agents_and_Chemotherapy \\\"Antimicrobial Agents and Chemotherapy\\\")_. **57** (4): 1935â€“1937\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1128/AAC.02445-12](https://doi.org/10.1128%2FAAC.02445-12). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3623324](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3623324). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [23318808](https://pubmed.ncbi.nlm.nih.gov/23318808).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3623324\",\"favicon\":\"\"},{\"id\":\"31\",\"title\":\"_**a**_ _**b**_ _**c**_ Khuntayaporn, P; Montakantikul, P; Mootsikapun, P; Thamlikitkul, V; Chomnawang, MT (2012). [\\\"Prevalence and genotypic relatedness of carbapenem resistance among multidrug-resistant P. aeruginosa in tertiary hospitals across Thailand\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3475077). _Annals of Clinical Microbiology and Antimicrobials_. **11** : 25. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1186/1476-0711-11-25](https://doi.org/10.1186%2F1476-0711-11-25). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3475077](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3475077). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22970983](https://pubmed.ncbi.nlm.nih.gov/22970983).\",\"description\":\"31. ^ _**a**_ _**b**_ _**c**_ Khuntayaporn, P; Montakantikul, P; Mootsikapun, P; Thamlikitkul, V; Chomnawang, MT (2012). [\\\"Prevalence and genotypic relatedness of carbapenem resistance among multidrug-resistant P. aeruginosa in tertiary hospitals across Thailand\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3475077). _Annals of Clinical Microbiology and Antimicrobials_. **11** : 25. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1186/1476-0711-11-25](https://doi.org/10.1186%2F1476-0711-11-25). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3475077](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3475077). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22970983](https://pubmed.ncbi.nlm.nih.gov/22970983).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3475077\",\"favicon\":\"\"},{\"id\":\"32\",\"title\":\"** Hudson, Corey; Bent, Zachary; Meagher, Robert; Williams, Kelly (June 6, 2014). [\\\"Resistance Determinants and Mobile Genetic Elements of an NDM-1-Encoding _Klebsiella pneumoniae_ Strain\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4048246). _PLOS ONE_. **9** (6): e99209. [Bibcode](Bibcode_\\\\(identifier\\\\) \\\"Bibcode \\\\(identifier\\\\)\\\"):[2014PLoSO...999209H](https://ui.adsabs.harvard.edu/abs/2014PLoSO...999209H). [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1371/journal.pone.0099209](https://doi.org/10.1371%2Fjournal.pone.0099209). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [4048246](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4048246). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [24905728](https://pubmed.ncbi.nlm.nih.gov/24905728).\",\"description\":\"32. **^** Hudson, Corey; Bent, Zachary; Meagher, Robert; Williams, Kelly (June 6, 2014). [\\\"Resistance Determinants and Mobile Genetic Elements of an NDM-1-Encoding _Klebsiella pneumoniae_ Strain\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4048246). _PLOS ONE_. **9** (6): e99209. [Bibcode](Bibcode_\\\\(identifier\\\\) \\\"Bibcode \\\\(identifier\\\\)\\\"):[2014PLoSO...999209H](https://ui.adsabs.harvard.edu/abs/2014PLoSO...999209H). [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1371/journal.pone.0099209](https://doi.org/10.1371%2Fjournal.pone.0099209). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [4048246](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4048246). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [24905728](https://pubmed.ncbi.nlm.nih.gov/24905728).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4048246\",\"favicon\":\"\"},{\"id\":\"33\",\"title\":\"** Pulcrano, G; Pignanelli, S; Vollaro, A; Esposito, M; Iula, VD; Roscetto, E; Soriano, AA; Catania, MR (Jun 2016). \\\"Isolation of Enterobacter aerogenes carrying blaTEM-1 and blaKPC-3 genes recovered from a hospital Intensive Care Unit\\\". _APMIS_. **124** (6): 516â€“21\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1111/apm.12528](https://doi.org/10.1111%2Fapm.12528). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [27004836](https://pubmed.ncbi.nlm.nih.gov/27004836). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [33234690](https://api.semanticscholar.org/CorpusID:33234690).\",\"description\":\"33. **^** Pulcrano, G; Pignanelli, S; Vollaro, A; Esposito, M; Iula, VD; Roscetto, E; Soriano, AA; Catania, MR (Jun 2016). \\\"Isolation of Enterobacter aerogenes carrying blaTEM-1 and blaKPC-3 genes recovered from a hospital Intensive Care Unit\\\". _APMIS_. **124** (6): 516â€“21\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1111/apm.12528](https://doi.org/10.1111%2Fapm.12528). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [27004836](https://pubmed.ncbi.nlm.nih.gov/27004836). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [33234690](https://api.semanticscholar.org/CorpusID:33234690).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"34\",\"title\":\"_**a**_ _**b**_ _**c**_ Pfeifer, Yvonne; Cullik, Angela; Witte, Wolfgang (Aug 2010). \\\"Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens\\\". _Int J Med Microbiol_. **300** (6): 371â€“9\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.ijmm.2010.04.005](https://doi.org/10.1016%2Fj.ijmm.2010.04.005). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [20537585](https://pubmed.ncbi.nlm.nih.gov/20537585).\",\"description\":\"34. ^ _**a**_ _**b**_ _**c**_ Pfeifer, Yvonne; Cullik, Angela; Witte, Wolfgang (Aug 2010). \\\"Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens\\\". _Int J Med Microbiol_. **300** (6): 371â€“9\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.ijmm.2010.04.005](https://doi.org/10.1016%2Fj.ijmm.2010.04.005). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [20537585](https://pubmed.ncbi.nlm.nih.gov/20537585).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"35\",\"title\":\"_**a**_ _**b**_ Mathers, AJ; Cox, HL; Kitchel, B; Bonatti, H; Brassinga, AK; Carroll, J; Scheld, WM; Hazen, KC; Sifri, CD (2011). [\\\"Molecular Dissection of an Outbreak of Carbapenem-Resistant Enterobacteriaceae Reveals Intergenus KPC Carbapenemase Transmission through a Promiscuous Plasmid\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202755). _mBio_. **2** (6): e00204â€“11. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1128/mBio.00204-11](https://doi.org/10.1128%2FmBio.00204-11). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3202755](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202755). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22045989](https://pubmed.ncbi.nlm.nih.gov/22045989).\",\"description\":\"35. ^ _**a**_ _**b**_ Mathers, AJ; Cox, HL; Kitchel, B; Bonatti, H; Brassinga, AK; Carroll, J; Scheld, WM; Hazen, KC; Sifri, CD (2011). [\\\"Molecular Dissection of an Outbreak of Carbapenem-Resistant Enterobacteriaceae Reveals Intergenus KPC Carbapenemase Transmission through a Promiscuous Plasmid\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202755). _mBio_. **2** (6): e00204â€“11. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1128/mBio.00204-11](https://doi.org/10.1128%2FmBio.00204-11). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3202755](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202755). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22045989](https://pubmed.ncbi.nlm.nih.gov/22045989).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202755\",\"favicon\":\"\"},{\"id\":\"36\",\"title\":\"** Dimou, V; Dhanji, H; Pike, R; Livermore, DM; Woodford, N (2012). [\\\"Characterization of Enterobacteriaceae producing OXA-48-like carbapenemases in the UK\\\"](https://doi.org/10.1093%2Fjac%2Fdks124). _The Journal of Antimicrobial Chemotherapy_. **67** (7): 1660â€“5\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1093/jac/dks124](https://doi.org/10.1093%2Fjac%2Fdks124). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22532467](https://pubmed.ncbi.nlm.nih.gov/22532467).,\",\"description\":\"36. **^** Dimou, V; Dhanji, H; Pike, R; Livermore, DM; Woodford, N (2012). [\\\"Characterization of Enterobacteriaceae producing OXA-48-like carbapenemases in the UK\\\"](https://doi.org/10.1093%2Fjac%2Fdks124). _The Journal of Antimicrobial Chemotherapy_. **67** (7): 1660â€“5\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1093/jac/dks124](https://doi.org/10.1093%2Fjac%2Fdks124). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22532467](https://pubmed.ncbi.nlm.nih.gov/22532467).,\",\"url\":\"https://doi.org/10.1093%2Fjac%2Fdks124\",\"favicon\":\"\"},{\"id\":\"37\",\"title\":\"_**a**_ _**b**_ Rumbo, Carlos; FernÃ¡ndez-Moreira, E; Merino, M; Poza, M; Mendez, JA; Soares, NC; Mosquera, A; Chaves, F; Bou, G (July 2011). [\\\"Horizontal transfer of the OXA-24 carbapenemase gene via outer membrane vesicles: a new mechanism of dissemination of carbapenem resistance genes in Acinetobacter baumanni\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3122458). _Antimicrobial Agents and Chemotherapy_. 7. **55** (7): 3084â€“3090\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1128/AAC.00929-10](https://doi.org/10.1128%2FAAC.00929-10). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3122458](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3122458). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [21518847](https://pubmed.ncbi.nlm.nih.gov/21518847).\",\"description\":\"37. ^ _**a**_ _**b**_ Rumbo, Carlos; FernÃ¡ndez-Moreira, E; Merino, M; Poza, M; Mendez, JA; Soares, NC; Mosquera, A; Chaves, F; Bou, G (July 2011). [\\\"Horizontal transfer of the OXA-24 carbapenemase gene via outer membrane vesicles: a new mechanism of dissemination of carbapenem resistance genes in Acinetobacter baumanni\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3122458). _Antimicrobial Agents and Chemotherapy_. 7. **55** (7): 3084â€“3090\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1128/AAC.00929-10](https://doi.org/10.1128%2FAAC.00929-10). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3122458](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3122458). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [21518847](https://pubmed.ncbi.nlm.nih.gov/21518847).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3122458\",\"favicon\":\"\"},{\"id\":\"38\",\"title\":\"** Landman, D; Salvani, JK; Bratu, S; Quale, J (November 2005). [\\\"Evaluation of techniques for detection of carbapenem-resistant _Klebsiella pneumoniae_ in stool surveillance cultures\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1287836). _Journal of Clinical Microbiology_. **43** (11): 5639â€“41\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1128/JCM.43.11.5639-5641.2005](https://doi.org/10.1128%2FJCM.43.11.5639-5641.2005). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [1287836](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1287836). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [16272497](https://pubmed.ncbi.nlm.nih.gov/16272497).\",\"description\":\"38. **^** Landman, D; Salvani, JK; Bratu, S; Quale, J (November 2005). [\\\"Evaluation of techniques for detection of carbapenem-resistant _Klebsiella pneumoniae_ in stool surveillance cultures\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1287836). _Journal of Clinical Microbiology_. **43** (11): 5639â€“41\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1128/JCM.43.11.5639-5641.2005](https://doi.org/10.1128%2FJCM.43.11.5639-5641.2005). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [1287836](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1287836). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [16272497](https://pubmed.ncbi.nlm.nih.gov/16272497).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1287836\",\"favicon\":\"\"},{\"id\":\"39\",\"title\":\"** Pournaras S; et al. (2013). [\\\"A Combined Disk Test for Direct Differentiation of Carbapenemase-Producing Enterobacteriaceae in Surveillance Rectal Swabs\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3754636). _J Clin Microbiol_. **51** (9): 2986â€“90\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1128/JCM.00901-13](https://doi.org/10.1128%2FJCM.00901-13). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3754636](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3754636). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [23843486](https://pubmed.ncbi.nlm.nih.gov/23843486).\",\"description\":\"39. **^** Pournaras S; et al. (2013). [\\\"A Combined Disk Test for Direct Differentiation of Carbapenemase-Producing Enterobacteriaceae in Surveillance Rectal Swabs\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3754636). _J Clin Microbiol_. **51** (9): 2986â€“90\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1128/JCM.00901-13](https://doi.org/10.1128%2FJCM.00901-13). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3754636](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3754636). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [23843486](https://pubmed.ncbi.nlm.nih.gov/23843486).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3754636\",\"favicon\":\"\"},{\"id\":\"40\",\"title\":\"** Sparbier, Katrin; Schubert, S; Weller, U; Boogen, C; Kostrzewa, M (May 2012). [\\\"Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry-Based FUnctional Assay for Rapid Detection of Resistance against B-Lactam Antibiotics\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3295133). _Journal of Clinical Microbiology_. **50** (3): 927â€“937\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1128/JCM.05737-11](https://doi.org/10.1128%2FJCM.05737-11). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3295133](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3295133). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22205812](https://pubmed.ncbi.nlm.nih.gov/22205812).\",\"description\":\"40. **^** Sparbier, Katrin; Schubert, S; Weller, U; Boogen, C; Kostrzewa, M (May 2012). [\\\"Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry-Based FUnctional Assay for Rapid Detection of Resistance against B-Lactam Antibiotics\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3295133). _Journal of Clinical Microbiology_. **50** (3): 927â€“937\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1128/JCM.05737-11](https://doi.org/10.1128%2FJCM.05737-11). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3295133](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3295133). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22205812](https://pubmed.ncbi.nlm.nih.gov/22205812).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3295133\",\"favicon\":\"\"},{\"id\":\"41\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ _**e**_ Kotsanas, Despina; Wijesooriya, WR; Korman, TM; Gillespie, EE; Wright, L; Snook, K; Williams, N; Bell, JM; et al. (18 March 2013). [\\\"\\\"Down the drain\\\": carbapenem-resistant bacteria in intensive care unit patients and handwashing sinks\\\"](https://doi.org/10.5694%2Fmja12.11757). _Medical Journal of Australia_. **198** (5): 267â€“269\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.5694/mja12.11757](https://doi.org/10.5694%2Fmja12.11757). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [23496403](https://pubmed.ncbi.nlm.nih.gov/23496403).\",\"description\":\"41. ^ _**a**_ _**b**_ _**c**_ _**d**_ _**e**_ Kotsanas, Despina; Wijesooriya, WR; Korman, TM; Gillespie, EE; Wright, L; Snook, K; Williams, N; Bell, JM; et al. (18 March 2013). [\\\"\\\"Down the drain\\\": carbapenem-resistant bacteria in intensive care unit patients and handwashing sinks\\\"](https://doi.org/10.5694%2Fmja12.11757). _Medical Journal of Australia_. **198** (5): 267â€“269\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.5694/mja12.11757](https://doi.org/10.5694%2Fmja12.11757). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [23496403](https://pubmed.ncbi.nlm.nih.gov/23496403).\",\"url\":\"https://doi.org/10.5694%2Fmja12.11757\",\"favicon\":\"\"},{\"id\":\"42\",\"title\":\"** Kahn, A. S.; Dancer, Humphreys (October 2012). \\\"Priorities in the prevention and control of multidrug-resistant Enterobacteriaceae in hospitals\\\". _Journal of Hospital Infection_. **82** (2): 85â€“93\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.jhin.2012.06.013](https://doi.org/10.1016%2Fj.jhin.2012.06.013). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22863084](https://pubmed.ncbi.nlm.nih.gov/22863084).\",\"description\":\"42. **^** Kahn, A. S.; Dancer, Humphreys (October 2012). \\\"Priorities in the prevention and control of multidrug-resistant Enterobacteriaceae in hospitals\\\". _Journal of Hospital Infection_. **82** (2): 85â€“93\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.jhin.2012.06.013](https://doi.org/10.1016%2Fj.jhin.2012.06.013). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22863084](https://pubmed.ncbi.nlm.nih.gov/22863084).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"43\",\"title\":\"** [\\\"CDC Infection Control Guidelines\\\"](https://www.cdc.gov/hai/organisms/cre/cre-toolkit/). 2019-11-04.\",\"description\":\"43. **^** [\\\"CDC Infection Control Guidelines\\\"](https://www.cdc.gov/hai/organisms/cre/cre-toolkit/). 2019-11-04.\",\"url\":\"https://www.cdc.gov/hai/organisms/cre/cre-toolkit/\",\"favicon\":\"\"},{\"id\":\"44\",\"title\":\"** Bilavsky, E; Schwaber, MJ; Carmeli, Y (2010). \\\"How to stem the tide of carbapenemase-producing enterobacteriaceae?: Proactive versus reactive strategies\\\". _Current Opinion in Infectious Diseases_. **23** (4): 327â€“31\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1097/QCO.0b013e32833b3571](https://doi.org/10.1097%2FQCO.0b013e32833b3571). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [20581673](https://pubmed.ncbi.nlm.nih.gov/20581673). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [20036704](https://api.semanticscholar.org/CorpusID:20036704).\",\"description\":\"44. **^** Bilavsky, E; Schwaber, MJ; Carmeli, Y (2010). \\\"How to stem the tide of carbapenemase-producing enterobacteriaceae?: Proactive versus reactive strategies\\\". _Current Opinion in Infectious Diseases_. **23** (4): 327â€“31\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1097/QCO.0b013e32833b3571](https://doi.org/10.1097%2FQCO.0b013e32833b3571). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [20581673](https://pubmed.ncbi.nlm.nih.gov/20581673). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [20036704](https://api.semanticscholar.org/CorpusID:20036704).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"45\",\"title\":\"** [\\\"Canadian Public Health Infection Prevention Guidelines\\\"](http://www.phac-aspc.gc.ca/nois-sinp/guide/ipcm-mpci/ipcm-mpci-eng.php). 2010-11-12.\",\"description\":\"45. **^** [\\\"Canadian Public Health Infection Prevention Guidelines\\\"](http://www.phac-aspc.gc.ca/nois-sinp/guide/ipcm-mpci/ipcm-mpci-eng.php). 2010-11-12.\",\"url\":\"http://www.phac-aspc.gc.ca/nois-sinp/guide/ipcm-mpci/ipcm-mpci-eng.php\",\"favicon\":\"\"},{\"id\":\"46\",\"title\":\"** Lowe, C; Katz, K; McGeer, A; Muller, MP; Toronto Esbl Working, Group (2012). \\\"Disparity in infection control practices for multidrug-resistant Enterobacteriaceae\\\". _American Journal of Infection Control_. **40** (9): 836â€“9\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.ajic.2011.11.008](https://doi.org/10.1016%2Fj.ajic.2011.11.008). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22361360](https://pubmed.ncbi.nlm.nih.gov/22361360). `{{cite journal}}`: `|first5=` has generic name (help)\",\"description\":\"46. **^** Lowe, C; Katz, K; McGeer, A; Muller, MP; Toronto Esbl Working, Group (2012). \\\"Disparity in infection control practices for multidrug-resistant Enterobacteriaceae\\\". _American Journal of Infection Control_. **40** (9): 836â€“9\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.ajic.2011.11.008](https://doi.org/10.1016%2Fj.ajic.2011.11.008). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22361360](https://pubmed.ncbi.nlm.nih.gov/22361360). `{{cite journal}}`: `|first5=` has generic name (help)\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"47\",\"title\":\"** Ciobotaro, P; Oved, M; Nadir, E; Bardenstein, R; Zimhony, O (October 2011). \\\"An effective intervention to limit the spread of an epidemic carbapenem-resistant _Klebsiella pneumoniae_ strain in an acute care setting: from theory to practice\\\". _American Journal of Infection Control_. **39** (8): 671â€“7\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.ajic.2011.05.004](https://doi.org/10.1016%2Fj.ajic.2011.05.004). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [21864942](https://pubmed.ncbi.nlm.nih.gov/21864942).\",\"description\":\"47. **^** Ciobotaro, P; Oved, M; Nadir, E; Bardenstein, R; Zimhony, O (October 2011). \\\"An effective intervention to limit the spread of an epidemic carbapenem-resistant _Klebsiella pneumoniae_ strain in an acute care setting: from theory to practice\\\". _American Journal of Infection Control_. **39** (8): 671â€“7\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.ajic.2011.05.004](https://doi.org/10.1016%2Fj.ajic.2011.05.004). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [21864942](https://pubmed.ncbi.nlm.nih.gov/21864942).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"48\",\"title\":\"** Carling, Philip C.; Michael F. Parry; Lou Ann Bruno-Murtha; Brian Dick (2010). \\\"Improving environmental hygiene in 27 intensive care units to decrease multidrug-resistant bacterial transmission\\\". _Critical Care Medicine_. **38** (4): 1054â€“1059\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1097/CCM.0b013e3181cdf705](https://doi.org/10.1097%2FCCM.0b013e3181cdf705). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [20081531](https://pubmed.ncbi.nlm.nih.gov/20081531). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [16166524](https://api.semanticscholar.org/CorpusID:16166524).\",\"description\":\"48. **^** Carling, Philip C.; Michael F. Parry; Lou Ann Bruno-Murtha; Brian Dick (2010). \\\"Improving environmental hygiene in 27 intensive care units to decrease multidrug-resistant bacterial transmission\\\". _Critical Care Medicine_. **38** (4): 1054â€“1059\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1097/CCM.0b013e3181cdf705](https://doi.org/10.1097%2FCCM.0b013e3181cdf705). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [20081531](https://pubmed.ncbi.nlm.nih.gov/20081531). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [16166524](https://api.semanticscholar.org/CorpusID:16166524).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"49\",\"title\":\"_**a**_ _**b**_ Falagas, ME; Kastoris, AC; Kapaskelis, AM; Karageorgopoulos, DE (2010). \\\"Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: A systematic review\\\". _The Lancet Infectious Diseases_. **10** (1): 43â€“50\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/S1473-3099(09)70325-1](https://doi.org/10.1016%2FS1473-3099%2809%2970325-1). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [20129148](https://pubmed.ncbi.nlm.nih.gov/20129148).\",\"description\":\"49. ^ _**a**_ _**b**_ Falagas, ME; Kastoris, AC; Kapaskelis, AM; Karageorgopoulos, DE (2010). \\\"Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: A systematic review\\\". _The Lancet Infectious Diseases_. **10** (1): 43â€“50\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/S1473-3099(09)70325-1](https://doi.org/10.1016%2FS1473-3099%2809%2970325-1). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [20129148](https://pubmed.ncbi.nlm.nih.gov/20129148).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"50\",\"title\":\"** [\\\"Tigecycline - Infectious Diseases\\\"](https://www.merckmanuals.com/professional/infectious-diseases/bacteria-and-antibacterial-drugs/tigecycline). _Merck Manuals Professional Edition_. Retrieved 2019-09-26.\",\"description\":\"50. **^** [\\\"Tigecycline - Infectious Diseases\\\"](https://www.merckmanuals.com/professional/infectious-diseases/bacteria-and-antibacterial-drugs/tigecycline). _Merck Manuals Professional Edition_. Retrieved 2019-09-26.\",\"url\":\"https://www.merckmanuals.com/professional/infectious-diseases/bacteria-and-antibacterial-drugs/tigecycline\",\"favicon\":\"\"},{\"id\":\"51\",\"title\":\"** Kelesidis T, Karageorgopoulos DE, Kelesidis I, Falagas ME (1 August 2008). [\\\"Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8445635). _Journal of Antimicrobial Chemotherapy_. **62** (5): 895â€“904\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1093/jac/dkn311](https://doi.org/10.1093%2Fjac%2Fdkn311). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [8445635](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8445635). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [18676620](https://pubmed.ncbi.nlm.nih.gov/18676620).\",\"description\":\"51. **^** Kelesidis T, Karageorgopoulos DE, Kelesidis I, Falagas ME (1 August 2008). [\\\"Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8445635). _Journal of Antimicrobial Chemotherapy_. **62** (5): 895â€“904\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1093/jac/dkn311](https://doi.org/10.1093%2Fjac%2Fdkn311). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [8445635](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8445635). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [18676620](https://pubmed.ncbi.nlm.nih.gov/18676620).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8445635\",\"favicon\":\"\"},{\"id\":\"52\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ Kanj, Souha; Zeina A. Kanafani (March 2011). [\\\"Current Concepts in Antimicrobial Therapy Against Resistant Gram-Negative Organisms: Extended-Spectrum Î²-lactamase-Producing Enterobacteriaceae, Carbapenem-Resistant Enterobacteriaceae, and Multidrug-Resistant Pseudomonas aeruginosa\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3046948). _Mayo Clinic Proceedings_. **86** (3): 250â€“259\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.4065/mcp.2010.0674](https://doi.org/10.4065%2Fmcp.2010.0674). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3046948](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3046948). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [21364117](https://pubmed.ncbi.nlm.nih.gov/21364117).\",\"description\":\"52. ^ _**a**_ _**b**_ _**c**_ _**d**_ Kanj, Souha; Zeina A. Kanafani (March 2011). [\\\"Current Concepts in Antimicrobial Therapy Against Resistant Gram-Negative Organisms: Extended-Spectrum Î²-lactamase-Producing Enterobacteriaceae, Carbapenem-Resistant Enterobacteriaceae, and Multidrug-Resistant Pseudomonas aeruginosa\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3046948). _Mayo Clinic Proceedings_. **86** (3): 250â€“259\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.4065/mcp.2010.0674](https://doi.org/10.4065%2Fmcp.2010.0674). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3046948](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3046948). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [21364117](https://pubmed.ncbi.nlm.nih.gov/21364117).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3046948\",\"favicon\":\"\"},{\"id\":\"53\",\"title\":\"** Brunkhorst, Frank; Oppert, M; Marx, G; Bloos, F; Ludewig, K; Putensen, C; Nierhaus, A; Jaschinski, U; et al. (13 June 2012). [\\\"Effect of Empirical Treatment With oxifloxacin and Meropenem vs Meropenem on Sepsis-Related Organ Dysfunction in Patients With Severe Sepsis: A Randomized Trial\\\"](https://doi.org/10.1001%2Fjama.2012.5833). _Journal of the American Medical Association_. **307** (22): 2390â€“9\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1001/jama.2012.5833](https://doi.org/10.1001%2Fjama.2012.5833). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22692171](https://pubmed.ncbi.nlm.nih.gov/22692171).\",\"description\":\"53. **^** Brunkhorst, Frank; Oppert, M; Marx, G; Bloos, F; Ludewig, K; Putensen, C; Nierhaus, A; Jaschinski, U; et al. (13 June 2012). [\\\"Effect of Empirical Treatment With oxifloxacin and Meropenem vs Meropenem on Sepsis-Related Organ Dysfunction in Patients With Severe Sepsis: A Randomized Trial\\\"](https://doi.org/10.1001%2Fjama.2012.5833). _Journal of the American Medical Association_. **307** (22): 2390â€“9\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1001/jama.2012.5833](https://doi.org/10.1001%2Fjama.2012.5833). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22692171](https://pubmed.ncbi.nlm.nih.gov/22692171).\",\"url\":\"https://doi.org/10.1001%2Fjama.2012.5833\",\"favicon\":\"\"},{\"id\":\"54\",\"title\":\"** Yigit, H; Queenan, AM; Anderson, GJ; Domenech-Sanchez, A; Biddle, JW; Steward, CD; Alberti, S; Bush, K; Tenover, FC (April 2001). [\\\"Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of _Klebsiella pneumoniae_ \\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC90438). _Antimicrobial Agents and Chemotherapy_. **45** (4): 1151â€“1161\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1128/AAC.45.4.1151-1161.2001](https://doi.org/10.1128%2FAAC.45.4.1151-1161.2001). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [90438](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC90438). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [11257029](https://pubmed.ncbi.nlm.nih.gov/11257029).\",\"description\":\"54. **^** Yigit, H; Queenan, AM; Anderson, GJ; Domenech-Sanchez, A; Biddle, JW; Steward, CD; Alberti, S; Bush, K; Tenover, FC (April 2001). [\\\"Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of _Klebsiella pneumoniae_ \\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC90438). _Antimicrobial Agents and Chemotherapy_. **45** (4): 1151â€“1161\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1128/AAC.45.4.1151-1161.2001](https://doi.org/10.1128%2FAAC.45.4.1151-1161.2001). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [90438](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC90438). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [11257029](https://pubmed.ncbi.nlm.nih.gov/11257029).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC90438\",\"favicon\":\"\"},{\"id\":\"55\",\"title\":\"** Temkin E, Adler A, Lerner A, Carmeli Y (2014). [\\\"Carbapenem-resistant Enterobacteriaceae: biology, epidemiology, and management\\\"](https://web.archive.org/web/20200530092436/https://www.openaccessrepository.it/record/21450). _Annals of the New York Academy of Sciences_. **1323** (1): 22â€“42\\\\. [Bibcode](Bibcode_\\\\(identifier\\\\) \\\"Bibcode \\\\(identifier\\\\)\\\"):[2014NYASA1323...22T](https://ui.adsabs.harvard.edu/abs/2014NYASA1323...22T). [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1111/nyas.12537](https://doi.org/10.1111%2Fnyas.12537). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [25195939](https://pubmed.ncbi.nlm.nih.gov/25195939). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [28242426](https://api.semanticscholar.org/CorpusID:28242426). Archived from [the original](https://www.openaccessrepository.it/record/21450) on May 30, 2020.\",\"description\":\"55. **^** Temkin E, Adler A, Lerner A, Carmeli Y (2014). [\\\"Carbapenem-resistant Enterobacteriaceae: biology, epidemiology, and management\\\"](https://web.archive.org/web/20200530092436/https://www.openaccessrepository.it/record/21450). _Annals of the New York Academy of Sciences_. **1323** (1): 22â€“42\\\\. [Bibcode](Bibcode_\\\\(identifier\\\\) \\\"Bibcode \\\\(identifier\\\\)\\\"):[2014NYASA1323...22T](https://ui.adsabs.harvard.edu/abs/2014NYASA1323...22T). [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1111/nyas.12537](https://doi.org/10.1111%2Fnyas.12537). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [25195939](https://pubmed.ncbi.nlm.nih.gov/25195939). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [28242426](https://api.semanticscholar.org/CorpusID:28242426). Archived from [the original](https://www.openaccessrepository.it/record/21450) on May 30, 2020.\",\"url\":\"https://web.archive.org/web/20200530092436/https://www.openaccessrepository.it/record/21450\",\"favicon\":\"\"},{\"id\":\"56\",\"title\":\"** Marchaim, D; Chopra, T; Pogue, JM; Perez, F; Hujer, AM; Rudin, S; Endimiani, A; Navon-Venezia, S; et al. (2011). [\\\"Outbreak of colistin-resistant, carbapenem-resistant _Klebsiella pneumoniae_ in metropolitan Detroit, Michigan\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3028794). _Antimicrobial Agents and Chemotherapy_. **55** (2): 593â€“9\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1128/AAC.01020-10](https://doi.org/10.1128%2FAAC.01020-10). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3028794](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3028794). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [21115786](https://pubmed.ncbi.nlm.nih.gov/21115786).\",\"description\":\"56. **^** Marchaim, D; Chopra, T; Pogue, JM; Perez, F; Hujer, AM; Rudin, S; Endimiani, A; Navon-Venezia, S; et al. (2011). [\\\"Outbreak of colistin-resistant, carbapenem-resistant _Klebsiella pneumoniae_ in metropolitan Detroit, Michigan\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3028794). _Antimicrobial Agents and Chemotherapy_. **55** (2): 593â€“9\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1128/AAC.01020-10](https://doi.org/10.1128%2FAAC.01020-10). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3028794](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3028794). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [21115786](https://pubmed.ncbi.nlm.nih.gov/21115786).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3028794\",\"favicon\":\"\"},{\"id\":\"57\",\"title\":\"** Binod, G.C.; Sapkota, R.; Rayamajhee, B.; Poudel, P.; Thapa, S.; Lekhak, S.; Khanal, S. (2018). [\\\"Detection of blaNDM-1 gene among the carbapenem resistant Escherichia coli and Klebsiella pneumoniae isolates\\\"](https://www.sciencedirect.com/science/article/pii/S187167841831358X). _New Biotechnology_. **44** (Supplement): S119. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.nbt.2018.05.1038](https://doi.org/10.1016%2Fj.nbt.2018.05.1038). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1871-6784](https://search.worldcat.org/issn/1871-6784).\",\"description\":\"57. **^** Binod, G.C.; Sapkota, R.; Rayamajhee, B.; Poudel, P.; Thapa, S.; Lekhak, S.; Khanal, S. (2018). [\\\"Detection of blaNDM-1 gene among the carbapenem resistant Escherichia coli and Klebsiella pneumoniae isolates\\\"](https://www.sciencedirect.com/science/article/pii/S187167841831358X). _New Biotechnology_. **44** (Supplement): S119. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.nbt.2018.05.1038](https://doi.org/10.1016%2Fj.nbt.2018.05.1038). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1871-6784](https://search.worldcat.org/issn/1871-6784).\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S187167841831358X\",\"favicon\":\"\"},{\"id\":\"58\",\"title\":\"** Bonomo, RA; van Duin, D; Kaye, KS; Neuner, EA (2013). [\\\"Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3947910). _Diagnostic Microbiology and Infectious Disease_. **75** (2): 115â€“120\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.diagmicrobio.2012.11.009](https://doi.org/10.1016%2Fj.diagmicrobio.2012.11.009). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3947910](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3947910). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [23290507](https://pubmed.ncbi.nlm.nih.gov/23290507).\",\"description\":\"58. **^** Bonomo, RA; van Duin, D; Kaye, KS; Neuner, EA (2013). [\\\"Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3947910). _Diagnostic Microbiology and Infectious Disease_. **75** (2): 115â€“120\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.diagmicrobio.2012.11.009](https://doi.org/10.1016%2Fj.diagmicrobio.2012.11.009). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3947910](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3947910). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [23290507](https://pubmed.ncbi.nlm.nih.gov/23290507).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3947910\",\"favicon\":\"\"},{\"id\":\"59\",\"title\":\"_**a**_ _**b**_ Esterly, JS; Wagner, J; McLaughlin, MM; Postelnick, MJ; Qi, C; Scheetz, MH (2012). [\\\"Evaluation of Clinical Outcomes in Patients with Bloodstream Infections Due to Gram-Negative Bacteria According to Carbapenem MIC Stratification\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3421845). _Antimicrobial Agents and Chemotherapy_. **56** (9): 4885â€“4890\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1128/AAC.06365-11](https://doi.org/10.1128%2FAAC.06365-11). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3421845](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3421845). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22777044](https://pubmed.ncbi.nlm.nih.gov/22777044).\",\"description\":\"59. ^ _**a**_ _**b**_ Esterly, JS; Wagner, J; McLaughlin, MM; Postelnick, MJ; Qi, C; Scheetz, MH (2012). [\\\"Evaluation of Clinical Outcomes in Patients with Bloodstream Infections Due to Gram-Negative Bacteria According to Carbapenem MIC Stratification\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3421845). _Antimicrobial Agents and Chemotherapy_. **56** (9): 4885â€“4890\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1128/AAC.06365-11](https://doi.org/10.1128%2FAAC.06365-11). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3421845](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3421845). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22777044](https://pubmed.ncbi.nlm.nih.gov/22777044).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3421845\",\"favicon\":\"\"},{\"id\":\"60\",\"title\":\"** Nguyen, M; Eschenauer, GA; Bryan, M; O'Neil, K; Furuya, EY; Della-Latta, P; Kubin, CJ (June 2010). \\\"Carbapenem-resistant _Klebsiella pneumoniae_ bacteremia: factors correlated with clinical and microbiologic outcomes\\\". _Diagnostic Microbiology and Infectious Disease_. **67** (2): 180â€“4\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.diagmicrobio.2010.02.001](https://doi.org/10.1016%2Fj.diagmicrobio.2010.02.001). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [20356699](https://pubmed.ncbi.nlm.nih.gov/20356699).\",\"description\":\"60. **^** Nguyen, M; Eschenauer, GA; Bryan, M; O'Neil, K; Furuya, EY; Della-Latta, P; Kubin, CJ (June 2010). \\\"Carbapenem-resistant _Klebsiella pneumoniae_ bacteremia: factors correlated with clinical and microbiologic outcomes\\\". _Diagnostic Microbiology and Infectious Disease_. **67** (2): 180â€“4\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.diagmicrobio.2010.02.001](https://doi.org/10.1016%2Fj.diagmicrobio.2010.02.001). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [20356699](https://pubmed.ncbi.nlm.nih.gov/20356699).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"61\",\"title\":\"** Borer, A; Saidel-Odes, L; Riesenberg, K; Eskira, S; Peled, N; Nativ, R; Schlaeffer, F; Sherf, M (October 2009). \\\"Attributable mortality rate for carbapenem-resistant _Klebsiella pneumoniae_ bacteremia\\\". _Infection Control and Hospital Epidemiology_. **30** (10): 972â€“6\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1086/605922](https://doi.org/10.1086%2F605922). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [19712030](https://pubmed.ncbi.nlm.nih.gov/19712030). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [33001455](https://api.semanticscholar.org/CorpusID:33001455).\",\"description\":\"61. **^** Borer, A; Saidel-Odes, L; Riesenberg, K; Eskira, S; Peled, N; Nativ, R; Schlaeffer, F; Sherf, M (October 2009). \\\"Attributable mortality rate for carbapenem-resistant _Klebsiella pneumoniae_ bacteremia\\\". _Infection Control and Hospital Epidemiology_. **30** (10): 972â€“6\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1086/605922](https://doi.org/10.1086%2F605922). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [19712030](https://pubmed.ncbi.nlm.nih.gov/19712030). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [33001455](https://api.semanticscholar.org/CorpusID:33001455).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"62\",\"title\":\"** Calfee, DP; Patel, G; Huprikar, S; Factor, SH; Jenkins, SG (2008). \\\"Outcomes of carbapenem-resistant _Klebsiella pneumoniae_ infection and the impact of antimicrobial and adjunctive therapies\\\". _Infection Control and Hospital Epidemiology_. **29** (12): 1099â€“1106\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1086/592412](https://doi.org/10.1086%2F592412). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [18973455](https://pubmed.ncbi.nlm.nih.gov/18973455). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [23992125](https://api.semanticscholar.org/CorpusID:23992125).\",\"description\":\"62. **^** Calfee, DP; Patel, G; Huprikar, S; Factor, SH; Jenkins, SG (2008). \\\"Outcomes of carbapenem-resistant _Klebsiella pneumoniae_ infection and the impact of antimicrobial and adjunctive therapies\\\". _Infection Control and Hospital Epidemiology_. **29** (12): 1099â€“1106\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1086/592412](https://doi.org/10.1086%2F592412). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [18973455](https://pubmed.ncbi.nlm.nih.gov/18973455). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [23992125](https://api.semanticscholar.org/CorpusID:23992125).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"63\",\"title\":\"** Patel, Gopi; Huprikar, S; Factor, SH; Jenkins, SG; Calfee, DP (December 2008). \\\"Outcomes of Carbapenem-Resistant _Klebsiella pneumoniae_ Infection and the Impact of Antimicrobial and Adjunctive Therapies\\\". _Infection Control \u0026 Hospital Epidemiology_. **29** (12): 1099â€“1106\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1086/592412](https://doi.org/10.1086%2F592412). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [18973455](https://pubmed.ncbi.nlm.nih.gov/18973455). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [23992125](https://api.semanticscholar.org/CorpusID:23992125).\",\"description\":\"63. **^** Patel, Gopi; Huprikar, S; Factor, SH; Jenkins, SG; Calfee, DP (December 2008). \\\"Outcomes of Carbapenem-Resistant _Klebsiella pneumoniae_ Infection and the Impact of Antimicrobial and Adjunctive Therapies\\\". _Infection Control \u0026 Hospital Epidemiology_. **29** (12): 1099â€“1106\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1086/592412](https://doi.org/10.1086%2F592412). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [18973455](https://pubmed.ncbi.nlm.nih.gov/18973455). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [23992125](https://api.semanticscholar.org/CorpusID:23992125).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"64\",\"title\":\"** Kalpoe, JS; Sonnenberg, E; Factor, SH; del Rio Martin, J; Schiano, T; Patel, G; Huprikar, S (2012). [\\\"Mortality associated with carbapenem-resistant _Klebsiella pneumoniae_ infections in liver transplant recipient\\\"](https://doi.org/10.1002%2Flt.23374). _Liver Transplantation_. **18** (4): 468â€“474\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1002/lt.23374](https://doi.org/10.1002%2Flt.23374). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22467548](https://pubmed.ncbi.nlm.nih.gov/22467548). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [46280258](https://api.semanticscholar.org/CorpusID:46280258).\",\"description\":\"64. **^** Kalpoe, JS; Sonnenberg, E; Factor, SH; del Rio Martin, J; Schiano, T; Patel, G; Huprikar, S (2012). [\\\"Mortality associated with carbapenem-resistant _Klebsiella pneumoniae_ infections in liver transplant recipient\\\"](https://doi.org/10.1002%2Flt.23374). _Liver Transplantation_. **18** (4): 468â€“474\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1002/lt.23374](https://doi.org/10.1002%2Flt.23374). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22467548](https://pubmed.ncbi.nlm.nih.gov/22467548). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [46280258](https://api.semanticscholar.org/CorpusID:46280258).\",\"url\":\"https://doi.org/10.1002%2Flt.23374\",\"favicon\":\"\"},{\"id\":\"65\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ Warnes, Sarah L.; Highmore, C. J.; Keevil, C. W. (November 27, 2012). [\\\"Horizontal Transfer of Antibiotic Resistance Genes on Abiotic Touch Surfaces: Implications for Public Health\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3509412). _mBio_. **3** (6): e00489â€“12. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1128/mBio.00489-12](https://doi.org/10.1128%2FmBio.00489-12). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3509412](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3509412). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [23188508](https://pubmed.ncbi.nlm.nih.gov/23188508).\",\"description\":\"65. ^ _**a**_ _**b**_ _**c**_ _**d**_ Warnes, Sarah L.; Highmore, C. J.; Keevil, C. W. (November 27, 2012). [\\\"Horizontal Transfer of Antibiotic Resistance Genes on Abiotic Touch Surfaces: Implications for Public Health\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3509412). _mBio_. **3** (6): e00489â€“12. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1128/mBio.00489-12](https://doi.org/10.1128%2FmBio.00489-12). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3509412](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3509412). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [23188508](https://pubmed.ncbi.nlm.nih.gov/23188508).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3509412\",\"favicon\":\"\"}],\"images\":[],\"fixedIssues\":[{\"criticality\":\"Critical\",\"issueType\":\"Mechanism/Specification Error\",\"problematicText\":\"They are resistant because they produce an enzyme called a carbapenemase that disables the drug molecule.\",\"explanation\":\"CRE encompasses resistance mechanisms beyond carbapenemase production, including porin loss, efflux pumps, and beta-lactamase combinations, which apply to non-carbapenemase-producing CRE; this misstates the primary resistance pathway as universal.\",\"fixedText\":\"Clarify that carbapenemase production causes resistance in CPE (a subset of CRE), while other CRE use non-enzymatic mechanisms like reduced outer membrane permeability and increased efflux.\",\"evidenceSource\":\"[](https://www.ncbi.nlm.nih.gov/books/NBK551704/)\"},{\"criticality\":\"Critical\",\"issueType\":\"Scope/Applicability Misstatement\",\"problematicText\":\"**Carbapenem-resistant Enterobacteriaceae** (**CRE**) or **carbapenemase-producing Enterobacteriaceae** (**CPE**) are gram-negative bacteria that are resistant to the carbapenem class of antibiotics\",\"explanation\":\"CPE refers specifically to CRE that produce carbapenemases; treating CRE and CPE as interchangeable overlooks non-carbapenemase CRE, leading to incomplete scope of resistance definitions.\",\"fixedText\":\"Revise to distinguish: CRE are gram-negative Enterobacterales resistant to carbapenems, including CPE that produce carbapenemases and others resistant via alternative mechanisms.\",\"evidenceSource\":\"[](https://www.health.nsw.gov.au/Infectious/controlguideline/Pages/cpe.aspx)\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"Both of these enzymes, as well as the enzyme VIM (Verona Integron-Mediated Metallo-Î²-lactamase) have also been reported in _Pseudomonas_.[5]\",\"explanation\":\"Reference [5] is a CDC page on Pseudomonas aeruginosa outbreaks with no content on KPC, NDM, or VIM enzymes; the page is inaccessible and does not support the claim.\",\"fixedText\":\"Remove the sentence, as it is out of scope for CRE (which are Enterobacterales, not Pseudomonas) and unsupported by the cited source.\",\"evidenceSource\":\"[5]\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"[Enterobacteriaceae](Enterobacteriaceae \\\"Enterobacteriaceae\\\")\",\"explanation\":\"The taxonomic classification was updated in 2016 from Enterobacteriaceae (family) to Enterobacterales (order); continued use without note misrepresents current microbiology nomenclature as of 2025.\",\"fixedText\":\"Update terminology to \\\"Enterobacterales\\\" for accuracy, noting CRE contextually refers to this group.\",\"evidenceSource\":\"[](https://www.health.nsw.gov.au/Infectious/diseases/Pages/cpe.aspx)\"},{\"criticality\":\"Missing Information\",\"issueType\":\"Missing Information\",\"problematicText\":\"No specific text; entire section lacks recent data.\",\"explanation\":\"The section omits recent epidemiological trends, such as the over 460% increase in NDM-producing CRE infections in the US from 2019 to 2023, which highlights ongoing public health urgency as of 2025.\",\"fixedText\":\"Add: As of 2023, NDM-producing CRE infections in the United States had increased by more than 460% since 2019.[](https://www.cdc.gov/media/releases/2025/2025-cdc-report-finds-sharp-rise-in-dangerous-drug-resistant-bacteria.html)\",\"evidenceSource\":\"[](https://www.cdc.gov/media/releases/2025/2025-cdc-report-finds-sharp-rise-in-dangerous-drug-resistant-bacteria.html)\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"Carbapenem-resistant Enterobacteriaceae (CRE)\",\"explanation\":\"The taxonomic classification was updated in 2016; the family Enterobacteriaceae is now the order Enterobacterales. Using the outdated name misrepresents current scientific nomenclature.\",\"fixedText\":\"Replace \\\"Enterobacteriaceae\\\" with \\\"Enterobacterales\\\" throughout the section.\",\"evidenceSource\":\"CDC website: https://www.cdc.gov/cre/about/index.html\"},{\"criticality\":\"Critical\",\"issueType\":\"Mechanism/Specification Error\",\"problematicText\":\"[Enterobacter aerogenes](Enterobacter_aerogenes \\\"Enterobacter aerogenes\\\")\",\"explanation\":\"The species Enterobacter aerogenes was reclassified as Klebsiella aerogenes in 2017 based on genomic studies. This outdated name leads to incorrect identification in medical and scientific contexts.\",\"fixedText\":\"\",\"evidenceSource\":\"\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"No specific text; entire section lacks current CDC surveillance criteria.\",\"explanation\":\"The section uses a 2015 study-specific definition without mentioning the broader CDC definition or MIC thresholds for resistance, which are essential for precise understanding and surveillance. As of 2024, CDC focuses on carbapenemase-producing subsets.\",\"fixedText\":\"Add the general CDC definition and note surveillance specifics, including MIC values where applicable.\",\"evidenceSource\":\"CDC: https://www.cdc.gov/cre/about/index.html\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"A person susceptible to CRE transmission is more likely to be female, have a greater number of parenteral nutrition-days (meaning days by which the person received nutrition via the bloodstream), and to have had a significant number of days breathing through a ventilator.[8]\",\"explanation\":\"Reference 8 (Chitnis et al., 2012) supports mechanical ventilation as a risk factor but does not mention female gender or parenteral nutrition-days as increasing susceptibility to CRE transmission.\",\"fixedText\":\"Revise to: \\\"A person susceptible to CRE transmission ... to have had a significant number of days breathing through a ventilator.[8]\\\" Remove female and parenteral nutrition parts.\",\"evidenceSource\":\"Ref 8; browse summary confirms only ventilation mentioned among these.\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"Another 2012 multicenter study found that over 30% of patients with recent exposure to LTAC were colonized or infected with CRE.[10]\",\"explanation\":\"No evidence found in Reference 10 (Savard \u0026 Perl, 2012) supporting the 30% figure for CRE colonization/infection in patients with recent LTAC exposure. Searches for the quote lead back to this article or similar, suggesting misattribution.\",\"fixedText\":\"Remove the sentence or recite with accurate source if available (e.g., approximate from other studies like Guh et al. 2015, but verify); otherwise, generalize without specific percentage.\",\"evidenceSource\":\"Web search results; no confirmation in ref 10.\"},{\"criticality\":\"Critical\",\"issueType\":\"Scope/Applicability Misstatement\",\"problematicText\":\"One study from Japan found that 6.4% of healthy adults carried ESBL (mostly cefotaximase)-producing strains compared to 58.4% in Thailand, where antibiotics are available over the counter and without prescription. An Egyptian research group found that 63.3% of healthy adults were colonized.[10]\",\"explanation\":\"The provided statistics refer to colonization with ESBL-producing strains, not specifically CRE. While unregulated antibiotic use contributes to broader antimicrobial resistance, including CRE, presenting ESBL data as CRE data misstates the scope and could mislead on CRE-specific risks.\",\"fixedText\":\"Clarify that these are for ESBL as an example of broader resistance risks from unregulated antibiotics, or remove if not directly relevant to CRE; add CRE-specific data if available.\",\"evidenceSource\":\"Web search confirms numbers for ESBL (e.g., in general resistance literature), not CRE; ref 10 is on CRE management.\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"### Transmission by animals Because the spread of CRE bacteria from animals to humans may become a problem in the future, it is advised to monitor CRE in livestock, as well as humans.\",\"explanation\":\"No citation provided for the claim of potential animal-to-human transmission risk or the recommendation to monitor livestock. Recent evidence (as of 2024) indicates emerging concerns about CRE in animals and potential zoonotic transmission, warranting sourcing and updating with current data.\",\"fixedText\":\"Add citation to authoritative source (e.g., CDC or WHO guidelines on monitoring AMR in animals); include recent context: \\\"As of 2024, limited evidence of direct transmission exists, but monitoring is recommended due to detection in livestock.\\\"\",\"evidenceSource\":\"CDC (2024): Few reports of animal-human spread; [](https://www.cdc.gov/cre/about/index.html)\"},{\"criticality\":\"Critical\",\"issueType\":\"Scope/Applicability Misstatement\",\"problematicText\":\"CR Pseudomonas aeruginosa is commonly present in intensive-care units, and can lead to dangerous infections.[31] In Thai hospitals, of 261 multidrug-resistant samples collected of P. aeruginosa (not part of the Enterobacteriaceae), 71.65% were carbapenem-resistant.[31]\",\"explanation\":\"The article focuses on Carbapenem-resistant Enterobacteriaceae (CRE), but this paragraph discusses Pseudomonas aeruginosa, which is not an Enterobacteriaceae member. Including specific statistics on P. aeruginosa resistance misapplies the scope, potentially confusing readers about CRE-specific mechanisms, despite the parenthetical note.\",\"fixedText\":\"Remove the paragraph on P. aeruginosa as it falls outside the article's scope on Enterobacteriaceae; mechanisms like efflux and porin loss are already covered generally for gram-negative bacteria earlier in the section.\",\"evidenceSource\":\"[31] supports the claim for P. aeruginosa but is irrelevant to Enterobacteriaceae.\"},{\"criticality\":\"Non-Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"\",\"explanation\":\"The section covers established mechanisms but lacks mention of emerging combinations, such as co-production of multiple carbapenemases (e.g., KPC and NDM) or novel variants like KPC-31, which confer resistance to newer inhibitors like avibactam. As of 2023-2025, these are increasingly reported in reviews, enhancing understanding of evolving resistance.\",\"fixedText\":\"Add a brief note in the carbapenemases subsection: \\\"Recent studies (as of 2023) highlight emerging co-production of multiple carbapenemases, such as KPC and NDM, and novel variants like KPC-31 resistant to ceftazidime-avibactam, contributing to multidrug resistance.\\\" Cite the 2023 review.\",\"evidenceSource\":\"[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10305383/)\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"In a Thailand-based study of CRE in hospital settings, carbapenem resistance was defined as any strain that shows resistance to at least one of three carbapenem antibiotics tested.[31]\",\"explanation\":\"Reference [31] is a study on carbapenem resistance in multidrug-resistant Pseudomonas aeruginosa in Thai hospitals, not on CRE (Enterobacteriaceae). This incorrectly attributes a definition of resistance to an irrelevant source, potentially misleading readers on the context of CRE detection.\",\"fixedText\":\"Remove the entire sentence, as it is not supported by the cited reference and does not add essential value to the description of the disc diffusion method.\",\"evidenceSource\":\"[31] Khuntayaporn et al. (2012) on P. aeruginosa\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"[Entire section lacks description of standard confirmatory tests for carbapenemase production]\",\"explanation\":\"The section describes screening and some detection methods but omits key current standards for confirming carbapenemase production, such as the modified carbapenem inactivation method (mCIM), which has been recommended by CLSI since 2015 and remains standard as of 2024-2025. This creates an outdated portrayal of laboratory practices for CRE identification, as phenotypic confirmation is essential for distinguishing carbapenemase-producing from non-carbapenemase CRE.\",\"fixedText\":\"Add a new subsection on \\\"Confirmatory tests for carbapenemase production\\\" describing mCIM and briefly noting its adoption, with citation to CLSI/CDC. Integrate to avoid duplication with mechanism section.\",\"evidenceSource\":\"CLSI M100 Performance Standards for Antimicrobial Susceptibility Testing, 34th ed. (2024)[](https://clsi.org/standards/products/microbiology/documents/m100/); CDC CRE Toolkit[](https://www.cdc.gov/infection-control/hcp/cre-toolkit/index.html)\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"No billing code exists for CRE under Medicare or Medicaid, making it difficult to track on a national level in the U.S.\",\"explanation\":\"The claim is outdated; ICD-10-CM code Z22.350 for \\\"Carrier of carbapenem-resistant Enterobacterales\\\" was added effective October 1, 2023, facilitating better national tracking of CRE cases under Medicare and Medicaid.\",\"fixedText\":\"Revise to: \\\"A specific ICD-10-CM billing code (Z22.350) for carriers of carbapenem-resistant Enterobacterales was introduced effective October 1, 2023, aiding national tracking in the U.S.\\\" Add new citation to CMS ICD-10 guidelines.\",\"evidenceSource\":\"ICD-10-CM updates from CMS and AAPC confirming code addition in FY 2024\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"No new drugs for the bacteria are in development and the bacteria's rapid adaptation to new drugs makes investment in their development unprofitable, as the new drug would quickly become useless.[2]\",\"explanation\":\"This claim from a 2012 source is no longer accurate as of 2025; several new antibiotics targeting CRE have been approved (e.g., cefiderocol in 2019, plazomicin in 2018) and others are in development or recently authorized, countering the assertion of no development.\",\"fixedText\":\"Remove the sentence or revise to: \\\"While challenges persist in antibiotic development due to resistance evolution, several new agents active against CRE, such as cefiderocol and eravacycline, have been approved since 2018.\\\" Add new citations to FDA approvals or IDSA guidelines.\",\"evidenceSource\":\"\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"\",\"explanation\":\"Section lacks recent updates on CRE epidemiology and prevention as of 2025, including the sharp rise in NDM-producing CRE reported by CDC in September 2025, which underscores the urgency of enhanced infection control measures.\",\"fixedText\":\"Add a paragraph or sentence noting the 2025 CDC report on a five-fold increase in NDM-CRE infections from 2019-2023, emphasizing continued focus on prevention strategies like surveillance and contact precautions.\",\"evidenceSource\":\"CDC media release September 23, 2025, on rise in NDM-CRE\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"\\\"A meta-analysis of 17 studies investigating the clinical effectiveness of fosfomycin in four multidrug-resistant strains of Enterobacteriaceae found 11 which reported that over 90% of bacterial isolates were susceptible to fosfomycin.\\\"\",\"explanation\":\"Ref [49] is a systematic review of fosfomycin for ESBL-producing and other MDR Enterobacteriaceae, but does not address carbapenem-resistant Enterobacteriaceae (CRE) specifically. CRE have distinct resistance mechanisms (e.g., carbapenemases) that differ from ESBL, making the susceptibility data inapplicable to CRE without qualification.\",\"fixedText\":\"Revise to clarify that the data applies to ESBL/MDR, not CRE broadly; note fosfomycin's role is limited to uncomplicated cystitis in CRE per current guidelines.\",\"evidenceSource\":\"[49]\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"\\\"A 2008 review of 42 studies of in vitro susceptibility of bacteria to tigecycline showed that MDR K. pneumoniae and E. coli, including those that were carbapenem resistant, were susceptible more than 90% of the time.\\\"\",\"explanation\":\"Ref [51] reviewed 26 microbiological studies and 10 clinical studies (total 36), not 42 in vitro susceptibility studies. This misrepresents the source's scope and could mislead on the breadth of evidence.\",\"fixedText\":\"Correct the number of studies to 26 microbiological studies; qualify susceptibility rates by criteria (e.g., FDA vs. EUCAST) and note limitations for CRE.\",\"evidenceSource\":\"[51]\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"\\\"In a separate study, CRE were treated with colistin, amikacin, and tigecycline, and emphasizes the importance of using gentamicin in patients undergoing chemotherapy or stem-cell therapy procedures.[16]\\\"\",\"explanation\":\"Ref [16] is a single case report of persistent CRE bacteremia in one patient with acute lymphoblastic leukemia, not a comparative study evaluating multiple treatments or emphasizing gentamicin broadly.\",\"fixedText\":\"Rephrase as \\\"A case report described treatment with colistin, amikacin, tigecycline, and gentamicin in a patient with persistent CRE bacteremia during chemotherapy.[16]\\\"\",\"evidenceSource\":\"[16]\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"\\\"One specific study showed a higher rate of carbapenem resistance when using meropenem alone compared with combination therapy with moxifloxacin.[53]\\\"\",\"explanation\":\"Ref [53] is a randomized trial on empirical treatment of severe sepsis with moxifloxacin + meropenem vs. meropenem alone, focusing on outcomes in general sepsis, not on preventing or rates of carbapenem resistance in CRE.\",\"fixedText\":\"Remove the claim or replace with sourced evidence on combination therapy for CRE; current guidelines prefer monotherapy with active agents.\",\"evidenceSource\":\"[53]\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"\\\"Several new agents are in development. The main areas where scientists are focusing is new Î²-lactamase inhibitors with activity against carbapenemases. Some of these include MK-7655, NXL104, and 6-alkylidenepenam sulfones. ... Another experimental agent with activity against CRE is eravacycline.[52]\\\"\",\"explanation\":\"Ref [52] is from 2011; by 2025, ceftazidime-avibactam (containing avibactam, formerly NXL104; approved 2015), imipenem-cilastatin-relebactam (containing relebactam, formerly MK-7655; approved 2020), and eravacycline (approved 2018) are established treatments. The section presents outdated \\\"in development\\\" status, omitting current standards like IDSA 2024 guidance.\",\"fixedText\":\"Update to reflect approved status and include current preferred treatments (e.g., ceftazidime-avibactam, meropenem-vaborbactam for KPC-CRE); cite IDSA 2024 guidance as of 2024.\",\"evidenceSource\":\"[](https://www.idsociety.org/practice-guideline/amr-guidance/)\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"No specific text; entire section lacks coverage of site-specific and carbapenemase-specific treatments.\",\"explanation\":\"The section omits key current recommendations from IDSA 2024 guidance, such as preferred agents for KPC-CRE (ceftazidime-avibactam, meropenem-vaborbactam), MBL-CRE (ceftazidime-avibactam + aztreonam, cefiderocol), and site-specific options (e.g., fosfomycin/nitrofurantoin for uncomplicated UTI; avoid tigecycline for BSI/pneumonia). This gap affects clinical applicability and accuracy as of 2025.\",\"fixedText\":\"Add subsections or paragraphs on current preferred treatments by CRE type (KPC, OXA-48, MBL) and infection site (UTI, BSI, pneumonia), citing IDSA 2024; note preferences for monotherapy over combinations.\",\"evidenceSource\":\"[](https://www.idsociety.org/practice-guideline/amr-guidance/)\"},{\"criticality\":\"Critical\",\"issueType\":\"Scope/Applicability Misstatement\",\"problematicText\":\"\\\"Tigecycline is capable of killing almost all of the ESBLs and multidrug-resistant (MDR) E. coli isolates and the large majority of ESBL and MDR isolates of Klebsiella species.\\\" and \\\"Although tigecycline is one of the first lines of defense against carbapenemase-producing isolates\\\"\",\"explanation\":\"Tigecycline has activity against some CRE but is not a first-line agent due to suboptimal pharmacokinetics (low serum levels, poor for BSI/UTI/pneumonia). Current guidelines (IDSA 2024) recommend it as an alternative only for certain sites, not broadly as \\\"first line.\\\"\",\"fixedText\":\"Qualify tigecycline's role as an alternative for intra-abdominal/peritoneal infections; note avoidance for BSI, pneumonia, and UTI; update with current evidence.\",\"evidenceSource\":\"[](https://www.idsociety.org/practice-guideline/amr-guidance/)\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"\\\"CRE have become increasingly common in the US. The Meropenem Yearly Susceptibility Test Information Collection Program noted that resistance within K. pneumoniae alone increased from 0.6% in 2004 to 5.6% in 2008.[11] The first outbreak involving colistin-resistant, carbapenem-resistant K. pneumoniae (CRKP) in the U.S. was discovered in Detroit, Michigan in 2009\\\"\",\"explanation\":\"These claims present historical data (up to 2009-2015) as indicative of ongoing trends without updating to reflect significant changes by 2025. CDC data shows a 460% surge in NDM-CRE infections from 2019-2023, with continued high levels in 2024, altering the understanding of current prevalence and risk.\",\"fixedText\":\"Add a paragraph summarizing recent US epidemiology as of 2025, citing CDC sources, while retaining historical context.\",\"evidenceSource\":\"[](https://www.cdc.gov/media/releases/2025/2025-cdc-report-finds-sharp-rise-in-dangerous-drug-resistant-bacteria.html)\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"\\\"Increases in CRE have not been limited to the US. By 2011, CRE was reported in at least 22 countries.[11] Between 2009 and 2012, 10 cases of CRE infections were documented in ICU patients in a Melbourne, Australia, hospital.[41]\\\"\",\"explanation\":\"Global data is outdated; as of 2025, ECDC reports ongoing high threat with increasing prevalence worldwide, including specific updates on CRE in Europe and Asia, which changes the scope of global epidemiology.\",\"fixedText\":\"Update with recent global trends, e.g., increasing prevalence in multiple regions as per 2024-2025 reviews, while keeping specific historical cases.\",\"evidenceSource\":\"[](https://www.ecdc.europa.eu/sites/default/files/documents/risk-assessment-carbapenem-resistant-enterobacterales-third-update-february-2025_0.pdf)\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"No specific text; overall section lacks recent data.\",\"explanation\":\"The section omits key recent developments up to 2025, such as the surge in NDM-producing CRE in the US, global trends from systematic reviews, and updated mortality estimates (e.g., 37.7% lethality in recent BSIs), which are essential for understanding current epidemiology and public health impact.\",\"fixedText\":\"Incorporate summaries of recent US and global prevalence, including specific figures like 460% increase in NDM-CRE (2019-2023) and ongoing cases in 2024-2025; add recent mortality data from studies post-2020.\",\"evidenceSource\":\"[](https://www.cdc.gov/mmwr/volumes/74/wr/mm7423a2.htm) [](https://pmc.ncbi.nlm.nih.gov/articles/PMC12093585/)\"},{\"criticality\":\"Critical\",\"issueType\":\"Scope/Applicability Misstatement\",\"problematicText\":\"\\\"This can be very important in future clinical and community settings, as an increase in copper utilization in hospital room equipment could help to greatly reduce the spread of antibiotic-resistant infection and the horizontal gene transfer of this antibiotic resistance.[65]\\\"\",\"explanation\":\"The statement presents copper surfaces as a straightforward solution for reducing spread of antibiotic-resistant infections without acknowledging limitations identified in recent research. A 2024 study on Enterobacteriaceae (including potential CRE-relevant strains) from hospital surfaces showed that while copper initially kills bacteria, it can lead to rapid development of copper resistance (in 83% of strains within 3 days), co-selecting for multidrug resistance via mechanisms like efflux pumps. This could undermine long-term efficacy in clinical settings and affect public health strategies.\",\"fixedText\":\"Add the following sentence immediately after the problematic text: However, recent research has shown that exposure to copper surfaces may promote the evolution of copper resistance in Enterobacteriaceae, potentially leading to co-selection of antibiotic resistance traits, which warrants further investigation for sustained use in healthcare environments.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11190421/)\",\"evidenceSource\":\"[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11190421/)\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"No specific text; overall section relies solely on 2012 study.\",\"explanation\":\"The section lacks updates on developments since the cited 2012 study, such as confirmatory research on copper's efficacy against CRE up to 2024, including in vitro and in situ reductions in bacterial burden, and broader reviews supporting its use as an adjunct to hygiene protocols. This gap affects the completeness of public health implications as of 2025.\",\"fixedText\":\"Incorporate a brief mention of recent confirmatory studies after the discussion of the 2012 findings: Subsequent studies, including a 2024 review, have confirmed copper's antimicrobial activity against CRE and other multidrug-resistant bacteria on hospital surfaces, with reductions in microbial load of up to 83% in clinical trials.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11920907/)\",\"evidenceSource\":\"[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11920907/)\"}],\"slug\":\"Carbapenem-resistant_enterobacteriaceae\",\"title\":\"Carbapenem-resistant Enterobacterales\",\"content\":\"$1f\",\"description\":\"Carbapenem-resistant Enterobacterales\\n\\nCarbapenem-resistant Enterobacterales (CRE) are gram-negative bacteria in the order Enterobacterales that are resistant to the carbapenem class of antibiotics,...\",\"metadata\":{\"categories\":[\"CRE\"],\"lastModified\":\"1761553317\",\"contentLength\":\"45735\",\"version\":\"1.0\",\"lastEditor\":\"system\",\"language\":\"en\",\"isRedirect\":false,\"redirectTarget\":\"\",\"isWithheld\":false},\"stats\":{\"totalViews\":\"29783\",\"recentViews\":\"29783\",\"dailyAvgViews\":992.7666625976562,\"qualityScore\":1,\"lastViewed\":\"1761886055\"},\"linkedPages\":null},\"found\":true},\"dataUpdateCount\":1,\"dataUpdatedAt\":1761886055959,\"error\":null,\"errorUpdateCount\":0,\"errorUpdatedAt\":0,\"fetchFailureCount\":0,\"fetchFailureReason\":null,\"fetchMeta\":null,\"isInvalidated\":false,\"status\":\"success\",\"fetchStatus\":\"idle\"},\"queryKey\":[\"page\",\"Carbapenem-resistant_enterobacteriaceae\"],\"queryHash\":\"[\\\"page\\\",\\\"Carbapenem-resistant_enterobacteriaceae\\\"]\"}]},\"children\":\"$L20\"}]\n"])</script><script nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli">self.__next_f.push([1,"c:{\"metadata\":[[\"$\",\"title\",\"0\",{\"children\":\"Carbapenem-resistant Enterobacterales\"}],[\"$\",\"meta\",\"1\",{\"name\":\"description\",\"content\":\"Carbapenem-resistant Enterobacterales (CRE) are gram-negative bacteria in the order Enterobacterales that are resistant to the carbapenem class of antibiotics, considered drugs of last resort for such infections. CRE include carbapenemase-producing Enterobacterales (CPE), which resist via production of an enzyme called a carbapenemase that disables the drug molecule, as well as non-CPE strains resistant through other mechanisms such as reduced outer membrane permeability and efflux pumps....\"}],[\"$\",\"meta\",\"2\",{\"name\":\"author\",\"content\":\"system\"}],[\"$\",\"link\",\"3\",{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\",\"crossOrigin\":\"$undefined\"}],[\"$\",\"meta\",\"4\",{\"name\":\"keywords\",\"content\":\"CRE\"}],[\"$\",\"meta\",\"5\",{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",\"6\",{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"link\",\"7\",{\"rel\":\"canonical\",\"href\":\"https://grokipedia.com/page/Carbapenem-resistant_enterobacteriaceae\"}],[\"$\",\"meta\",\"8\",{\"property\":\"og:title\",\"content\":\"Carbapenem-resistant Enterobacterales\"}],[\"$\",\"meta\",\"9\",{\"property\":\"og:description\",\"content\":\"Carbapenem-resistant Enterobacterales (CRE) are gram-negative bacteria in the order Enterobacterales that are resistant to the carbapenem class of antibiotics, considered drugs of last resort for such infections. CRE include carbapenemase-producing Enterobacterales (CPE), which resist via production of an enzyme called a carbapenemase that disables the drug molecule, as well as non-CPE strains resistant through other mechanisms such as reduced outer membrane permeability and efflux pumps....\"}],[\"$\",\"meta\",\"10\",{\"property\":\"og:url\",\"content\":\"https://grokipedia.com/page/Carbapenem-resistant_enterobacteriaceae\"}],[\"$\",\"meta\",\"11\",{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",\"12\",{\"property\":\"og:locale\",\"content\":\"en\"}],[\"$\",\"meta\",\"13\",{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",\"14\",{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",\"15\",{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",\"16\",{\"property\":\"og:image:alt\",\"content\":\"Carbapenem-resistant Enterobacterales\"}],[\"$\",\"meta\",\"17\",{\"property\":\"og:type\",\"content\":\"article\"}],[\"$\",\"meta\",\"18\",{\"property\":\"article:modified_time\",\"content\":\"1970-01-21T09:19:13.317Z\"}],[\"$\",\"meta\",\"19\",{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",\"20\",{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",\"21\",{\"name\":\"twitter:title\",\"content\":\"Carbapenem-resistant Enterobacterales\"}],[\"$\",\"meta\",\"22\",{\"name\":\"twitter:description\",\"content\":\"Carbapenem-resistant Enterobacterales (CRE) are gram-negative bacteria in the order Enterobacterales that are resistant to the carbapenem class of antibiotics, considered drugs of last resort for such infections. CRE include carbapenemase-producing Enterobacterales (CPE), which resist via production of an enzyme called a carbapenemase that disables the drug molecule, as well as non-CPE strains resistant through other mechanisms such as reduced outer membrane permeability and efflux pumps....\"}],[\"$\",\"meta\",\"23\",{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"link\",\"24\",{\"rel\":\"icon\",\"href\":\"/favicon.ico\",\"type\":\"image/x-icon\",\"sizes\":\"16x16\"}],[\"$\",\"$L21\",\"25\",{}]],\"error\":null,\"digest\":\"$undefined\"}\n"])</script><script nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli">self.__next_f.push([1,"11:\"$c:metadata\"\n"])</script><script nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli">self.__next_f.push([1,"22:I[61172,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"PageEditorProvider\"]\n"])</script><script nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli">self.__next_f.push([1,"23:I[63493,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="YTlkNGFlNWItYzM1OC00ZTI3LTk1MWUtZDYyNmMwNDk3MTli">self.__next_f.push([1,"20:[\"$\",\"$L22\",null,{\"children\":[\"$\",\"$L23\",null,{\"slug\":\"Carbapenem-resistant_enterobacteriaceae\"}]}]\n"])</script></body></html>